Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
METHODS FOR DETERMINING CANCER RESISTANCE TO HISTONE DEACETYLASE INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2008/095050
Kind Code:
A1
Abstract:
[00153] Described herein are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are methods and compositions for increasing the likelihood of a therapeutically effective treatment in a patient, comprising an analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nucleic acids derived from a cancer sensitive to or resistant to a histone deacetylase inhibitor. Further described are kits and indications that are used in conjunction with the aforementioned methods and compositions.

Inventors:
BUGGY JOSEPH J (US)
BALASUBRAMANIAN SRIRAM (US)
Application Number:
US2008/052540
Publication Date:
August 07, 2008
Filing Date:
January 30, 2008
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
PHARMACYCLICS INC (US)
BUGGY JOSEPH J (US)
BALASUBRAMANIAN SRIRAM (US)
International Classes:
A61K49/00; C12Q1/68; G01N33/574
Foreign References:
US20030166026A12003-09-04
Other References:
LE PAGE C. ET AL.: "From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CAI125 as serum-based markers in epithelial ovarian cancer", INT. J. CANCER, vol. 118, no. 7, 1 April 2006 (2006-04-01), pages 1750 - 1758, XP003011117
NATRAJAN R. ET AL.: "Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse", J. PATHOL., vol. 210, no. 1, September 2006 (2006-09-01), pages 49 - 58, XP008111928
See also references of EP 2107911A4
Attorney, Agent or Firm:
HOSTETLER, Michael, J. (Wilson Sonsini Goodrish & Rosati, 650 Page Mill RoadPalo Alto, California, 94304-1050, US)
Download PDF:
Claims:
WHAT IS CLAIMED IS:

1. A method for classifying a cancer in a patient, comprising comparing the expression levels of at least four biomarker genes in the cancer to expression level to a first or second set of expression level threshold values for the biomarker genes, and indicating that the cancer is sensitive to a HDAC inhibitor if the expression levels of the biomarker genes are lower than the first set of expression level threshold values, or indicating that the cancer is resistant to a HDAC inhibitor if the expression levels are greater than the second set of expression level threshold values, wherein the at least four biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl , CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT12, TPKl, DEFA6, EPLIN, CLIC5, PERP, SYK, SLCl 2 A2, GUC Y2C. TM4SF4, TGFA, FGFBPl, PTK6, EVAl , EPHA2, ITGA6, TNFRSF21, TM4SF3, 1L18, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCL15, DPEPl, NOXOl, IFI27, CYP3A43, and PKP2.

2. The method of claim 1, wherein at least one of the at least four marker genes are selected from DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, FITN3, EPH A2, FGFBPl, ABCC3, TPMT, ILl 8, and DPEPl .

3. The method of claim 1 , wherein the at least four biomarker genes include at least one of DEFA6, RAB25, TM4SF4, or IL18.

4. The method of claim 1 , wherein the at least four biomarker genes include DEFA6, ITGB4, TM4SF3, SYK, PPAP2C, and RAB25.

5. The method of claim 1 , wherein the at least four biomarker genes include DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl , TM4SF4, PTPN3, EPHA2, FGFBPl , ABCC3, TPMT, IL 18, and DPEPl.

6. The method of claim 1 , wherein one or more of the expression levels is an mRN A expression level.

7. The method of claim 1 , wherein one or more of the expression levels is a polypeptide expression level.

8. The method of claim 1 , wherein the cancer is a colon cancer.

9. The method of claim 1 , further comprising determining the level of expression of the at least four biomarker genes in the cancer prior to the step of comparing.

10. The method of claim 1 , wherein the HDAC inhibitor is PCI-24781.

1 1. The method of claim 1, wherein the expression levels of the at least four biomarker genes are compared to the first set and the second set of biomarker gene expression level threshold level values.

12. A method for classifying a cancer in a patient, comprising determining the expression levels of at least four biomarker genes in the cancer, comparing the expression levels of the at least four biomarker genes in the cancer to expression level to a first or second set of expression level threshold values for the biomarker genes, and indicating that the cancer is sensitive to a HDAC inhibitor if the expression levels of the biomarker genes are lower than the first set of expression level threshold values, or indicating that the cancer is resistant to a HDAC inhibitor if the expression levels are greater than the second set of expression level threshold values, wherein the at least four biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl, CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT12, TPKl, DEFA6, EPLIN, CLIC5, PERP, SYK, SLC12A2, GUCY2C, TM4SF4, TGFA, FGFBPl, PTK6, EVAl , EPHA2, ITGA6, TNFRSF21, TM4SF3, IL18, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCL15, DPEPl, NOXOl, IFI27, CYP3A43, and PKP2.

13. The method of claim 12, wherein at least one of the at least four marker genes are selected from DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, IL18,.and DPEPl.

14. The method of claim 12, wherein the at least four biomarker genes include at least one of DEFA6, RAB25, TM4SF4, or ILl 8.

15. The method of claim 12, wherein the at least four biomarker genes include DEFA6, ITGB4, TM4SF3, SYK, PPAP2C, and RAB25.

16. The method of claim 12, wherein the at least four biomarker genes include DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl , TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, IL 18, and DPEPl .

17. The method of claim 12, wherein one or more of the expression levels is an mRNA expression level.

18. The method of claim 12, wherein one or more of the expression levels is a polypeptide expression level.

19. The method of claim 12, wherein the cancer is a colon cancer.

20. The method of claim 12, further comprising prescribing or administering an HDAC inhibitor to the patient based on the comparison.

21. The method of claim 12, wherein the HDAC inhibitor is PCI-24781.

22. The method of claim 12, wherein the expression levels of the at least four biomarker genes are compared to the first set and the second set of biomarker gene expression level threshold level values.

23. An isolated population of nucleic acids comprising a plurality of nucleic acids derived from a cancer cell, wherein the cancer cell is a type of cancer cell that is sensitive to an HDAC inhibitor compound.

24. The isolated population of claim 23, wherein the isolated population contains RNAs.

25. The isolated population of claim 23, wherein the isolated population contains cDNAs.

26. The isolated population of claim 23, wherein the HDAC inhibitor is PCI-24781.

27. The isolated population of claim 23, wherein the cell was isolated from a population of cells grown in vitro.

28. The isolated population of claim 23, wherein the cancer cell is a colon carcinoma cell.

29. The isolated population of claim 28, wherein the colon carcinoma cell is derived from colon carcinoma R1059261097, R4498160614, R5456781761, R7424107588, or R0948311023.

3,0. The isolated population of claim 23, wherein the nucleotide sequences of at least four of DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl , ABCC3, TPMT, ILl 8, or DPEPl are represented in the isolated population.

31. An isolated population of nucleic acids comprising a plurality of nucleic acids derived from a cancer cell, wherein the cancer cell is a type of cancer cell that is resistant to an HDAC inhibitor compound.

32. The isolated population of claim 31 , wherein the isolated population contains RNAs.

33. The isolated population of claim 31, wherein the isolated population contains cDNAs.

34. The isolated population of claim 31 , wherein the HDAC inhibitor is PCI-24781.

35. The isolated population of claim 31, wherein the cell was isolated from a population of cells grown in vitro.

36. The isolated population of claim 31, wherein the cancer cell is a colon carcinoma cell.

37. The isolated population of claim 36, wherein the colon carcinoma cell is derived from colon carcinoma R5247682266, R9866135153, R1078103114, or R4712781606.

38. The isolated population of claim 31, wherein the nucleotide sequences of at least four of DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl , ABCC3, TPMT, ILl 8, or DPEPl are represented in the isolated population.

39. A kit comprising the isolated population of claim 31 and an insert indicating the ratio of a biomarker gene nucleic acid level in the population to an internal expression control gene nucleic acid level in the population.

40. The kit of claim 31 and an insert indicating the ratio of a biomarker gene nucleic acid level in the population to a nucleic acid level of the biomarker gene in a population of nucleic acids derived from a cancer cell, wherein the cancer cell is a type of cancer cell that is sensitive to the HDAC inhibitor compound.

41. A method for generating an expression level reference population of nucleic acids for expression profiling, comprising deriving an isolated population of nucleic acids from a cancer cell, wherein the cancer cell is a type of cancer cell that is sensitive to an HDAC inhibitor compound.

42. The method of claim 41, wherein the isolated population contains RNAs.

43. The method of claim 41, wherein the isolated population contains cDNAs.

44. The method of claim 41, wherein the HDAC inhibitor compound is PCI-24781.

45. The method of claim 41, wherein the cancer cell is present in a biopsy sample.

46. The method of claim 41 , wherein the cancer cell is present in a population of cells grown in vitro.

47. The method of claim 41, wherein the cancer cell is a colon carcinoma cell.

48. The method of claim 47, wherein the carcinoma cell is derived from colon carcinoma R1059261097, R4498160614, R5456781761, R7424107588, or R0948311023.

49. The method of claim 41 , wherein the nucleotide sequences of at least four of DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, ILl 8, or DPEPl are represented in the isolated population.

50. The method of claim 41 , further comprising determining, prior to the isolating step, that the type of cancer cell is sensitive to an HDAC inhibitor compound.

51. The method of claim 50, wherein the cancer cell determined to be sensitive to an HDAC inhibitor compound is determined to be resistant to an HDAC inhibitor compound in vitro.

52. The method of claim 51, wherein the HDAC inhibitor compound is PCI-24781.

53. A method for generating an expression level reference sample for expression profiling, comprising deriving an isolated population of nucleic acids from a cancer cell, wherein the cancer cell is a type of cancer cell that is resistant to an HDAC inhibitor compound.

54. The method of claim 53, wherein the isolated population contains RNAs.

55. The method of claim 53, wherein the isolated population contains cDNAs.

56. The method of claim 53, wherein the HDAC inhibitor compound is PCI-24781.

57. The method of claim 52, wherein the cell is present in a biopsy sample.

58. The method of claim 53, wherein the cell is present in a population of cells grown in vitro.

59. The method of claim 53, wherein the cancer cell is a colon carcinoma cell.

60. The method of claim 59, wherein the carcinoma cell is derived from colon carcinoma R5247682266, R9866135153, R 1078103114, or R4712781606.

61. The method of claim 53, wherein the nucleotide sequences of at least four of DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, ILl 8, or DPEPl are represented in the isolated population.

62. The method of claim 53, further comprising, prior to the isolating step, determining that the type of cancer cell is sensitive to an HDAC inhibitor compound.

63. The method of claim 51, wherein the HDAC inhibitor compound is PCI-24781.

64. A human cancer cell line that is resistant to an HDAC inhibitor compound in vitro.

65. The human cancer cell line of claim 64, wherein the human cell line expresses DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, ILl 8, and DPEPl .

66. The human cancer cell line of claim 64, wherein the HDAC inhibitor compound is PCI-24781.

67. The human cancer cell line of claim 66, wherein the human cell line is resistant to a PCI-24781 concentration of at least about 1 μM.

68. The human cancer cell line of claim 64, wherein the human cancer cell line is a colon carcinoma cell line.

69. The colon carcinoma cell line of claim 68, wherein the colon carcinoma cell line is R5247682266, R9866135153, R1078103114, or R4712781606.

70. A method for increasing the likelihood of therapeutically effective treatment of a cancer with an HDAC inhibitor, comprising providing an indication that a cancer in a patient is sensitive to treatment with an HDAC inhibitor if expression levels of at least four biomarker genes in a sample from the patient's cancer are lower than expression level threshold values for the four biomarker genes, or providing an indication that the cancer is resistant to treatment with the HDAC inhibitor if the expression levels of the biomarker genes are higher than the expression level threshold values, wherein the at least four biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl, CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNTl 2, TPKl, DEFA6, EPLIN, CLIC5, PERP 1 SYK, SLC12A2, GUCY2C, TM4SF4, TGFA, FGFBPl, PTK6, EVAl, EPHA2, ITGA6, TNFRSF21 , TM4SF3, ILl 8, BMP4, SMPDL3B, TMPRSS2, GDA, MSTl R, ITGB4, ANXA3, CCL15, DPEPl , NOXOl, IF127, CYP3A43, and PKP2, whereby the likelihood of therapeutically effective treatment of the cancer with the HDAC inhibitor is increased.

71. The method of claim 70, wherein the indication is provided in a digital medium.

72. The method of claim 70, wherein the indication is provided in a hardcopy medium.

73. The method of claim 70, wherein the indication is a biomedical publication reference.

74. The method of claim 70, wherein the indication refers to expression levels of at least two of the biomarker genes.

75. The method of claim 70, wherein the at least four biomarker genes include DEFA6, RAB25, TM4SF4, or IL 18.

76. The method of claim 70, wherein the at least four biomarker genes include DEFA6, ITGB4, TM4SF3, SYK, PPAP2C, and RAB25.

77. The method of claim 70, wherein the at least four biomarker genes include DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, IL 18, and DPEPl.

78. The method of claim 70, wherein the cancer is colon cancer.

79. The method of claim 70, wherein the HDAC inhibitor is PCI-24781.

80. A method for optimizing selection of an anti-cancer agent for treating a cancer in combination with an HDAC inhibitor compound, the method comprising

(i) comparing a first set of biomarker genes the expression of which is correlated to resistance or sensitivity of the cancer to the anti-cancer agent to a second set of biomarker genes the expression of which is correlated with resistance to the HDAC inhibitor compound; and

(ii) selecting the anti-cancer agent for treatment of the cancer in combination with the HDAC inhibitor if the biomarker genes in the first set are different from the biomarker genes in the second set, wherein

the biomarker genes in the second set are DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, IL18, and DPEPl.

81. The method of claim 80, further comprising comparing the expression level of the second set of biomarker genes in a plurality of cancer cells treated with the HDAC inhibitor together with a second anti-cancer agent.

82. An indication of the likelihood of a therapeutically effective treatment of a cancer with an HDAC inhibitor compound, comprising a means of communicating an interpretation of expression levels of at least four biomarker genes selected from DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, IL18, and DPEP.

83. The indication of claim 82, further comprising the expression levels of the at least four biomarker genes.

84. The indication of claim 82, wherein the means of communicating is a paper document or an electronic document.

85. The indication of claim 82, wherein the interpretation includes a biomedical publication reference.

86. The indication of claim 82, wherein the interpretation includes a graph.

87. The indication of claim 82, wherein the interpretation includes information that indicates that a cancer in a patient is sensitive to treatment with an HDAC inhibitor if expression levels of the biomarker genes in a sample from the patient's cancer are lower than expression level threshold values for the four biomarker genes, or information that indicates that the cancer is resistant to treatment with the HDAC inhibitor if the expression levels of the biomarker genes are higher than the expression level threshold values.

88. A method for determining the likelihood of effectively treating a cancer in a patient with an HDAC inhibitor compound, comprising

(i) determining in the cancer the expression levels of at least four biomarker genes selected from DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, ILl 8, and DPEP; and

(ii) comparing the expression levels of that at least four biomarker genes in the cancer to expression levels of the at least four biomarker genes in an expression level reference sample derived from cancer cells previously determined to be resistant to the HDAC inhibitor compound, wherein the likelihood of effectively treating the cancer is higher if the expression level of the at least four biomarkers in the cancer from the patient is lower than the expression levels of the biomarker genes in the expression level reference sample.

89. The method of claim 88, further comprising selecting an anti-cancer agent other than an HDAC inhibitor compound for treating the cancer.

90. A method for classifying a cancer in a patient, comprising comparing the expression levels of at least four biomarker genes in the cancer to to a first or second set of expression level values for the biomarker genes, and for each comparison assigning a probability to the biomarker gene expression level that the cancer in the patient is resistant to a histone deacetylase inhibitor compound, wherein

(i) the first set of expression level values were measured in cancer cells determined to be resistant to the histone deacetylase inhibitor compound;

(ii) the second set of expression level values were measured in cancer cells determined to be sensitive to the histone deacetylase inhibitor compound;

(iii) the assigned probability is inversely proportional to a negative deviation of the biomarker gene expression level from the first set of expression level values and directly proportional to a positive deviation of the biomarker gene expression level from the second set of expression level values; and

(iv) the at least four biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl, CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT12, TPKl, DEFA6, EPLIN, CLIC5, PERP, SYK, SLC12A2, GUCY2C, TM4SF4, TGFA, FGFBPl, PTK6, EVAl, EPHA2, ITGA6, TNFRSF21, TM4SF3, IL18, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCL15, DPEPl , NOXOl, EFI27, CYP3A43, and PKP2.

91. A method for classifying a population of cells, comprising comparing the expression levels of at least four biomarker genes in the population of cells to a first or second set of expression level threshold values for the biomarker genes, and indicating that the population of cells is sensitive to a HDAC inhibitor if the expression levels of the biomarker genes are lower than the first set of expression level threshold values, or indicating that the population of cells is resistant to a HDAC inhibitor if the expression levels are greater than the second set of expression level threshold values, wherein the at least four biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl, CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT 12, TPKl, DEFA6, EPLIN, CLIC5, PERP, SYK, SLC12A2, GUCY2C, TM4SF4, TGFA, FGFBPl , PTK6, EVAl, EPHA2, ITGA6, TNFRSF21, TM4SF3, IL18, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCL15, DPEPl, NOXOl, IFI27, CYP3A43, and PKP2.

92. A method for determining HDAC inhibition in vivo, comprising determining the expression level of an HDAC inhibitor-responsive biomarker gene in a biological sample obtained from a subject after the subject had been administered an HDAC inhibitor compound, wherein the HDAC inhibitor- responsive biomarker genes are any of the genes listed in Table 5.

93. A method for determining the most responsive tissues and the tumors derived therefrom to an HDAC inhibitor, comprising

(i) providing a first tissue of the tissue type (including blood) at a first time point and administration of HDAC inhibitor compound to the first tissue by any applicable route at a first time point,

(ii) providing a second tissue of the tissue type (including blood) at a second time point and administration of HDAC inhibitor compound to the second tissue by any applicable route at a second time point,

(iii) determining expression profiles in the first and second tissues for any of the genes listed in Table 5.

94. A method for classifying one or more cells, comprising determining the expression levels of no more than four to fifty biomarker genes in the one or more cells, wherein at least four of the biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl, CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNTl 2, TPKl, DEFA6, EPLIN, CLIC5, PERP, SYK, SLC12A2, GUC Y2C, TM4SF4, TGFA, FGFBPl, PTK6, EVAl, EPH A2, ITG A6, TNFRSF21, TM4SF3, ILl 8, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCL15, DPEPl, NOXOl, IFI27, CYP3A43, and PKP2.

95. The method of claim 94, further comprising comparing the expression levels to a first or second set of expression level threshold values for the biomarker genes, and indicating that the one or more cells are sensitive to a HDAC inhibitor if the expression levels of the biomarker genes are lower than the first set of expression level threshold values, or indicating that the one or more cells are resistant to a HDAC inhibitor if the expression levels are greater than the second set of expression level threshold values.

96. The method of claim 94, wherein the one or more cells are, cancer cells.

97. The method of claim 94, wherein the four to fifty biomarker comprises one or more genes selected from DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, IL 18, and DPEP

98. The method of claim 94, comprising determining determining the expression levels of no more than four to twenty biomarker genes.

99. The method of claim 98, comprising determining the expression levels of no more than four biomarker genes.

100. The method of claim 99, wherein the four biomarker genes consist of DEFA6, RAB25, TM4SF4, and IL 18.

101. A nucleic acid hybridization array, comprising nucleic acid probes that hybridize under high stringency hybridization conditions to nucleic acids of no more than four to fifty biomarker genes, wherein at least four of the biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl, CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT12, TPKl , DEFA6, EPLIN, CLIC5, PERP, SYK, SLC12A2, GUCY2C, TM4SF4, TGFA, FGFBPl, PTK6, EVAl , EPHA2, ITGA6, TNFRSF21 , TM4SF3, IL18, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCL15, DPEPl , NOXOl , IFI27, CYP3A43, and PKP2.

102. The nucleic acid hybridization array of claim 101, wherein the at least four biomarker genes are selected from DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl , TM4SF4, PTPN3, EPHA2, FGFBPl , ABCC3, TPMT, DL18, and DPEP.

103. The nucleic acid hybridization array of claim 102, wherein the at least four biomarker genes consist of DEFA6, RAB25, TM4SF4, and ILl 8.

Description:

METHODS FOR DETERMINING CANCER RESISTANCE TO HISTONE DEACETYLASE

INHIBITORS

RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Patent Application No.

60/887,318, entitled "Methods for determining cancer resistance to histone deacetylase inhibitors," filed January 30, 2007, and U.S. Provisional Patent Application No. 60/911,855 entitled "Methods for determining cancer resistance to histone deacetylase inhibitors," filed April 13, 2007, the contents of both of which are incorporated by reference in their entirety.

BACKGROUND OF THE INVENTION

[0002] The highly heterogeneous response of the same type of cancer (e.g., colon cancer) to a given anti-cancer compound in different patients is one of the most vexing and tragic problems of modern medicine. It is widely thought that human genetic and epigenetic diversity underlies much of the variation in response to chemotherapy. Thus, there is an ongoing effort to identify in the human population the molecular genetic correlates (i.e., molecular signatures) of cancer resistance and sensitivity to specific therapeutic agents. It is hoped that such efforts will ultimately enable physicians to predetermine the likelihood that a patient's cancer can be effectively treated with a particular anticancer compound.

SUMMARY OF THE INVENTION [0003] Described herein are methods and compositions for classifying a cancer in a patient as resistant or sensitive to a histone deacetylase inhibitor (HDACi) compound by (i) comparing the expression levels of at least four biomarker genes to a first set of biomarker gene expression level values, which was determined in cancer cells known to be resistant to the HDACi compound, or by comparing the expression levels to a second set of biomarker gene expression level values, which was determined in cancer cells known to be sensitive to the HDACi compound, and (ii) indicating that the cancer is sensitive to the HDACi compound if the biomarker gene expression levels are significantly lower than the first set of expression level values, or indicating that the cancer is resistant to the HDACi compound if the biomarker gene expression levels are greater than the second set of expression level values. The referred-to biomarker genes include PTPN3, ABCC3, SARG, PPAP2C, NPDCl, CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT12, TPKl, DEFA6, EPLIN, CLIC5, PERP, SYK, SLC12A2, GUCY2C, TM4SF4, TGFA, FGFBPl, PTK6, EVAl, EPHA2, ITGA6, TNFRSF21, TM4SF3, IL18, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCL15, DPEPl, NOXOl, IFI27, CYP3A43, and PKP2.

[0004] Accordingly, in one aspect provided herein is a method for classifying a cancer in a patient, comprising comparing the expression levels of at least four biomarker genes in the cancer to expression level to a first or second set of expression level threshold values for the biomarker genes, and indicating that the cancer is sensitive to a HDAC inhibitor if the expression levels of the biomarker genes are lower than the first set of expression level threshold values, or indicating that the cancer is resistant to a HDAC inhibitor if the expression levels are greater than the second set of expression level threshold values, wherein the at least four biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl , CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT12, TPKl, DEF A6, EPLIN, CLIC5, PERP, SYK, SLC12A2, GUCY2C, TM4SF4, TGFA, FGFBPl, PTK6, EVAl, EPHA2, ITGA6, TNFRSF21, TM4SF3, ILl 8, BMP4, SMPDL3B,

TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCL15, DPEPl, NOXOl, IFI27, CYP3A43, and PKP2. In some embodiments, the at least four marker genes are selected from DEF A6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, ILl 8, and DPEP 1. In some embodiments, the at least four biomarker genes include at least one of DEF A6, RAB25, TM4SF4, or IL18. In some embodiments, the at least four biomarker genes include DEF A6, ITGB4, TM4SF3, SYK, PPAP2C, and RAB25. In some embodiments, the at least four biomarker genes include DEF A6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl , ABCC3, TPMT, ILl 8, and DPEPl . In some embodiments, one or more of the above-mentioned expression levels is an mRNA expression level. In some embodiments, one or more of the expression levels is a polypeptide expression level. In some embodiments, the patient's cancer is a colon cancer. In some embodiments, the method for classifying the cancer further comprises determining the level of expression of the at least four biomarker genes in the cancer prior to the step of comparing. In some embodiments, the referred-to HDAC inhibitor is PCI-24781. In some embodiments, the expression levels of the at least four biomarker genes are compared to the first set and the second set of biomarker gene expression level threshold level values.

[0005) In another aspect provided herein is a method for classifying a cancer in a patient, comprising determining the expression levels of at least four biomarker genes in the cancer, comparing the expression levels of the at least four biomarker genes in the cancer to expression level to a first or second set of expression level threshold values for the biomarker genes, and indicating that the cancer is sensitive to a HDAC inhibitor if the expression levels of the biomarker genes are lower than the first set of expression level threshold values, or indicating that the cancer is resistant to a HDAC inhibitor if the expression levels are greater than the second set of expression level threshold values, wherein the at least four biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl , CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT12, TPKl , DEFA6. EPLIN, CLIC5, PERP, SYK, SLC12A2, GUCY2C, TM4SF4, TGFA, FGFBPl , PTK6,

EVAl , EPHA2, ITGA6, TNFRSF21, TM4SF3, IL18, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR 3 ITGB4, ANXA3, CCL15, DPEPl, NOXOl, EFI27, CYP3A43, and PKP2.

[0006] In some embodiments, at least one of the at least four marker genes are selected from

DEF A6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl 1 ABCC3, TPMT, IL18, and DPEPl . In some embodiments, the at least four biomarker genes include at least one of DEFA6, RAB25, TM4SF4, or ILl 8. In some embodiments, the at least four biomarker genes include DEF A6, ITGB4, TM4SF3, SYK, PPAP2C, and RAB25. In some embodiments, the at least four biomarker genes include DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, 1L18, and DPEPl . In some embodiments, wherein one or more of the expression levels of the referred-to biomarker genes is an mRNA expression level. In some embodiments, one or more of the expression levels is a polypeptide expression level. In some embodiments, the patient's cancer is a colon cancer. In some embodiments, the HDAC inhibitor is PCI-24781. In some embodiments, the method further comprises prescribing or administering an HDAC inhibitor to the patient based on the comparison of the biomarker gene expression levels. In some embodiments, the expression levels of the at least four biomarker genes are compared to the first set and the second set of biomarker gene expression level threshold level values.

[0007] In a further aspect provided herein is an isolated population of nucleic acids comprising a plurality of nucleic acids derived from a cancer cell, wherein the cancer cell is a type of cancer cell that is sensitive to an HDAC inhibitor compound. In some embodiments, the isolated population contains RNAs. In some embodiments, the isolated population contains cDNAs. In some embodiments, the referred-to HDAC inhibitor is PCI-24781. In some embodiments, the referred-to cancer cell was isolated from a population of cells grown in vitro. In some embodiments, the cancer cell is a colon carcinoma cell. In some embodiments, the colon carcinoma cell is derived from colon carcinoma R1059261097, R4498160614, R5456781761, R7424107588, or R0948311023. In some embodiments, the nucleotide sequences of at least four of DEFA6, 1TGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl , ABCC3, TPMT, IL18, or DPEPl are represented in the isolated population of nucleic acids. [0008J In a related aspect provided herein is an isolated population of nucleic acids comprising a plurality of nucleic acids derived from a cancer cell, wherein the cancer cell is a type of cancer cell that is resistant to an HDAC inhibitor compound. In some embodiments, the isolated population contains RNAs. In some embodiments, the isolated population contains cDNAs. In some embodiments, the referred-to HDAC inhibitor is PCI-24781. In some embodiments, the referred-to cancer cell was isolated from a population of cells grown in vitro. In some embodiments, the cancer cell is a colon carcinoma cell. In some embodiments, the colon carcinoma cell is derived from colon carcinoma R1059261097, R4498160614, R5456781761, R7424107588, or R094831 1023. In some embodiments, the nucleotide sequences of at least four of DEFA6, ITGB4, TM4SF4, SYK, PPAP2C,

RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl 1 ABCC3, TPMT, IL18, or DPEPl are represented in the isolated population of nucleic acids.

[0009] In some embodiments provided herein is a kit comprising the above referred-to isolated population of nucleic acids and an insert indicating the ratio of a biomarker gene nucleic acid level in the population to an internal expression control gene nucleic acid level in the population. [0010] In some embodiments provided herein is a kit comprising the above referred-to isolated population of nucleic acids and an insert indicating the ratio of a biomarker gene nucleic acid level in the population to a nucleic acid level of the biomarker gene in a population of nucleic acids derived from a cancer cell, wherein the cancer cell is a type of cancer cell that is sensitive to the HDAC inhibitor compound.

[0011] In another aspect provided herein is a method for generating an expression level reference population of nucleic acids for expression profiling, comprising deriving an isolated population of nucleic acids from a cancer cell, wherein the cancer cell is a type of cancer cell that is sensitive to an HDAC inhibitor compound. In some embodiments, the isolated population contains RNAs. In some embodiments, the isolated population contains cDNAs. hi some embodiments, the just-referred to HDAC inhibitor compound is PCI-24781. In some embodiments, the cancer cell is present in a biopsy sample. In some embodiments, the cancer cell is present in a population of cells grown in vitro. In some embodiments, the cancer cell is a colon carcinoma cell. In some embodiments, the carcinoma cell is derived from colon carcinoma R1059261097, R4498160614, R5456781761, R7424107588, or R0948311023. In some embodiments, the nucleotide sequences of at least four of DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl , TM4SF4, PTPN3, EPHA2, FGFBPl , ABCC3, TPMT, IL18; or DPEPl are represented in the above referred-to isolated population of nucleic acids. In some embodiments, the method further comprises determining, prior to the isolating step, that the type of cancer cell is sensitive to an HDAC inhibitor compound, hi some embodiments, the type of cancer cell determined to be sensitive to an HDAC inhibitor compound HDAC inhibitor compound in vitro. In some embodiments, the HDAC inhibitor compound is PCI-24781.

[0012] In a related aspect provided herein is a method for generating an expression level reference sample for expression profiling, comprising deriving an isolated population of nucleic acids from a cancer cell, wherein the cancer cell is a type of cancer cell that is resistant to an HDAC inhibitor compound, hi some embodiments, the isolated population contains RNAs. In some embodiments, the isolated population contains cDNAs. In some embodiments, the just-referred to HDAC inhibitor compound is PCI-24781. In some embodiments, the cancer cell is present in a biopsy sample. In some embodiments, the cancer cell is present in a population of cells grown in vitro. In some embodiments, the cancer cell is a colon carcinoma cell. In some embodiments, the carcinoma cell is derived from colon carcinoma R1059261097, R4498160614, R5456781761, R7424107588, or R094831 1023. In some embodiments,, the nucleotide sequences of at least four of

DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT 1 IL18, or DPEPl are represented in the above referred-to isolated population of nucleic acids. In some embodiments, the method further comprises determining, prior to the isolating step, that the type of cancer cell is resistant to an HDAC inhibitor compound. In some embodiments, the type of cancer cell determined to be resistant to an HDAC inhibitor compound HDAC inhibitor compound in vitro. In some embodiments, the HDAC inhibitor compound is PCI- 24781.

[0013] In another aspect provided herein is a human cancer cell line that is resistant to an

HDAC inhibitor compound in vitro. In some embodiments, the human cell line expresses DEF A6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl , ABCC3, TPMT, ILl 8, and DPEPl . In some embodiments, the HDAC inhibitor compound to which the referred-to human cancer cell line is resistant is PCI 24781. In some embodiments, the PCI 24781 -resistant human cancer cell line is resistant to a PCI 24781 concentration of at least about 1 μM. In some embodiments, the human cancer cell line is a colon carcinoma cell line. In some embodiments, the colon carcinoma cell line is R5247682266, R9866135153-, R1O781O31 14, or R4712781606.

[0014] In a further aspect provided herein is a method for increasing the likelihood of therapeutically effective treatment of a cancer with an HDAC inhibitor, comprising providing an indication that a cancer in a patient is sensitive.to treatment with an HDAC inhibitor if expression levels of at least four biomarker genes in a sample from the patient's cancer are lower than expression level threshold values for the four biomarker genes, or providing an indication that the cancer is resistant to treatment with the HDAC inhibitor if the expression levels of the biomarker genes are higher than the expression level threshold values, wherein the at least four biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl, CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT12, TPKl, DEF A6, EPLIN, CLIC5, PERP, SYK, SLC12A2,

GUCY2C, TM4SF4, TGFA, FGFBPl, PTK6, EVAl, EPHA2, ITGA6, TNFRSF21, TM4SF3, ILl 8, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCL15, DPEPl, NOXOl, IFI27, CYP3A43, and PKP2, whereby the likelihood of therapeutically effective treatment of the cancer with the HDAC inhibitor is increased. In some embodiments, the indication is provided in a digital medium. In some embodiments, the indication is provided in a hardcopy medium. In some embodiments, the indication is a biomedical publication reference. In some embodiments, the indication refers to expression levels of at least two of the biomarker genes. In some embodiments, the at least four biomarker genes include DEF A6, RAB25, TM4SF4, or ILl 8. In some embodiments, the at least four biomarker genes include DEFA6, ITGB4, TM4SF3, SYK, PPAP2C, and RAB25. In some embodiments, the at least four biomarker genes include DEF A6, ITGB4, TM4SF4, SYK,

PPAP2C, RAB25, HEPH, NOXOl , TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, IL18, and

DPEPl . In some embodiments, the cancer is colon cancer. In some embodiments, the HDAC inhibitor is PCI-24781.

[0015] In yet another aspect provided herein is a method for optimizing selection of an anti- cancer-agent for treating a cancer in combination with an HDAC inhibitor compound, by: (i) comparing a first set of biomarker genes the expression of which is correlated to resistance or sensitivity of the cancer to the anti-cancer agent to a second set of biomarker genes the expression of which is correlated with resistance to the HDAC inhibitor compound; and (ii) selecting the anticancer agent for treatment of the cancer in combination with the HDAC inhibitor if the biomarker genes in the first set are different from the biomarker genes in the second set, where the biomarker genes in the second set are DEF A6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl ,

TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, IL18, and DPEPl . In some embodiments, the method further comprises comparing the expression level of the second set of biomarker genes in a plurality of cancer cells treated with the HDAC inhibitor together with a second anti-cancer agent. [0016] In a further aspect provided herein is an indication of the likelihood of a therapeutically effective treatment of a cancer with an HDAC inhibitor compound, comprising a means of communicating an interpretation of expression levels of at least four biomarker genes selected from DEF A6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl , TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, IL18, and DPEP. In some embodiments, the indication further comprises the expression levels of the at least four biomarker genes. In some embodiments, the means of communicating is a paper document or an electronic document. In some embodiments, the interpretation includes a biomedical publication reference. In some embodiments, the interpretation includes a graph. In some embodiments, the interpretation includes information that indicates that a cancer in a patient is sensitive to treatment with an HDAC inhibitor if expression levels of the biomarker genes in a sample from the patient's cancer are lower than expression level threshold values for the four biomarker genes, or information that indicates that the cancer is resistant to treatment with the HDAC inhibitor if the expression levels of the biomarker genes are higher than the expression level threshold values.

[0017] In another aspect provided herein is a method for determining the likelihood of effectively treating a cancer in a patient with an HDAC inhibitor compound, comprising: (i) determining in the cancer the expression levels of at least four biomarker genes selected from

DEFA6, 1TGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl , ABCC3, TPMT, IL 18, and DPEP; and (ii) comparing the expression levels of that at least four biomarker genes in the cancer to expression levels of the at least four biomarker genes in an expression level reference sample derived from cancer cells previously determined to be resistant to the HDAC inhibitor compound, wherein the likelihood of effectively treating the cancer is higher if the expression level of the at least four biomarkers in the cancer from the patient is lower than the expression levels of the biomarker genes in the expression level reference sample. In some

embodiments, the method further comprises selecting an anti-cancer agent other than an HDAC inhibitor compound for treating the cancer.

|0018| Tn yet another aspect provided herein is a method for classifying a cancer in a patient, comprising comparing the expression levels of at least four biomarker genes in the cancer to to a first or second set of expression level values for the biomarker genes, and for each comparison assigning a probability to the biomarker gene expression level that the cancer in the patient is resistant to a histone deacetylase inhibitor compound, where: (i) the first set of expression level values were measured in cancer cells determined to be resistant to the histone deacetylase inhibitor compound; (ii) the second set of expression level values were measured in cancer cells determined to be sensitive to the histone deacetylase inhibitor compound; (iii) the assigned probability is inversely proportional to a negative deviation of the biomarker gene expression level from the first set of expression level values and directly proportional to a positive deviation of the biomarker gene expression level from the second set of expression level values; and (iv) the at least four biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl, CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT12, TPKl, DEFA6, EPLIN, CLIC5, PERP, SYK, SLC12A2, GUCY2C, TM4SF4, TGFA, FGFBPl , PTK6, EVAl , EPHA2, ITGA6, TNFRSF21, TM4SF3, IL 18, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCL15, DPEPl, NOXOl, IFI27, CYP3A43, and PKP2. [0019] In another aspect provided herein is a method for classifying a population of cells, comprising comparing the expression levels of at least four biomarker genes in the population of cells to a first or second set of expression level threshold values for the biomarker genes, and indicating that the population of cells is sensitive to a HDAC inhibitor if the expression levels of the biomarker genes are lower than the first set of expression level threshold values, or indicating that the population of cells is resistant to a HDAC inhibitor if the expression levels are greater than the second set of expression level threshold values, wherein the at least four biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl, CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT12, TPKl, DEFA6, EPLIN, CLIC5, PERP, SYK, SLC12A2, GUCY2C, TM4SF4, TGFA, FGFBPl, PTK6, EVAl, EPHA2, ITGA6, TNFRSF21, TM4SF3, IL 18, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCL15, DPEPl, NOXOl, IFI27, CYP3A43, and PKP2. [0020] In another aspect provided herein is a method for determining HDAC inhibition in vivo, comprising determining the expression level of an HDAC inhibitor-responsive biomarker gene in a biological sample obtained from a subject after the subject had been administered an HDAC inhibitor compound, wherein the HDAC inhibitor-responsive biomarker genes are any of the genes listed in Table 5.

[0021] In another aspect provided herein is a method for determining the most responsive tissues and the tumors derived therefrom to an HDAC inhibitor, comprising: (i) providing a first tissue of the tissue type (including blood) at a first time point and administration of HDAC inhibitor compound to the first tissue by any applicable route at a first time point, (ii) providing a second tissue of the tissue type (including blood) at a second time point and administration of HDAC inhibitor compound to the second tissue by any applicable route at a second time point, and (iii) determining expression profiles in the first and second tissues for any of the genes listed in Table 5. (0022] In a further aspect provided herein is a method for classifying one or more cells, comprising determining the expression levels of no more than four to fifty biomarker genes in the one or more cells, wherein at least four of the biomarker genes are selected from PTPN3, ABCC3,

SARG, PPAP2C, NPDCl , CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNTl 2, TPKl, DEFA6, EPLIN, CLIC5, PERP, SYK, SLC12A2, GUCY2C, TM4SF4, TGFA, FGFBPl , PTK6, EVAl, EPHA2, ITGA6, TNFRSF21, TM4SF3, IL18, BMP4, SMPDL3B, TMPRSS2, GDA, MSTl R, ITGB4, ANXA3, CCL15, DPEPl, NOXOl, IFI27, CYP3A43, and PKP2. In some embodiments, the method further comprises comparing the expression levels of the four to fifty biomarker genes to a first or second set of expression level threshold values for the biomarker genes, and indicating that the cancer is sensitive to a HDAC inhibitor if the expression levels of the biomarker genes are lower than the first set of expression level threshold values, or indicating that the cancer is resistant to a HDAC inhibitor if the expression levels are greater than the second set of expression level threshold values. In some embodiments, the one or more cells are cancer cells. In some embodiments, the at least four biomarker genes are selected from DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl , TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, ILl 8, and DPEP. In some embodiments, the method further comprises determining determining the expression levels of no more than four to twenty biomarker genes. In some embodiments, the method comprises determining the expression levels of no more than four biomarker genes. In some embodiments, the four biomarker genes consist of DEFA6, RAB25, TM4SF4, and ILl 8. [0023] In yet another aspect provided herein is a nucleic acid hybridization array comprising nucleic acid probes that hybridize under high stringency hybridization conditions to nucleic acids of no more than four to fifty biomarker genes, wherein at least four of the biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl, CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT 12, TPKl, DEF A6, EPLIN, CLIC5, PERP, SYK, SLCl 2 A2, GUCY2C, TM4SF4, TGFA, FGFBPl , PTK6, EVAl , EPHA2, ITGA6, TNFRSF21, TM4SF3, ILl 8, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCLl 5, DPEPl , NOXOl , IFI27, CYP3A43, and PKP2. In some embodiments, the nucleic acid hybridization array comprises at least four biomarker genes selected from DEF A6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl , TM4SF4,

PTPN3, EPHA2, FGFBPl , ABCC3, TPMT, IL18, and DPEP. In some embodiments, the at least four biomarker genes consist of DEFA6, RAB25, TM4SF4, and ILl 8.

[0024] It is to be understood that the methods and compositions described herein are not limited to the particular methodology, protocols, cell lines, constructs, and reagents described herein and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the methods and compositions described herein, which will be limited only by the appended claims.

[0025] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly indicates otherwise.

|0026] The term "biomarker gene" refers to a gene whose expression or activity yields at least one expression product the level of which is quantitatively correlated to a phenotypic state of interest (e.g., drug resistance, pathology).

[0027| The term "detectable label" refers to a label which is observable using analytical techniques including, but not limited to, fluorescence, chemiluminescence, electron-spin resonance, ultraviolet/visible absorbance spectroscopy, mass spectrometry, nuclear magnetic resonance, magnetic resonance, and electrochemical methods. [0028| The terms "differentially expressed gene," "differential gene expression," and their synonyms, which are used interchangeably, refer to a gene whose expression is upregulated or downregulated in a first cell population relative to the expression of the same gene in a second population of cells. Such differences are evidenced by, e.g., a change in mRNA levels, surface expression, secretion or other partitioning of a polypeptide. Differential gene expression includes, in some embodiments, a comparison of expression between two or more genes or their gene products, or a comparison of the ratios of the expression between two or more genes or their gene products, or even a comparison of two differently processed products of the same gene, which differ between two populations of cells. Differential expression includes both quantitative, as well as qualitative, differences in the temporal or cellular expression pattern in a gene or its expression products among, for example, normal and diseased cells, or among cells which have undergone different disease events or disease stages, or cells that are significantly sensitive or resistant to certain therapeutic drugs. [0029] The term "fluorophore" refers to a molecule which upon excitation emits photons and is thereby fluorescent. [0030] The phrase "gene amplification" refers to a process by which multiple copies of a gene or gene fragment are formed in a particular cell or cell line. The duplicated region (a stretch of amplified DNA) is often referred to as "amplicon." Frequently, the amount of the messenger RNA (mRNA) produced, i.e., the level of gene expression, also increases in proportion to the number of copies made of the particular gene. [0031] The term "gene expression profiling," unless otherwise specified, is used in the broadest sense, and includes methods of quantification of a gene's mRNA or nucleic acids derived therefrom, and/or protein levels or peptides derived therefrom and/or protein functions in a biological sample.

(0032] The term "high stringency hybridization" refers to hybridization conditions of incubating at 68 0 C for an hour, followed by washing 3 times for 20 minutes each at room temperature in 2X SSC and 0.1% SDS and twice at 50 0 C in 0.1X SSC and 0.1% SDS, or any art-recognized equivalent hybridization conditions. [0033] The term "internal expression control gene" refers to a gene the expression level of which is known to or expected to be very similar in cells that differ in one or more phenotypes, or which have been subjected to differing experimental treatments. For example, the expression of the gene HDAC3 is shown to be to very similar in colon cancer cells that are resistant or sensitive to treatment with an FTDACi compound. [0034] The term "isolated" refers to separating and removing a component of interest from components not of interest. Isolated substances are optionally in either a dry or semi-dry state, or in solution, including but not limited to an aqueous solution. The isolated component is optionally in a homogeneous state or the isolated component is optionally a part of a pharmaceutical composition that comprises additional pharmaceutically acceptable carriers and/or excipients. Purity and homogeneity are determined, for example, using analytical chemistry techniques including, but not limited to, polyacrylamide gel electrophoresis or high performance liquid chromatography. In addition, when a component of interest is isolated and is the predominant species present in a preparation, the component is described herein as substantially purified. The term "purified," as used herein, refers to a component of interest which is at least 85% pure, at least 90% pure, at least 95% pure, at least 99% or greater pure. By way of example only, nucleic acids or proteins are "isolated" when such nucleic acids or proteins are free of at least some of the cellular components with which it is associated in the natural state, or that the nucleic acid or protein has been concentrated to a level greater than the concentration of its in vivo or in vitro production. [0035] The term "label" refers to a substance which is incorporated into a compound and is readily detected, whereby its physical distribution is detected and/or monitored.

|0036] The term "microarray" refers to an ordered arrangement of hybridizable array elements, preferably polynucleotide probes, on a substrate.

|0037| The term "nucleic acid" or "nucleic acid probe," when used in singular or plural, generally refers to any polyribonucleotide or polydeoxribonucleotide, which includes unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, nucleic acids as defined herein include, without limitation, single- and double-stranded DNA, DNA including single- and double-stranded regions, single- and double-stranded RNA, and RNA including single- and double-stranded regions, hybrid molecules comprising DNA and RNA that are optionally single-stranded or, more typically, double-stranded or include single- and double-stranded regions. In addition, the term "nucleic acid" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions are optionally from the same molecule or from different molecules. The regions optionally include all of one or more of the molecules, but more typically involve only a

region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. The term "nucleic acid" specifically includes cDNAs. The term includes DNAs (including cDNAs) and RNAs that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "nucleic acids" as referred to herein. DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritiated bases, are included within the term "nucleic acid" as defined herein. In general, the term "nucleic acid" embraces all chemically, enzymatically and/or metabolically modified forms of unmodified polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells. (0038) The term "oligonucleotide" refers to a relatively short polynucleotide, including, without limitation, single-stranded deoxyribonucleotides, single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are often synthesized by chemical methods, for example using automated oligonucleotide synthesizers that are commercially available. However, oligonucleotides are optionally made by a variety of other methods, including in vitro recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms.

|0039] The terms "prediction," "predicting," "prognostic," or "prognosis" are used herein to refer to the likelihood that a patient will respond either favorably or unfavorably to a drug (e.g., an anti-cancer compound) or set of drugs, and also the extent of those responses. The predictive methods of described herein are valuable tools in predicting if a patient suffering from a cancer is likely to respond favorably to an HDAC inhibitor compound treatment regimen alone or in combination with another therapeutic agent (e.g., a second anti-cancer compound).

[0040] The term "subject" or "patient" refers to an animal which is the object of treatment, observation or experiment. By way of example only, a subject includes, but is not limited to, a mammal including, but not limited to, a human.

|0041] The term "substantially purified" refers to a component of interest that is substantially or essentially free of other components which normally accompany or interact with the component of interest prior to purification. By way of example only, a component of interest is "substantially purified" when the preparation of the component of interest contains less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% (by dry weight) of contaminating components. Thus, a "substantially purified" component of interest optionally has a purity level of about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or greater.

[0042] The term "therapeutically effective amount" refers to the amount of a composition administered to a patient already suffering from a disease, condition or disorder, sufficient to cure or at least partially arrest, or relieve to some extent one or more of the symptoms of the disease, disorder or condition being treated. The effectiveness of such compositions depend conditions including, but not limited to, the severity and course of the disease, disorder or condition, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician. By way of example only, therapeutically effective amounts are determined by methods, including but not limited to a dose escalation clinical trial. [0043] The terms "treat," "treating" or "treatment," include alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition,, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition. The terms "treat," "treating" or "treatment", include, but are not limited to, prophylactic and/or therapeutic treatments.

[0044] The term "tumor" or "cancer" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. [0045] Unless otherwise indicated, conventional methods of cell culture, protein chemistry, biochemistry, recombinant DNA techniques including gene amplification and hybridization techiques, mass spectroscopy, and pharmacology, are employed.

BRIEF DESCRIPTION OF THE DRAWINGS

[0046] FIG. 1 is an illustrative schematic flow diagram of a method for identifying biomarker genes for HDACi compound.resistance in cancer cells based on gene expression profiling, and the clinical application of expression profiling of the identified biomarker genes.

[0047] FIG. 2 is an illustrative graph showing in vitro inhibition of cell proliferation versus concentration of the HDACi compound PCI-24781 for a series of colon carcinoma cell lines. [0048] FIG. 3 is an illustrative flow diagram illustrating the statistical approach used to analyze microarray data to identify differentially expressed genes in populations of cancer cells resistant to a HDACi compound versus cancer cells that are sensitive to the compound.

[0049] FIG. 4 is an illustrative scatter plot illustrating principal component analysis of gene expression microarray data in HDACi compound-treated and untreated cancer cells, and sensitive and resistant cancer cells. [0050] FIG. 5 is an illustrative bar graph comparing the results of a microarray method versus TaqMan* quantitative RT-PCR method for determining the ratio of mRNA expression levels for a series of identified HDACi compound resistance biomarker genes in PCI-24781 -resistant versus PCI-24781 colon carcinoma cells.

[0051] FIG. 6 is an illustrative bar graph comparing relative expression levels of four

HDACi compound resistance biomarker genes in cancer cells that are resistant to the HDAC inhibitor compound (PCI-24781) versus expression of the biomarker genes in cancer cells that are sensitive to the compound. [0052] FIG. 7 (A) is an illustrative bar graph showing the time course of tubulin acetylation in peripheral blood mononuclear cells from mice treated with the HDAC inhibitor compound PCI- 24781 ; (B) is a time course of the expression profile of genes whose mRNA levels are correlated with changes in tubulin acetylation. [0053) FIG. 8 is an illustrative set of two line graphs illustrating the expression profiles of two HDAC inhibitor-responsive biomarker genes as determined by microarray analysis, quantitative RT-PCR, and immunoblotting.

[0054] FIG. 9 is an illustrative bar graph showing average in vivo mRNA levels in various tissues of five of the HDAC inhibitor-responsive biomarker genes at 3 and 8 hours post-HDAC inhibitor treatment. [0055] FIG. 10 is an illustrative series of dose response curves for the effect of the HDAC inhibitor PCI-24781 on tumors derived from the indicated tumors.

[0056] FIG. 1 1 (A) is a series of line graphs illustrating the amount of in vitro growth inhibition by the HDAC inhibitor PCI-24781 of primary colon tumor cells derived from newly diagnosed, naive colon cancer patients; (B) is a series of line graphs illustrating the amount of HI vitro growth inhibition by the HDAC inhibitor PCI-24781 of colon cancer cells derived from patients having advanced, metastatic colon tumors; (C) is a bar graph illustrating the correlation between tumor cell resistance to an HDAC inhibitor HI vitro and the mRNA expression level of the HDAC resistance biomarker gene DEFA6.

DETAILED DESCRIPTION OF THE INVENTION [0057] The methods described herein include classifying a cancer in a patient as resistant or sensitive to a histone deacetylase inhibitor (HDACi) compound by comparing the expression levels of at least four biomarker genes expressed in the cancer to biomarker gene expression level threshold values, as described herein. Where the expression levels of at least four biomarker genes are greater than the expression level threshold values, the cancer is indicated as being resistant to the HDACi compound. Conversely, if the expression levels of the at least four biomarker genes are lower than the expression level threshold values, the cancer is indicated to be sensitive to the HDACi compound. |0058] Also described herein is a population of nucleic acids derived from a cancer cell, where the cancer cell is a type of cancer cell that is resistant to an HDACi compound. Further described herein is a population of nucleic acids derived from a cancer cell, where the cancer cell is a type of cancer cell that is sensitive to an HDACi compound. Also described herein are methods for generating these populations of nucleic acids. Such populations of nucleic acids are optionally used as

expression level reference standards for setting biomarker gene expression threshold levels as described herein. Further described herein are cell lines determined to be resistant to an HDACi compound. Also described herein are cell lines determined to be sensitive to an HDACi compound. |0059] Also described herein is a method for increasing the likelihood of therapeutically effective treatment of a cancer with an HDACi compound by providing an indication that a cancer is sensitive to treatment with an HDACi compound if the expression levels of at least four of the biomarker genes described herein are lower than the expression level threshold values for those biomarker genes, or providing an indication that a cancer is resistant to treatment with an HDACi compound if the expression levels of at least four of the biomarker genes described herein are higher than the expression level threshold values for those biomarker genes.

[0060] Further described herein are methods for optimizing selection of an anti-cancer agent for treating cancer in combination with an HDACi compound by comparing a first set of biomarker genes the expression of which is correlated to resistance or sensitivity of the cancer to the anti-cancer agent to a second set of biomarker genes the expression of which is correlated with resistance to the HDACi compound, and then selecting the anti-cancer agent for treatment of the cancer in combination with the HDAC inhibitor only if all of the biomarker genes in the first set are different from the biomarker genes in the second set.

Identification of HDACi compound resistance biomarker genes (HDACiR-BGs) [0061] Described herein are methods for identifying genes whose expression levels in cancer cells are significantly and consistently correlated with resistance of the cells to an HDACi compound.

Such genes are termed HDACi compound resistance biomarker genes (HDACiR-BGs). In an exemplary embodiment, HDACiR-BGs are identified as follows.

]0062] The ex-vivo response of primary tumor cells (e.g., colon cancer cells) from various patients to an HDAC inhibitor is determined by culturing the cells in the presence of varying concentrations of the HDACi compound.

[0063] After determining the HDACi compound sensitivity the cancer cells from each patient, mRNA expression profiles are determined for HDACi-resistant and sensitive tumors. Total

RNA is isolated and fluorescent probes are prepared and hybridized to a whole genome cDNA microarray (e.g., Codelink Human Whole Genome oligonucleotide microarrays containing ~55,OOO unique probes; GE Healthcare Bio-Sciences Corp., Piscataway, NJ) according to the manufacturer's instructions. Following hybridization, the microarrays are scanned (e.g., in a GenePix 4000B scanner;

Molecular Devices Corporation, Sunnyvale CA). The images are then processed with Codelink software and the data are normalized to the median.

(0064] The median-normalized microarray data are imported into a microarray data analysis program for principal component analysis (PCA) and hierarchical clustering analysis (e.g., Genespring software from Agilent). Multiple analysis methods are employed to provide additional confidence in the mRNA expression analysis. For multiple hypothesis correction, the q-values approach for false discovery rates (FDR) are optionally used as described in Storey et al. (2003), Proc. Nat. Acad. ScL USA, 100:9440-9445. As a second analytical approach the Bayesian ANOVA approach described in Ishwaran et al. (2003), J. Amer. Stat. Assoc, 98:438-455 is optionally used. [0065] In the Bayesian ANOVA method, the contributions of irrelevant genes to the

ANOVA model are selectively shrunk to balance total false detections against total false non- detections. The output is a Zcut score which identifies genes whose contribution to the ANOVA model is larger than the standard z-score. See Ishwaran et al., ibid., and the website at bamarray.com. [0066] The just-described method and variants thereof is optionally used to identify biomarker genes for other specific phenotypic states, e.g., resistance to anti-cancer agents other than HDACi compounds.

[0067] HDACiR-BGs identified by the just-described methods include those listed in Table

1. The sequence for the mRNA of each of the listed genes is included herein in an appendix .

Classification of individual patient cancers as resistant or sensitive to an HDACi compound [0068] In some embodiments, gene expression profiling is performed on a biological sample obtained from an individual patient suffering from a cancer (e.g., a colon cancer tumor) to classify the cancer in the patient as resistant or sensitive to an HDACi compound. The gene expression profiling includes profiling the expression of at least one of the HDACi compound resistance biomarker genes (HDACiR-BGs) listed in Table 1, which were identified as described herein. [0069| In some embodiments the HDACiR-BG is selected from among DEF A6, TM4SF4,

TGFA, FGFBPl, EPH A2, TNFRSF2, TM4SF3, IL 18, TMPRSS2, and CCLl 5. [0070] In some embodiments, at least four of the HDACiR-BGs are expression profiled. In some embodiments, at least one of the four HDACiR-BGs are selected from among DEF A6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl , TM4SF3, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, ILl 8, or DPEPl . In some embodiments, all of the at least four HDACiR-BGs are selected from among DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF3, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, IL18, or DPEPl .

[0071] In some embodiments, the expression of at least sixteen of the HDACiR-BGs is profiled. In some embodiments, the at least sixteen HDACiR-BGs include one or more of DEFA6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF3, PTPN3, EPHA2, FGFBPl , ABCC3, TPMT, ILl 8, or DPEPl . In some embodiments, the at least 16 HDACiR-BGs include DEF A6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl , TM4SF3, PTPN3, EPHA2, FGFBPl , ABCC3, TPMT, IL18, or DPEPl.

|0072] In various embodiments, the types of cancers and tumors that are optionally classified

(from individual patients) for resistance or sensitivity to an HDACi compound include, but are not limited to, colorectal cancer, ovarian cancer, pancreatic cancer biliary tract cancer; bladder cancer; bone cancer; brain and CNS cancer; breast cancer; cervical cancer; choriocarcinoma; connective

tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer, cancer of the head and neck; gastric cancer; intra-epithelial neoplasm; kidney cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small cell and non-small cell); lymphoma including Hodgkin's and non-Hodgkin's lymphoma; melanoma; myeloma; neuroblastoma; oral cavity cancer (e.g., lip, tongue, mouth, and pharynx); prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; renal cancer; cancer of the respiratory system; sarcoma; skin cancer; stomach cancer; testicular cancer; thyroid cancer; uterine cancer; cancer of the urinary system, as well as other carcinomas and sarcomas. [0073| Types of cancer cells that are optionally classified in various embodiments include, but are not limited to, squamous cell papilloma, squamous cell carcinoma, basal cell tumor, basal cell carcinoma, transitional cell papilloma, transitional cell carcinoma, glandular epithelium adenoma, melanocytes glomus tumor, melanocyte nevus, malignant melanoma, fibroma, fibrosacroma, an adenocarcinoma, gastrinoma, malignant gastrinoma, an oncocytoma, cholangiocellular adenoma, cholangiocellular carcinoma, hepatocellular adenoma, hepatocellular carcinoma, renal tubular adenoma, renal cell carcinom(Grawitz tumor), myxoma, myxosarcoma, lipoma, liposarcoma, leiomyoma, leiomyosarcoma, rhabdomyoma, rhabdomyosarcoma, benign teratoma, malignant teratoma, hemangioma, hemangiosarcoma, Kaposi sarcoma, lymphangioma, lymphangiosarcoma, an osteoma, an osteosarcoma, an osteogenic sarcoma, cartilage chondroma, chondrosarcoma, meninges meningioma, malignant meningioma, oligoastrocytoma, an ependymoma, an astrocytoma, pilocytic astrocytoma, glioblastommultiforme, an oligodendroglioma, neuroblastoma, schwanoma, retinoblastoma, or neurofibroma. Other types of cancers and tumors include those described in reference sources, e.g., the "International Classification of Diseases for Oncology," 3rd Edition, International Association of Cancer Registries. [0074] A biological sample is any biological sample that includes cellular material from which DNA, RNA or protein are optionally isolated, e.g., solid tissue samples, such as a biopsy specimen or tissue cultures or cells derived therefrom and the progeny thereof, blood and other liquid samples of biological origin, e.g., sputum (including saliva, buccal wash, or bronchial brush), stool, semen, urine, ascitic fluid, cerebral spinal fluid, bladder wash, or pleural fluid. The term "biological sample" also encompasses samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components. The term encompasses a clinical sample, and also includes cells in cell culture, cell supernatants, cell lysates, serum, plasma, biological fluids, and tissue samples, e.g, freshly collected tissue, frozen tissue, archived tissue, orbiological fluids [0075] In some embodiments, the biological sample is a tumor biopsy (e.g., a core biopsy, a needle biopsy, or an excisional biopsy) containing one or more cancer cells. In one embodiment the biological sample is a population of cancer cells obtained by laser capture dissection from a tumor tissue section as described in, e.g., U.S. Patent No. 6,040,139. Methods for optimizing tissue sample

preparation and processing for expression profiling include, e.g., Bova el al. (2005), Methods MoI. Med., 103: 15-66.

[00761 In some embodiments, one or more cells (e.g., from a cultured cancer cell line), are classified by determining the expression levels of no more than four to fifty biomarker genes described herein., e.g., 5, 6, 7, 8, 9, 10, 12, 16, 18, 20, 24, 30, 32, 35, 40, 44, 45, 47, or any other number of biomarker genes from four to fifty. In some embodiments, four to fourty four of the biomarker genes are selected from Table 3, e.g., 5, 6, 7, 8, 9, 10, 12, 16, 18, 20, 24, 30, 32, 35, 40, or any other number of biomarker genes from four to fourty four is selected from Table 3. In some embodiments, at least four of the biomarker genes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl , CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT12, TPKl , DEFA6, EPLIN, CLIC5, PERP, SYK, SLC12A2, GUCY2C, TM4SF4, TGFA, FGFBPl, PTK6, EVAl, EPHA2, ITGA6, TNFRSF21, TM4SF3, IL18, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCL15, DPEPl, NOXOl, IFI27, CYP3A43, and PKP2. In some embodiments, the four to fifty biomarker comprises one or more genes selected from DEF A6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, IL18, and DPEP In some embodiments, classification of the cells comprises comparing the determined expression levels to a first or second set of expression level threshold values for the biomarker genes, and indicating that the one or more cells are sensitive to a HDAC inhibitor if the expression levels of the biomarker genes are lower than the first set of expression level threshold values, or indicating that the one or more cells are resistant to a HDAC inhibitor if the expression levels are greater than the second set of expression level threshold values. In some embodiments, the expression of no more than four to twenty biomarker genes is determined. In some embodiments, the expression levels of no more than four biomarker genes is determined. In some embodiments, the four biomarker genes the expression level of which is determined are: DEF A6, RAB25, TM4SF4, and IL 18. Methods for HDACiR-BG Expression Profiling

|0077] HDACiR-BG expression profiles are optionally generated by any convenient means for determining differential gene expression between two samples, e.g. quantitative hybridization of mRNA, labeled mRNA, amplified mRNA, cRNA, etc., quantitative PCR, ELISA for protein quantitation, and the like. [0078] In some embodiments, HDACiR-BG mRNA levels (including cDNA copy or aRNA copies) are quantified. The expression profile is optionally generated from the initial nucleic acid sample using any convenient protocol. While a variety of different manners of generating expression profiles are known, such as those employed in the field of differential gene expression analysis, one representative and convenient type of protocol for generating expression profiles is array based gene expression profile generation protocols. Such applications are hybridization assays in which a nucleic acid that displays "probe" nucleic acids for each of the genes to be assayed/profiled in the profile to be generated is employed. In these assays, a sample of target nucleic acids is first prepared from the

initial nucleic acid sample being assayed, where preparation optionally includes labeling of the target nucleic acids with a label, e.g., a member of signal producing system. Following target nucleic acid sample preparation, the sample is contacted with the array under hybridization conditions, whereby complexes are formed between target nucleic acids that are complementary to probe sequences attached to the array surface. HDACiR-BG hybridization complexes are then detected and quantified. [0079] Specific hybridization technologies which are optionally practiced to generate the

HDACiR-BG expression profiles employed in the methods described herein includes the technology described in U.S. Pat. Nos. 5,143,854; 5,288,644; 5,324,633; 5,432,049; 5,470,710; 5,492,806; 5,503,980; 5,510,270; 5,525,464; 5,547,839; 5,580,732; 5,661,028; 5,800,992; as well as WO 95/21265; WO 96/31622; WO 97/10365; WO 97/27317; EP 373 203; and EP 785 280. In these methods, an array of "probe" nucleic acids that includes a probe for each of the phenotype determinative genes whose expression is being assayed is contacted with target nucleic acids as described above. Contact is carried out under hybridization conditions, e.g., stringent hybridization conditions as those conditions are practiced in the art, and unbound nucleic acid is then removed. The resultant pattern of hybridized nucleic acid provides quantitative information regarding expression for each of the HDACiR-BGs that have been probed.

[0080] Evaluation of differences in expression values is optionally performed using any convenient methodology, e.g., by comparing digital images of the expression profiles, by comparing databases of expression data, etc. Patents describing ways of comparing expression profiles include, but are not limited to, U.S. Pat. Nos. 6,308,170 and 6,228,575 and U.S. Patent Application Serial No. 10/858,867.

[0081] In some embodiments, the methods described herein are performed on nucleic acid hybridization arrays comprising nucleic acid probes that hybridize under high stringency hybridization conditions to nucleic acids of no more than four to fifty biomarker genes, e.g., 5, 6, 7, 8, 9, 10, 12, 16, 18, 20, 24, 30, 32, 35, 40, 44, 45, 47, or any other number of biomarker genes from four to fifty. In some embodiments, four to fourty four of the biomarker genes are selected from Table 3, e.g., 5, 6, 7, 8, 9, 10, 12, 16, 18, 20, 24, 30, 32, 35, 40, or any other number of biomarker genes from four to fourty four is selected from Table 3. In some embodiments, at least four of the biomarker genes for the array probes are selected from PTPN3, ABCC3, SARG, PPAP2C, NPDCl , CTEN, RAB25, HEPH, TPMT, PKP3, GALNT5, CALML4, GALNT12, TPKl , DEF A6, EPLIN, CLIC5, PERP, SYK, SLCl 2 A2, GUC Y2C, TM4SF4, TGFA, FGFBPl, PTK6, EVAl, EPHA2, ITG A6, TNFRSF21, TM4SF3, IL18, BMP4, SMPDL3B, TMPRSS2, GDA, MSTlR, ITGB4, ANXA3, CCL15, DPEPl, NOXOl, IFI27, CYP3A43, and PKP2. In some embodiments, the at least four biomarker genes are selected from DEF A6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl , TM4SF4, PTPN3, EPHA2, FGFBPl, ABCC3, TPMT, IL18, and DPEP. In some embodiments, the at least four biomarker genes are DEF A6, RAB25, TM4SF4, and IL 18.

[0082] Alternatively, non-array based methods for quantitating the levels of one or more nucleic acids in a sample are employed, including quantitative PCR, and the like. [0083] In some embodiments, expression profiling of HDACiR-BGs expressed in a biological sample (e.g., a tumor biopsy) is done by a quantitative reverse transcription PCR assay (qRT-PCR). In this method, RNA from a biological sample is reverse transcribed to generate segments of cDNA which are then be amplified by gene-specific quantitative PCR. The rate of accumulation of specific PCR products is optionally correlated to the abundance of the corresponding RNA species in the original sample and thereby provide an indication of gene expression levels. (0084] In one embodiment, the qPCR assay is a TaqMan™ assay. In brief, PCR typically utilizes the 5' exonuclease activity of Taq or Tth polymerase to hydrolyze a fluorescently-labelled hybridization probe bound to its target amplicon, but any enzyme with equivalent 5' exonuclease activity is optionally used. Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction. A third oligonucleotide, or probe, is designed to hybridize to a nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is 5' labeled with a reporter fluorescent dye and a 3 1 labeled with a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe. During the amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner. The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second chromophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.

[0085] qRT-PCR is optionally performed using commercially available equipment, such as, for example, the ABI PRISM 7900™ Sequence Detection System™ (Perkin-Elmer-Applied Biosystems, Foster City, CA), or LightCycler™. (Roche Molecular Biochemicals, Mannheim,

Germany). In one embodiment, the 5' exonuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7900™ Sequence Detection System™ or one of the similar systems in this family of instruments. The system consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in 96-well or 384 well formats on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optic cables for all reaction wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.

[0086] Exonuclease assay data are initially expressed as a C τ value, i.e., the PCR cycle at which the fluorescent signal is first recorded as statistically significant.

[0087] In order to minimize errors and the effects of sample-to-sample variation and process variability mRNA level measurements are generally normalized to the expression level of an internal expression control gene. Methods for normalizing qPCR assays include, see, e.g., the website at normalisation.gene-quantification.info. The ideal internal expression control gene is one that is expressed at a relatively constant level among different patients or subjects, and is unaffected by the experimental treatment.

[0088| In some embodiments, the internal expression control gene is RNA polymerase II

(GenBank Accession No. X74870). [0089) In other embodiments, the internal expression control gene is HDAC3 (NM OO3883). [0090) In further embodiments, the internal expression control gene is ZNF217

(NM_006526).

[0091) In some embodiments, HDAiR-BG mRNA expression levels for each sample are normalized by the total amount of RNA in each sample. The amount of RNA in a sample is optionally determined, e.g., by UV-spectrophotometry or by using an RNA detection reagent, e.g., RiboGreen ® from Invitrogen (Carlsbad, CA).

[0092] Where the HDACiR-BG expression profile to be determined is a protein expression profile, any convenient protein quantitation protocol is optionally employed, where the levels of one or more proteins in the assayed sample are determined. Representative methods include, but are not limited to; proteomic arrays, mass spectrometry, or standard immunoassays (e.g., RIA or ELISA). See, e.g.. the methods set forth in R. Scopes, Protein Purification, Springer- Verlag, N. Y. (1982); Sandana (1997) Bioseparation of Proteins, Academic Press, Inc.; Bollag et al. (1996) Protein Methods. 2nd Edition Wiley-Liss, NY; Walker (1996) The Protein Protocols Handbook Humana Press, NJ, Harris and Angal (1990) Protein Purification: Principles and Practice 3rd Edition Springer Verlag, NY; Janson and Ryden (1998) Protein Purification: Principles, High Resolution Methods and Applications, Second Edition Wiley- VCH, NY; and Satinder Ahuja ed., Handbook ofBioseparations, Academic Press (2000); Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 353-355 (1988).

[0093) Proteomic expression profiling methods detection methods include various multidimensional electrophoresis methods (e.g., 2-D gel electrophoresis), mass spectrometry based methods e.g., SELDl, MALDI, electrospray, etc.), or surface plasmon reasonance methods. For example, in MALDI, a sample is usually mixed with an appropriate matrix, placed on the surface of a probe and examined by laser desorption/ionization. See, e.g., U.S. Pat. Nos. 5,045,694, 5,202,561, and 6,11 1,251. Similarly, for SELDI, a first aliquot is contacted with a solid support-bound (e.g., substrate-bound) adsorbent. A substrate is typically a probe (e.g., a biochip) that is optionally positioned in an interrogatable relationship with a gas phase ion spectrometer. SELDI has been applied to diagnostic proteomics. See, e.g. Issaq et al. (2003), Anal. Chem. 75: 149A-155A.

[0094] In one embodiment, any of the just-described protein detection methods are used to determine the expression level of one or more HDACiR-BG proteins that are known to be secreted proteins, e.g., DEFA6, TM4SF4, TM4SF3.TGFA, FGFBPl, EPHA2, TNFRSF2, IL18, CCL15, or TMPRSS2.

Expression Level Reference Samples

[0095] In some embodiments, expression profiles of HDACiR-BGs in a biological sample of interest (e.g., a colon cancer biopsy) are compared to HDACiR-BG expression profiles in an expression level reference sample. The expression level reference sample is a biological sample derived from one or more cancer patients determined to be suffering from a particular cancer or tumor for which sensitivity or resistance to treatment with an HDACi compound (e.g., PCI-24781) has been determined. In other words, the expression level reference sample serves as a standard with which to compare expression level values for each HDACiR-BG in a test sample. The deviation of HDACiR- BG expression levels from the expression level values in a reference sample indicates whether the cancer in the patient from the biological sample was derived is sensitive or resistant to treatment with an HDACi compound. In some embodiments, HDACiR-BG threshold expression level values are optionally set based on one or more statistical criteria for deviation from HDACiR-BG expression level values in an expression level reference sample, e.g., two or more SDs away from the value for a reference sample HDACiR-BG expression level. [0096] In some embodiments, the expression level reference sample is a "negative" reference sample, i.e., a sample derived from a patient having a cancer or tumor determined to be sensitive to an HDACi compound. Thus, where expression levels of multiple HDACiR-BGs (e.g. at least 4, 5, 6, 8, 10, 12, or 16) are significantly greater than the threshold expression level values based on the negative reference sample, the patient's cancer is indicated as resistant to the HDACi compound. [0097] In some embodiments, the expression level reference sample is a "positive" reference sample, i.e., a sample derived from a patient having a cancer or tumor determined to be resistant to an HDACi compound. Thus, where expression levels of multiple HDACiR-BGs (e.g. at least 4, 5, 6, 8, 10, 12, or 16) are significantly lower than the threshold expression level values based on the negative reference sample, the patient's cancer is indicated as sensitive to the HDACi compound. |0098] In some embodiments, HDACiR-BG expression profiles are compared to those in both positive and negative reference samples. .

|0099] In some embodiments, HDACiR-BGs expression level measurements are performed in parallel for the biological sample of interest and the (positive or negative) expression level reference. For example, where an array hybridization method is used, HDACiR-BG mRNA levels in the biological sample of interest and in an expression level reference sample are optionally measured simultaneously by separately labeling nucleic acid populations (e.g., mRNA, cDNA, aRNA

populations) from each with a detectably distinct fluorophore, and then hybridizing the fluorescently labeled nucleic acids to the same array.

[00100] In some embodiments an expression level reference sample is a population of nucleic acids (e.g., mRNAs, aRNAs, cDNAs, or aRNAs) derived from a cancer biopsy sample within which the sequences of at least four HDACiR-BGs are represented, and for which sensitivity to an HDACi compound has been determined. In some embodiments, the population of nucleic acids is derived from patient tumor cells cultivated in culture. In other embodiments, the population is derived directly from a biopsy without a cell culture step. [00101] In some, embodiments, the population of nucleic acids serving as an expression level reference sample is generated as follows. A cancer biopsy is obtained from a patient as described above, and afterwards viable tumors cells are then isolated and grown in culture as described in, e.g., Kern et al. (1990), J. Natl. Cancer Inst., 82:582-588. In order to determine if cancer cells are sensitive to an HDACi compound, they are then grown in the presence of the HDACi compound at a range of concentrations, e.g., (0-10 μM), and cell proliferation is measured by any number of methods, e.g., tritiated thymidine incorporation. Inhibition of tumor cell proliferation by the HDACi compound is measured relative to tumor cell proliferation in the absence of the compound (i.e., no inhibition). Assignment of the cancer as sensitive or resistant is optionally determined based on a number of cell proliferation criteria. For example, if the IC 50 of the HDACi compound in the tested cancer cells is significantly lower (e.g., by 2 SDs) than that observed for cells known to be sensitive to the compound, the cancer is characterized as resistant. Thus, cells derived from the resistant cancer (e.g., directly or after passage in culture) are optionally used to generate a population of nucleic acids serving as an expression level (positive) reference sample used for setting HDACiR-BG expression level threshold values as described above. Conversely, tumor cells found to be sensitive to an HDACi compound are used generate a population of nucleic acids serving as an expression level (negative) reference sample.

[00102] Methods for obtaining RNA from biological samples (e.g., tissues or cells) including linear aRNA amplification from single cells include, e.g., Luzzi et al. (2005), Methods MoI Biol., 293: 187-207. Further, diverse kits for high quality RNA purification are available commercially, e.g., from Qiagen (Valencia, CA), Invitrogen (Carlsbad, CA), Clontech (Palo Alto, CA), and Stratagene (La Jolla, CA).

[00103] In some embodiments, the expression level reference sample is an RNA sample isolated from one or more HDACi compound-resistant colon cancer cells. In one embodiment, the cells were derived from colon carcinoma biopsy R5247682266, R9866135153, R10781031 14, or R4712781606 described herein.

HDACi inhibitor Compounds

[00104] In another embodiment, HDACi inhibitor tumor compounds for which cancer resistance or sensitivity include, but are not limited to carboxylates, short-chain fatty acids, hydroxamic acids, electrophilic ketones, epoxides, cyclic peptides, and benzamides. In a further embodiment, HDACi inhibitor tumor compounds for which cancer resistance or sensitivity include, but are not limited to hydroxamic acids having the structure of Formula (A):

O

Q — L — C OR 1

N

H Formula (A) wherein

Q is an optionally substituted C 5 .i 2 aryl or an optionally substituted C 5 .n heteroaryl; L is a linker having at least 4 atoms; R 1 is H or alkyl; and a pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, pharmaceutically acceptable solvate thereof. [00105] HDACi inhibitor tumor compounds for which cancer resistance or sensitivity include, but are not limited to compounds having the structure of Formula (I):

Formula (I) wherein:

R 1 is hydrogen or alkyl;

X is -O-, -NR 2 -, or -S(O) n where n is 0-2 and R 2 is hydrogen or alkyl; Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkylsulfinyl, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy;

Ar 1 is phenylene or heteroarylene wherein said Ar 1 is optionally substituted with one or two groups independently selected from alkyl, halo, hydroxy, alkoxy, haloalkoxy, or haloalkyl; R 3 is hydrogen, alkyl, hydroxyalkyl, or optionally substituted phenyl; and

Ar 2 is aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl. heteroaralkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl; and individual stereoisomers, individual geometric isomers, or mixtures thereof; or a pharmaceutically acceptable salt thereof.

[00106] In another embodiment, HDACi inhibitor tumor compounds for which cancer resistance or sensitivity include, but are not limited to, PCI-24781.

[00107| In some embodiments, a patient is prescribed or administered an HDAC inhibitor to the patient based on a classification of the patient's cancer as being sensitive or resistant to an HDAC inhibitor according to the methods described herein.

100108] hi some embodiments, the methods described herein are used to optimize the selection of an anti-cancer agent for use in combination with an HDACi compound. In some embodiments, optimized selection of the second anti-cancer agent is performed by first comparing the set of known biomarker genes for resistance to the HDACi compound to sets of biomarker genes identified for other anti-cancer agents. The second anti-cancer agent is then selected for use in combination with the HDACi compound based on minimal overlap of the respective sets of resistance biomarker genes.

[00109] Examples of anti-cancer agents that are optionally used in combination with an

HDACi compound include, but are not limited to, any of the following: gossyphol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec®), geldanamycin, 17-N-Allylamino-17-

Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11- 7082, PKC412, or PD 184352, Taxol™, also referred to as "paclitaxel", is an anti-cancer drug which acts by enhancing and stabilizing microtubule formation, and analogs of Taxol™, such as Taxotere™. Compounds that have the basic taxane skeleton as a common structure feature, have also been shown to have the ability to arrest cells in the G2-M phases due to stabilized microtubules and are optionall useful for treating cancer in combination with the compounds described herein. [00110] Further examples of anti-cancer agents for use in combination with an HDACi compound include inhibitors of mitogen-activated protein kinase signaling, e.g., UO 126, PD98059, PD184352, PD0325901 , ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002.

[00111] Other anti-cancer agents that are optionally employed in combination with an HDACi compound include Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; barimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflomithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride;

estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin Il (including recombinant interleukin II, or rlL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl ; interferon alfa-n3; interferon beta-1 a; interferon gamma-1 b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride.

[00112] Other anti-cancer agents that are optionally employed in combination with an HDACi compound include: 20-epi-l ,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein- 1 ; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1 ; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived

inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9- dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1 -based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphteφin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron;

perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocaφine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfϊromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A- based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists; raltitrexed; ramosetron; ras famesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; Ru retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone Bl ; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1 ; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen- binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1 ; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.

[00113] Yet other anticancer agents that are optionally employed in combination with an

HDACi compound include alkylating agents, antimetabolites, natural products, or hormones, e.g., nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates

(e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, etc), or triazenes (decarbazine, etc.).

Examples of antimetabolites include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).

[00114] Examples of natural products useful in combination with an HDACi compound include but are not limited to vinca alkaloids (e.g., vinblastin, vincristine), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), or biological response modifiers (e.g., interferon alpha).

(00115) Examples of alkylating agents that are optionally employed in combination an

HDACi compound include, but are not limited to, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan, etc.), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin, etc.), or triazenes (decarbazine, etc). Examples of antimetabolites include, but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxouridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin. [00116] Examples of hormones and antagonists useful in combination with an HDACi compound include, but are not limited to, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), gonadotropin releasing hormone analog (e.g., leuprolide). Other agents that are optionally used in the methods and compositions described herein for the treatment or prevention of cancer include platinum coordination complexes (e.g., cisplatin, carboblatin), anthracenedioπe (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide).

[00117] Examples of anti-cancer agents which act by arresting cells in the G2-M phases due to stabilized microtubules and which are optionally used in combination with an HDACi compound include without limitation the following marketed drugs and drugs in development: Erbulozole (also known as R-55104), Dolastatin 10 (also known as DLS-10 and NSC-376128), Mivobulin isethionate (also known as CI-980), Vincristine, NSC-639829, Discodermolide (also known as NVP-XX-A-296), ABT-751 (Abbott, also known as E-7010), Altorhyrtins (such as Altorhyrtin A and Altorhyrtin C), Spongistatins (such as Spongistatin 1 , Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (also known as LU- 103793 and NSC-D-669356), Epothilones (such as Epothilone A, Epothilone B, Epothilone C (also known as desoxyepothilone A or dEpoA), Epothilone D (also referred to as KOS- 862, dEpoB, and desoxyepothilone B ), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B (also known as BMS-310705), 21 -hydroxyepothilone D (also known as Desoxyepothilone F and dEpoF), 26-fluoroepothilone), Auristatin PE (also known as NSC-654663), Soblidotin (also known as TZT-1027), LS-4559-P (Pharmacia, also known as LS-4577), LS-4578 (Pharmacia, also known as LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), Vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, also known as WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, also known as 1LX-651 and LU-223651 ),

SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM-132 (Armad), AM- 138 (Armad/Kyowa Hakko), 1DN-5005 (Indena), Cryptophycin 52 (also known as LY-

355703), AC-7739 (Ajinomoto, also known as AVE-8063A and CS-39.HCI), AC-7700 (Ajinomoto, also known as AVE-8062, AVE-8062A, CS-39-L-Ser.HCI, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (also known as NSC-106969), T-138067 (Tularik, also known as T-67, TL-138067 and TI-138067), COBRA-I (Parker Hughes Institute, also known as DDE-261 and WHI-261), HlO (Kansas State University), H16 (Kansas State University), Oncocidin Al (also known as BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolide B, Laulimalide, SPA-2 (Parker Hughes Institute), SPA-I (Parker Hughes Institute, also known as SPIKET-P), 3-lAABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-191), TMPN (Arizona State University), Vanadocene acetylacetonate, T-138026 (Tularik), Monsatrol, lnanocine (also known as NSC-698666), 3-lAABE (Cytoskeleton/Mt. Sinai School of Medicine), A- 204197 (Abbott), T-607 (Tuiarik, also known as T-900607), RPR- 115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, lsoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica),

Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A- 259754 (Abbott), Diozostatin, (-)-Phenylahistin (also known as NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-4341 1 (Zentaris, also known as D-81862), A- 289099 (Abbott), A-318315 (Abbott), HTI-286 (also known as SPA-110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC- 12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi).

Applications of HDACiR-BGs

[00118] The methods and compositions described herein are optionally used to increase the likelihood of a therapeutically effective treatment of a patient's cancer with an HDACi compound by providing an indication (e.g. by oral or written communication in any analog or digital medium) of which genes are HDACiR-BGs, as well as HDACiR-BG expression level reference values (e.g., expression level threshold values) above which HDACi compound resistance is likely (i.e., greater than the probability by chance) or below which HDACi compound sensitivity is likely. [00119) In some embodiments, the indication includes a document with an interpretation of expression levels of at least four biomarker genes selected from Table 1 as to the likelihood that a patient's cancer is resistant or sensitive to treatment with an HDACi compound. [00120] In some embodiments, the document includes an interpretation of the expression levels of at least one HDACiR-BG selected from DEF A6, ITGB4, TM4SF4, SYK, PPAP2C, RAB25, HEPH, NOXOl, TM4SF4, PTPN3, EPHA2, FGFBPl , ABCC3, TPMT, IL18, and DPEPl .

[00121] In some embodiments an indication is provided in one or more databases containing information concerning one or more HDACiR-BGs, including one or more expression level threshold values that permit the interpretation of the effect of HDACiR-BG expression levels on the resistance or sensitivity of a cancer to an HDACi compound according to any of the methods described herein. Such expression level threshold values include those set based on, e.g., deviation of HDACiR-BG expression levels in a test sample from the corresponding HDACiR-BG expression levels in an expression level (positive or negative) reference sample as described herein. Alternatively, or in addition, expression level threshold values are optionally set based on deviation of the expression ratios of HDACiR-BGs to one or more internal expression control genes (e.g., RNA polymerase π, HDAC3, or ZNF217). For example, as described herein, the mean expression ratio (based on TaqMan fluorescence intensity) of the HDACiR-BG DEFA6 to the internal expression control gene ZNF217 is 5.83 in HDACi-resistant colon cancer cells and 0.24 in HDACi -sensitive colon cancer cells. [00122] In some embodiments, the databases include HDACiR-BG expression level profiles or thresholds associated with resistance to one or more HDACi compounds for one or more types of cancer.

[00123] Other information that is optionally included in the databases or in other types of indication include, but are not limited to, HDACiR-BG sequence information, frequency distributions of HDACiR-BG expression levels in a particular cancer population, descriptive information concerning the clinical status of a biological sample analyzed for HDACiR-BG expression profiles, or the clinical status of the patient from which the sample was derived. The database is optionally be designed to include different parts, for instance an HDACiR-BG list database, and an informative HDACiR-BG expression profile database, e.g., a database associating with each HDACiR-BG expression profile record the probability that the expressin profile is associated with resistance to an HDACi compound. Methods for the configuration and construction of databases are widely available, for instance, see U.S. Pat. No. 5,953,727.

[00124] The databases described herein are optionally linked to an outside or external database. In some embodiments, the database optionally communicates with outside data sources, such as database of the developmental therapeutics program of the national cancer institute or the National Center for Biotechnology Information through the internet. [00125] Any appropriate computer platform is used to perform the methods for interpreting one or more HDACiR-BG expression profiles by the methods described herein, hi some embodiments, the computer platform receive direct input from a database, e.g., one of the databases described herein. For example, a large number of computer workstations are available from a variety of manufacturers, such has those available from Silicon Graphics. Client-server environments, database servers and networks are also widely available and are appropriate platforms for the databases described herein.

[00126] The databases described herein are optionally used to present information identifying a set of HDACiR-BG expression profiles in an individual and such a presentation is optionally used to predict or diagnose the likelihood of a effective therapeutic treatment of the individual's cancer with a particular HDACi compound based on a statistical comparison of the individual's expression profile to HDACiR-BG expression level thresholds as desribed herein. Accordingly, one chooses to partition cancer patients into subgroups at any threshold value of the measured HDACiR-BG expression, where all patients with expression values above the threshold have higher risk, and all patients with expression values below the threshold have lower risk, of and HDACi compound-resistant cancer resistanceor vice versa, depending on whether the expression level threshold is based on an expression level in a cancer determined to be resistant to an HDACi compound treatment (i.e., a positive reference sample) or sensitive to the HDACi compound treatment (i.e., a negative reference sample). Alternatively, HDACiR-BG expression profiles ranked on a probability continuum, where the more an HDACiR-BG expression level deviates negatively from (i.e., is less than) an expression level positive reference value, the higher the probability that the cancer is sensitive to treatment with an HDACi compound. Conversely, the more an HDACiR-BG expression level deviates positively from (i.e., is greater than) an expression level negative reference value, the higher the probability that the cancer is resistant to treatment with an HDACi compound.

EXAMPLES [00127J The following specific examples are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent.

Example 1 : mRNA expression profiling of HDACi sensitive versus resistant colorectal tumor cells ex vivo

[00128] We and others previously developed several pharmacodynamic markers for HDACi compounds (such as tubulin or histone acetylation, p21 expression etc). However, there is currently no clinically predictive biomarker for response to these agents available. In this work, we developed a strategy to identify such biomarkers for the HDACi compound PCI-24781 in primary human colorectal tumors.

[00129] The method used soft agar chemosensitivity assays in which primary human tumors were exposed in culture to PCl-24781. Either a trititated thymidine or alamar blue assay was then used to estimate the percentage of resistance to PCI-24781. For example in the trititated thymidine assay, sensitive tumor cells affected by the drug divided less and therefore incorporated less thymidine, whereas resistant tumor cells continued to grow and divide and therefore incorporated more thymidine into their DNA. It has been shown historically that under the optimized conditions of

this assay, a patient whose tumor is classified as resistant to a given drug has < 1% probability of response to that drug in the clinic (in published correlations to clinical outcome, these assays predicted resistance with an accuracy of 99% in solid cancers and 92% in blood cancers). For example, a recent paper correlated in vitro sensitivity or resistance to fludarabine in the DiSC assay in B-cell CLL patients with clinical outcome (median survival 7.9 months in resistant vs 41.7 months in sensitive patients). Similar data has also been published for solid tumors : e.g., for sensitivity or resistance to Pt in ovarian tumors, and to CPX and DOX in breast tumors.

[00130] After determining ex vivo sensitivity or resistance to PCI-24781 for each tumor, RNA isolated from tumor cells was then profiled on microarrays and a marker set was identified by statistical analysis of the data. This marker set was validated by RT-PCR (TaqMan™) analysis. Such pharmacogenomic biomarkers that are used for patient stratification in the clinic provide a competitive advantage in the development of PCI-24781. A graphic summary of the method and its clinical applications is illustrated in Fig. 1. [00131] We examined the ex-vivo response of primary colorectal tumors from various patients to an HDAC inhibitor, PCI-24781, and subsequently determined whether there were robust differences in the mRNA expression profiles of sensitive versus resistant tumor cells prior to HDACi treatment.

[00132] Primary colorectal cancer (CRC) samples were obtained from patient biopsies (Table

2). Viable tumor cells were plated and cultured in soft agar as described in Kern et al. (1990), J. Natl. Cancer Inst., 82:582-588, and were treated with a range of PCI-24781 concentrations (0.01-2μM). Tritiated thymidine was added to the culture after 3 days of exposure to the drug, and the amount of radioactivity incorporated into the cells after a further 2 days was quantified. The percentage of cell growth inhibition (%GI) was calculated by comparing the treated cells to the control cells, and from these growth profiles the tumors were classified as either sensitive or resistant based on deviation from the median profile. As shown in Fig. 2, primary tumors displayed a spectrum of growth inhibition phenotypes from 100% to 0% relative to control at the PCI-24781 concentrations tested (up to 2 μM).

Table 2

[001331 After determining tumor sensitivity to PCI-24781 , gene expression profiles were determined for resistant and sensitive tumors that were treated with PCI-24781 (2 μM) or untreated. Total RNA was isolated using Qiagen procedures (Qiagen, Inc., Valencia, CA) and fluorescent probes were prepared and hybridized to Codelink Human Whole Genome oligonucleotide microarrays containing -55,000 unique probes (GE Healthcare Bio-Sciences Corp., Piscataway, NJ) according to the manufacturer's instructions. The microarrays were scanned in a GenePix 4000B scanner (Molecular Devices Corporation, Sunnyvale CA). The images were processed with Codelink software and the exported data was analyzed as follows. [00134] The median-normalized microarray data were imported into Genespring software (Agilent), and principal component analysis (PCA) and hierarchical clustering analysis were performed. We looked for consistent results from multiple analysis methods to provide additional confidence in our results. For multiple hypothesis correction, we used the q-values approach for false discovery rates (FDR) as described in Storey et al. (2003), Proc. Nat. Acad. Sci. USA, 100:9440-9445. As a second analytical approach we adopted the Bayesian ANOVA approach described in Ishwaran et al. (2003), J. Amer. Stat. Assoc, 98:438-455.

[001351 In the Bayesian ANOVA method, the contribution of irrelevant genes to the ANOVA model are selectively shrunk to balance total false detections against total false non-detections. The output is a Zcut score which identifies genes whose contribution to the ANOVA model is larger than the standard z-score. See Ishwaran et al., ibid., and the website at bamarray.com. For the identification of biomarkers predictive of PCI-24781 resistance, we used only the untreated control samples divided into pools based on the sensitivity or resistance classification in the assay described above. This analytical approach is summarized in Fig. 3.

[00136] As shown in Fig. 4, principal components analysis clearly distinguished untreated cell expression profiles from treated cell expression profiles. Controls (arrowhead) are more similar to each other and well separated from the treated samples. The major component PCAl clearly resolves treated from control samples. Interestingly, the resistant cell expression profiles (circled in both the treated and untreated samples) clustered together before and after treatment, whereas the sensitive samples varied widely in their profiles after treatment with PCI-24781. This suggested that it is easier to identify patients with the most resistant tumors and exclude them from a clinical trial rather than to identifying patients with sensitive tumors.

[00137| Based on the microarray analysis, we identified a total of 44 genes (see table 3) whose level of expression was significantly higher (z-score greater than 3.5) in PCI-24781 resistant cells than in PCI-24781 sensitive cells (data not shown). Of note, the expression of the identified biomarker genes was not altered by treatment with PCI-24781.

[00138] Analysis of the biological pathways associated with these genes showed that homologous recombination, nucleotide excision repair, cell cycle, and apoptosis were among those that affect sensitivity to PCI-24781.

[00139] In order to validate the higher expression of each resistance biomarker gene identified by microarray analysis, we analyzed the expression of each biomarker gene by the TaqMan ® quantitave RT-PCR method as described below.

[00140] TaqMan ® Gene Expression Assays for selected genes were obtained from Applied Biosystems (Foster City, CA). One-step RT-PCR was carried out in triplicate on 25 ng of total RNA from each sample on an ABI PRISM ® 7900HT sequence detection system. The mRNA levels for each gene were normalized to the amount of RNA in the well as measured in parallel using Ribogreen (Invitrogen, Inc., Carlsbad, CA). We then calculated the ratios of expression levels of the biomarker genes in the resistant & sensitive samples (R/S).and compared them to the corresponding ratios obtained from the microarray analysis. The comparative analysis for 16 of the biomarker genes listed in Table 3 is shown in Table 4. As a further validation of our microarray analysis, we performed TaqMan assays for three genes whose expression, as measured by microarray hybridization, was not found to correlate with PCI-24781 resistance (see last three genes in Table 3).

Table 4

Microarray vs TaqMan Analysis of Genes Upregulated in PCI-24781 -Resistant vs Sensitive Colorectal Tumor Cells

O

[00141| The comparison of microarray versus results is graphically summarized in Fig. 2. As shown in Table 4 and Fig. 2, genes found to be significantly upregulated by the microarray method were also found to be upregulated by the TaqMan method, though the latter generally yielded higher R/S ratios. Likewise, three genes whose expression did not differ significantly in the microarray analysis also showed no significant difference in the TaqMan assay.

[00142) Interestingly, several of the identified biomarker genes have previously been studied in relation to cancer, e.g., DEF A6, RAB25 small GTPase, MRP3 (ABCC3), and TM4SF4. Further, a number of the identified genes encode secreted proteins or transmembrane proteins that shed their extracellular domains. Genes encoding secretable proteins include, e.g., DEF A6 (NM_001926), TM4SF4 (NM_004617), TGFA (NM_003236), FGFBP 1 (NM_005130), EPHA2 (NM_004431 ),

TNFRSF21 (NMJM4452), TMF4SF3 (NM_004616), IL18 (NM_001562), TMPRSS2 (NM_005656), and CCL15 (NM_032965).

[00143] Based on these data, we concluded that the expression pattern of subsets (e.g., four or more) of the identified biomarker genes provide "resistance signatures" that are optionally used to reliably identify colorectal tumors that are resistant or susceptible to the HDAC inhibitor PCI-24781. [00144] In a validation experiment, we found that ex vivo cultured primary colon tumor cells from twelve newly diagnosed, naive patients were all sensitive to growth inhibition by the HDAC inhibitor PCI-24781 (Fig. 1 IA). In contrast, we found that in a number of cases, advanced metastatic colon tumor cells were resistant to growth inhibition by the HDAC inhibitor PCI-24781 (Fig. 1 IB), and the DEF A6 mRNA expression levels were higher in HDAC -resistant cells than in HDAC- sensitive cells (Fig. 1 1C).

Example 2: Identification and cross-validation of functional biomarkers for HDAC inhibitor compounds and selection of clinical indications [00145] In order to determine relevant rumor types and to identify pharmacodynamic (PD) markers that are useful in the clinic, we first identified biomarkers of HDAC inhibition in mice and used these to identify HDACi- "sensitive" tissues. This was done by identifying, in HDACi-treated mice, genes in peripheral blood mononuclear cells (PBMC) whose mRNA levels showed the same timecourse as acetylated tubulin levels, an index of HDAC inhibition. These biomarker genes were then used to to identify HDACi responsive mouse tissues. Primary human tumors corresponding to sensitive tissues were then tested ex-vivo with PCI-24781 , and it was found that tumors from tissues that showed higher levels of activity were sensitive to inhibition by PCI-24781, thus validating that this technique does indeed predict sensitive tumor types.

[00146] In brief, female BALB/c mice were injected IV with 50 mg/kg PCI-24781 or vehicle.

Blood and various tissues were collected at 0.25, 0.5, 1, 2, 3 & 8 hours after dosing. For acetylated histone and tubulin detection, organs/tissues were pooled for each vehicle and drug-treated organ group. RNA and protein were extracted from the samples with the PARIS Protein and RNA Isolation

System (Ambion). Levels of acetylated and total a-tubulin & histones were evaluated by immunoblotting.

[00147] RNA expression profiles were determined using on a GE-Codelink Mouse Unisetl

1OK oligonucleotide arrays in duplicate. Each treated sample was normalized to the corresponding vehicle control.

In order to validate the expression profile of HDADi-responsive genes identified by the gene expression array assays, Taqman gene expression assays were performed using Applied Biosystems Inc. assays. One-step RT-PCR was carried out in triplicate on 25 ng of total RNA from each sample on a ABI PRISM 7700 instrument. The mRNA levels for each gene were normalized to the amount of RNA in the well as measured in parallel using Ribogreen (Molecular Probes). The treated samples were then normalized to the vehicle control at that time point.

|00148] A set of 16 genes (Table 5) whose expression profile in PBMC (Fig. 7A) closely tracked increases in tubulin acetylation levels (Fig. 7B) following treatment with the HDAC inhibitor PCI-24781.

Table 5: HDAC Inhibitor (HDACi)-Responsive Biomarker Genes

4-.

[00149] Subsequently, we validated the expression profile of two of HDACi-responsive genes, Fgfl 5 and Syngr2, by quantitative RT-PCR and immunoblotting. As shown in Fig. 8, the expression profiles obtained the three different methods closely matched one another, suggesting that the microarray analysis identified HDACi-responsive genes reliably. (0015Oj We then determined the in vivo expression levels for five of the HDACi-responsive biomarker genes in various tissues following 3 hours or 8 hours following administration of PCI- 24781 (50 mg/kg). A Taqman assay was performed to determine mRNA expression levels in brain, colon, kidney, liver, stomach, ovary, uterus, mammary, muscle, heart, lung, spleen, and pancreas. The mean and SD for mRNA expression levels of all 5 genes in each tissue at each time point are shown in Fig. 9. The issue distribution pattern was very reproducible across the biomarker set. Ovary showed the highest level of induction, followed by uterus.

[001511 Subsequently, primary human tumor samples were obtained and viable tumor cells were plated in soft agar and treated with the HDAC inhibitor PCl-24781. Tritiated thymidine was added after 3 days, and 2 days later the radioactivity incorporated into the DNA was quantified. The tumors were then classified as either resistant (EDR: Extreme Drug Resistance), sensitive (LDR) or intermediate (EDR) based on deviation from the median profile (Oncotech, Inc. Tustin, CA). As predicted based on the HDACi responsive biomarker gene profiles hematopoietic tumors had the lowest proportion of resistant (EDR) tumors, and colon the most (38%). See Fig. 10 and Table 6. Among the solid tumors, ovarian had the lowest proportion of resistant tumors, consistent with the high HDACi- biomarker responsiveness of this tissue.

Table 6: Tumor Resistance to HDAC Inhibitor PCI-24781

[00152] Based on the above results, we concluded that expression profiles of the orthologous human biomarkers will reflect PCI-24781 activity in human blood, and serve as PD markers in the clinic. Further, the identified set of HDACi-responsiveness biomarker genes accurately predicts tumor sensitivity to treatment with HDAC inhibitors.

APPENDIX Nucleotide Sequences for HDACi Compound Resistance Biomarker Genes

1 tgaatagttt gctggtagca agacggatga agacctatat gggagattct ttatctctag

61 agctagcata tttacttgca tactttgttt cttttccaca tggatatttt actgctaaat

121 ggcagaggtg ggagggagat gtcacacagt accataaccc catattgaaa acaagaaacc

181 accagaaagt ttgcagctaa ggggcagggg attcagttcc tacgcccact cagcactaac

241 tacttgcggg cctggttgct tagaagctct acctctcttt cattatctgt aaaatagaaa 301 caatacttag gactttagtt ggaacatgag gattgaataa gatcacgcta ttcatgtgac 361 tttttatcgg ctagaacagc aacagacact gctgtgggtg agttacttag aaaagtttag 421 ttatcagtga ttagcccaaa aacacatcag tcaaaaatag aatccactgg atttttgtct 481 ctctttttag agacagggtc tcactgtcgc ccaggctgga gtacagtggc atgatcattg 541 ttcactgcag cctcaaattc ctgggctcaa gcaatcctcg cacctcagcc tcctgagtag 601 ccgggactat aggcacatgc cacctcacct ggcttgtgtg tgtgtgtgtg tgtgtgtgtg 661 tgtgtgtgtg tgtgtgtgta gagacaggat cttgatgtgt cgcctaggct ggtctcaaac 721 tcctggcctc aagtgatctt cccacctcag^ cctccaaaac tgttgggatt ataggcgtga 781 gccactgtgc ccagcctaac tgggttttta tgagaggaaa atagaaaatg ctcttctaga 841 agagagagaa caagagcaca aaataatctg gactcacaaa aattcagcaa gctccaagaa 901 agggggatgg agggaacgct ggcaaaaatt taaatgccat taggatattt agcaagttat 961 tactgtttgg taaaaatgca tcatcaccct gtgtgcaaaa tgcttgcaaa gtagtctaaa 1021 tgtctttgga gatgggtgtt ttactgcttt tttccaaaaa caaattgttt attatggttg 1081 cagaaatgca gccattacgg tcacataaat ttctaaaaag cctaccaaag gttgcaagca 1141 gtcttctgcc actgggcagg ccagcagttc agacccagcg aggttgccag gaacaaatcc 1201 aggaaatact gggaagaaca agacaagaga attacctaaa agagcaaaca attcaagtaa 1261 atcctgtagc tattaccact taaaatccgt agctcaagat tcctgtttca ccaccttata 1321 cacttaagca attatactta agcctttttt tagtcctaag tgaagaacta catcagaatc 1381 aggataagta ttttgcctgg gaaatttggc tgcatatgaa tggagaagac atttacatcc 1441 tatgttctgg cactttctga aagatctaat taaacatgtt gatgtgccaa tttaatcaag 1501 atgagagatc cctgctggtg tcaccctcta gaacctgcac ttggtgtttt gactttccag 1561 aagaaaaaaa tgcaactttg gttagggggc agtggttgga tcacacagtt gtctttcgtt 1621 tcctaccaca gtaattcata tttaaatatg cttttagatt agtgtggata ctattgctgc 1681 tgtgttgcta cctgaccttt ttctgggggg ggtacctcag aaatgagcat ttgagggcaa 1741 gcgaaaaagc cctcttcatc ctccagaggc aacaaagagg cagcagaaat ggggaaagat 1801 tgtgagaggc agggcttggg tctagacctg gacttaggca agatatgttg ccctcaaccc 1861 tgagttttct tatatgtaaa aagggaaggt tgggctggac tagatgaggt caagatttgc 1921 cattctggga ggctgatatt ccagagaatc aaaattaatc ctaaaccaaa gctttatggc 1981 tgctacagag acatgtcaca tttctgagac ttgtcaccaa gagtttgtcc ctcagacttt 2041 ggcgctgttg aatgcaaaga caaggatggc caccttctgg ttcttgcctg ttgtcctcag

2101 ctgagagcag tctcggtaaa ggtggcaaag attctgtgac ctcagaccgg ggaccaaatg 2161 cttgggagtc tgatggccgg gctgggccac cattctcata gctctcattc tgtttggagc 2221 aaccaaagga tttgtgtgaa gttatttgga aaaggacctt aactgagcag taatcttttt 2281 tctgtatatt tggaatgttt ttcattctga cctgttctgt cagtgattct actgaaaaac 2341 aatttaatca atataaaaat gttcaagcta tgcaac

1 ctccggcgcc cgctctgccc gccgctgggt ccgaccgcgc tcgccttcct tgcagccgcg 61 cctcggcccc atggacgccc tgtgcggttc cggggagctc ggctccaagt tctgggactc 121 caacctgtct gtgcacacag aaaacccgga cctcactccc tgcttccaga actccctgct 181 ggcctgggtg ccctgcatct acctgtgggt cgccctgccc tgctacttgc tctacctgcg 241 gcaccattgt cgtggctaca tcatcctctc ccacctgtcc aagctcaaga tggtcctggg 301 tgtcctgctg tggtgcgtct cctgggcgga ccttttttac tccttccatg gcctggtcca 361 tggccgggcc cctgcccctg ttttctttgt cacccccttg gtggtggggg tcaccatgct 421 gctggccacc ctgctgatac agtatgagcg gctgcagggc gtacagtctt cgggggtcct 481 cattatcttc tggttcctgt gtgtggtctg cgccatcgtc ccattccgct ccaagatcct 541 tttagccaag gcagagggtg agatctcaga ccccttccgc ttcaccacct tctacatcca 601 ctttgccctg gtactctcta ccctcatctt ggcctgcttc agggagaaac ctccattttt 661 ctccgcaaag aatgtcgacc ctaaccccta ccctgagacc agcgctggct ttctctcccg 721 cctgtttttc tggtggttca caaagatggc catctatggc taccggcatc ccctggagga 781 gaaggacctc tggtccctaa aggaagagga cagatcccag atggtggtgc agcagctgct 841 ggaggcatgg aggaagcagg aaaagcagac ggcacgacac aaggcttcag cagcacctgg 901 gaaaaatgcc tccggcgagg acgaggtgct gctgggtgcc cggcccaggc cccggaagcc 961 ctccttcctg aaggccctgc tggccacctt cggctccagc ttcctcatca gtgcctgctt 1021 caagcttatc caggacctgc tctccttcat caatccacag ctgctcagca tcctgatcag 1081 gtttatctcc aaccccatgg ccccctcctg gtggggcttc ctggtggctg ggctgatgtt 1141 cctgtgctcc atgatgcagt cgctgatctt acaacactat taccactaca tctttgtgac 1201 tggggtgaag tttcgtactg ggatcatggg tgtcatctac aggaaggctc tggttatcac 1261 caactcagtc aaacgtgcgt ccactgtggg ggaaattgtc aacctcatgt cagtggatgc 1321 ccagcgcttc atggaccttg cccccttcct caatctgctg tggtcagcac ccctgcagat 1381 catcctggcg atctacttcc tctggcagaa cctaggtccc tctgtcctgg ctggagtcgc 1441 tttcatggtc ttgctgattc cactcaacgg agctgtggcc gtgaagatgc gcgccttcca 1501 ggtaaagcaa atgaaattga aggactcgcg catcaagctg atgagtgaga tcctgaacgg 1561 catcaaggtg ctgaagctgt acgcctggga gcccagcttc ctgaagcagg tggagggcat 1621 caggcagggt gagctccagc tgctgcgcac ggcggcctac ctccacacca caaccacctt 1681 cacctggatg tgcagcccct tcctggtgac cctgatcacc ctctgggtgt acgtgtacgt 1741 ggacccaaac aatgtgctgg acgccgagaa ggcctttgtg tctgtgtcct tgtttaatat 1801 cttaagactt cccctcaaca tgctgcccca gttaatcagc aacctgactc aggccagtgt 1861 gtctctgaaa cggatccagc aattcctgag ccaagaggaa cttgaccccc agagtgtgga 1921 aagaaagacc atctccccag gctatgccat caccatacac agtggcacct tcacctgggc 1981 ccaggacctg ccccccactc tgcacagcct agacatccag gtcccgaaag gggcactggt 2041 ggccgtggtg gggcctgtgg gctgtgggaa gtcctccctg gtgtctgccc tgctgggaga 2101 gatggagaag ctagaaggca aagtgcacat gaagggctcc gtggcctatg tgccccagca 2161 ggcatggatc cagaactgca ctcttcagga aaacgtgctt ttcggcaaag ccctgaaccc

2221 caagcgctac cagcagactc tggaggcctg tgccttgcta gctgacctgg agatgctgcc 2281 tggtggggat cagacagaga ttggagagaa gggcattaac ctgtctgggg gccagcggca 2341 gcgggtcagt ctggctcgag ctgtttacag tgatgccgat attttcttgc tggatgaccc 2401 actgtccgcg gtggactctc atgtggccaa gcacatcttt gaccacgtca tcgggccaga 2461 aggcgtgctg gcaggcaaga cgcgagtgct ggtgacgcac ggcattagct tcctgcccca 2521 gacagacttc atcattgtgc tagctgatgg acaggtgtct gagatgggcc cgtacccagc 2581 cctgctgcag cgcaacggct cctttgccaa ctttctctgc aactatgccc ccgatgagga 2641 ccaagggcac ctggaggaca gctggaccgc gttggaaggt gcagaggata aggaggcact 2701 gctgattgaa gacacactca gcaaccacac ggatctgaca gacaatgatc cagtcaccta 2761 tgtggtccag aagcagttta tgagacagct gagtgccctg tcctcagatg gggagggaca 2821 gggtcggcct gtaccccgga ggcacctggg tccatcagag aaggtgcagg tgacagaggc 2881 gaaggcagat ggggcactga cccaggagga gaaagcagcc attggcactg tggagctcag 2941 tgtgttctgg gattatgcca aggccgtggg gctctgtacc acgctggcca tctgtctcct 3001 gtatgtgggt caaagtgcgg ctgccattgg agccaatgtg tggctcagtg cctggacaaa 3061 tgatgccatg gcagacagta gacagaacaa cacttccctg aggctgggcg tctatgctgc 3121 tttaggaatt ctgcaagggt tcttggtgat gctggcagcc atggccatgg cagcgggtgg 3181 catccaggct gcccgtgtgt tgcaccaggc actgctgcac aacaagatac gctcgccaca 3241 gtccttcttt gacaccacac catcaggccg catcctgaac tgcttctcca aggacatcta 3301 tgtcgttgat gaggttctgg cccctgtcat cctcatgctg ctcaattcct tcttcaacgc 3361 catctccact cttgtggtca tcatggccag cacgccgctc ttcactgtgg tcatcctgcc 3421 cctggctgtg ctctacacct tagtgcagcg cttctatgca gccacatcac ggcaactgaa 3481 gcggctggaa tcagtcagcc gctcacctat ctactcccac ttttcggaga cagtgactgg 3541 tgccagtgtc atccgggcct acaaccgcag ccgggatttt gagatcatca gtgatactaa 3601 ggtggatgcc aaccagagaa gctgctaccc ctacatcatc tccaaccggt cagaagccgc 3661 ctccctcgct ccctgctcct ccaggaattc ccagcaggct ctctggtgtt cagggtcctt 3721 gtccctcctt tcccctaagc agaaaactgg ccctgccctg cccctgcccc atttcctcct 3781 catctgatcc cccataggcg gctgagcatc ggagtggagt tcgtggggaa ctgcgtggtg 3841 ctctttgctg cactatttgc cgtcatcggg aggagcagcc tgaacccggg gctggtgggc 3901 ctttctgtgt cctactcctt gcaggtgaca tttgctctga actggatgat acgaatgatg 3961 tcagatttgg aatctaacat cgtggctgtg gagagggtca aggagtactc caagacagag 4021 acagaggcgc cctgggtggt ggaaggcagc cgccctcccg aaggttggcc cccacgtggg 4081 gaggtggagt tccggaatta ttctgtgcgc taccggccgg gcctagacct ggtgctgaga 4141 gacctgagtc tgcatgtgca cggtggcgag aaggtgggga tcgtgggccg cactggggct 4201 ggcaagtctt ccatgaccct ttgcctgttc cgcatcctgg aggcggcaaa gggtgaaatc 4261 cgcattgatg gcctcaatgt ggcagacatc ggcctccatg acctgcgctc tcagctgacc 4321 atcatcccgc aggaccccat cctgttctcg gggaccctgc gcatgaacct ggaccccttc 4381 ggcagctact cagaggagga catttggtgg gctttggagc tgtcccacct gcacacgttt 4441 gtgagctccc agccggcagg cctggacttc cagtgctcag agggcgggga gaatctcagc 4501 gtgggccaga ggcagctcgt gtgcctggcc cgagccctgc tccgcaagag ccgcatcctg 4561 gttttagacg aggccacagc tgccatcgac ctggagactg acaacctcat ccaggctacc 4621 atccgcaccc agtttgatac ctgcactgtc ctgaccatcg cacaccggct taacactatc 4681 atggactaca ccagggtcct ggtcctggac aaaggagtag tagctgaatt tgattctcca 4741 gccaacctca ttgcagctag aggcatcttc tacgggatgg ccagagatgc tggacttgcc 4801 taaaatatat tcctgagatt tcctcctggc ctttcctggt tttcatcagg aaggaaatga 4861 caccaaatat gtccgcagaa tggacttgat agcaaacact gggggcacct taagattttg 4921 cacctgtaaa gtgccttaca gggtaactgt gctgaatgct ttagatgagg aaatgatccc 4981 caagtggtga atgacacgcc taaggtcaca gctagtttga gccagttaga ctagtccccc 5041 ggtctcccga ttcccaactg agtgttattt gcacactgca ctgttttcaa ataacgattt 5101 tatgaaatga cctctgtcct ccctctgatt tttcatattt tcctaaagtt tcgtttctgt 5161 tttttaataa aaagcttttt cctcctggaa cagaagacag ctgctgggtc aggccacccc 5221 taggaactca gtcctgtact ctggggtgct gcctgaatcc attaaaaatg ggagtactga 5281 tgaaataaaa ctacatggtc aacagtaaaa

1 gtgggggcca ggcagcacag atgaagcatt tacctatcta ggtaagtcag gaggagctca

61 aaaggagaag aaaacagtag gaggcagggg aagcagcctc tgtctccatc tctgcccttt

121 gaaacaaaag ggtatttctt ttctctcttc agcccccaac ccagtggagg cccggcttgg 181 gacattgttc acttcccctc gcttcccctc tagaagcccc ctttgccatc cctgcacctt

241 gtttcgggtg atgcccgaga gggagctgtg gccagcgggg actggctcag aacccgtgac

301 ccgtgtcggc agctgtgaca gcatga ' tgag cagcacctcc acccgctctg gatctagtga

361 tagcagctac gacttcctgt ccactgaaga gaaggagtgt ctgctcttcc tggaggagac

421 cattggctca ctggacacgg aggctgacag cggactgtcc actgacgagt ctgagccagc 481 cacaactccc agaggtttcc gagcactgcc cataacccaa cccactcccc ggggaggtcc 541 agaggagacc atcactcagc aaggacgaac gccaaggaca gtaactgagt ccagctcatc 601 ccaccctcct gagccccagg gcctaggcct caggtctggc tcctacagcc tccctaggaa 661 tatccacatt gccagaagcc agaacttcag gaaaagcacc acccaggcta gcagtcacaa 721 ccctggagaa ccggggaggc ttgcgccaga gcctgagaaa gaacaggtca gccagagcag 781 ccaacccagg caggcacctg ccagccccca ggaggctgcc cttgacttgg acgtggtgct 841 catccctccg ccagaagctt tccgggacac ccagccagag cagtgtaggg aagccagcct 901 gcccgagggg ccaggacagc agggccacac accccagctc cacacaccat ccagctccca 961 ggaaagagag cagactcctt cagaagccat gtcccaaaaa gccaaggaaa cagtctcaac 1021 caggtacaca caaccccagc ctcctcctgc agggttgcct cagaatgcaa gagctgaaga 1081 tgctcccctc tcatcagggg aggacccaaa cagccgacta gctcccctca caacccctaa 1141 gccccggaag ctgccaccta atattgttct gaagagcagc cgaagcagtt tccacagtga 1201 cccccagcac tggctgtccc gccacactga ggctgcccct ggagattctg gcctgatctc 1261 ctgttcactg caagagcaga gaaaagcacg taaagaagct ctagagaagc tggggctacc 1321 ccaggatcaa gatgagcctg gactccactt aagtaagccc accagctcca tcagacccaa 1381 ggagacacgg gcccagcatc tgtccccagc tccaggtctg gctcagcctg cagctccagc 1441 ccaggcctca gcagctattc ctgctgctgg gaaggctctg gctcaagctc cggctccagc 1501 tccaggtcca gctcagggac ctttgccaat gaagtctcca gctccaggca atgttgcagc 1561 tagcaaatct atgccaattc ctatccctaa ggccccaagg gcaaacagtg ccctgactcc 1621 accgaagcca gagtcagggc tgactctcca ggagagcaac acccctggcc tgagacagat 1681 gaacttcaag tccaacactc tggagcgctc aggcgtggga ctgagcagct acctttcaac 1741 tgagaaagat gccagcccca aaaccagcac ttctctggga aagggctcct tcttggacaa 1801 gatctcgccc agtgtcttac gtaattctcg gccccgcccg gcctccctgg gcacggggaa 1861 agattttgca ggtatccagg taggcaagct ggctgacctg gagcaggagc agagctccaa 1921 gcgcctgtcc taccaaggac agagccgtga caagcttcct cgccccccct gtgtcagtgt 1981 caagatctcc ccaaagggtg tccccaatga acacagaagg gaggccctga agaagctggg 2041 actgttgaag gagtagactc tgcgaccagt acagaccctg tcctggctga acaagaagag 2101 acacatgctc cacttgggag cctttgccac cacgcaactc agggctcaag atgaatggga 2161 gggagagatt tgagtccaag catacattta tattcagtgt tgtgccattg agttcccatg 2221 tggatcattc tgaaggtgat ctccacaaga gggtgtgtgt gtgtgtgttt ggtgtgtgtg 2281 tggagggggg gccgctggat acatcactga agctattgat ataacacaat gagtcactgt 2341 tcagaatttt gctcttgtta gatgttttct tacattgggt agagtccagc ctagtgagag 2401 ctgagtgaag gggctggcca tgcctgagac aaaaagtcaa atgagacaat ggacgtgtca 2461 atgacttgaa aaaaagtcac atccagcaaa tgcagggtca catgaaatat gggcctcctg 2521 gaatccctac agtggatgga gactggctca taccttgcca gatccctctc tcagttccag 2581 ccttctggac aaggcctggg ctaagaggag ctgattcgtt atctcttcac ccactgccct 2641 ctcagtatca ccagtcccaa agacaggata cgtccctgta acccaatctc tcggttgatt 2701 gatagcagaa cagctcttgt tggtctgaga aggcaggata agtgaccaca tatttatgcc 2761 actacctcca ccagggagag tccttctcca caggcttgat aaattcaatc accaactgtg 2821 ctgtcgtccc tgactctgct actcccgttc ttcctgcttt cctgctccgt atctcagtct 2881 gcactgaccc cagggctggg ctgacatcaa gatgggagcc cagcccacgg gctttataaa 2941 cacccaagaa ccgtttcaga tcttctctgt gctgatgcag gtagttttaa atttttctca

3001 gttccagtga tagaaaaccc acacaataca tcctctgcca gtcttaatag aatatcagag 3061 gtaagagggg cctcagagaa gctctgacgc agtgctgctg gggaagggaa gtgactaacc 3121 ccgggtcagc ctgccattta gggaaagagc tgaggttctt acccttgttg catgctgcca 3181 cctctcctta gccagtgctc ttgtacatcc acacagcacc ctaaggagcc atagtcacca 3241 tcaaagactc aaccctaagg cccttcaaga tctcaaagtg ccttctgaag catcagagat 3301 taaatattgt tcaaactaat agttattgct gtggctttta attttatctt tggaagatag 3361 ctatatggta actcatcatt aaccagaaca cctctcccct caaattccgt gaccaagttg 3421 tgcagcttga gcaaatgccg aaagagggta ttatgggtgg gtggtgtggg cttgcaaata 3481 caagcttgga ggtgagacat ggccagacat gactcctgct tccccttagg aagtaaatct 3541 tacttatggt tgtgaactgc ttggagtcca ggatgcccag atgtgagggg cagatgaagg 3601 gaatgttgct ggaaaggtgc cttttaaggc tgctgagaat ttctggactg tgtcctgatg 3661 gacgcagcac catcaaagcc cagaatttct gaaaacggtg acaaggttaa cataaggaca 3721 acaaatactc caccctgtca tggtatgtga ggtgtgggtg tggcggtttc tgtgtacgtt 3781 tgctcataca cgcacatcca aaagcctgtg cctcattcct ggccatgggt gaggacttgg 3841 tctgtcacgg ctgatgagga ctcccacaac cggccaagtt atgtcttatt atacaccccc 3901 agaaagagag aaagctgcct tctggaggac tgattccaca tgctatattc agctgagttg 3961 atttctgtgt ctatttcaac ccataacctg aagaatgatc accttattcc ttattcatta 4021 attttcttga ttaataggga aacttgggaa tagctataaa gtaaaacttg ggtggaacct 4081 ggggccctgg catcacacaa gtgtgattag gatggtcaag gtcatcagga gtacagccta 4141 ttatattccc acatcctgag aaaggtcatt tctcccacac acgacaaagt cacagacatc 4201 ctgcacctgc cactaggcat cctcatccta ctgacatgcc catttctcca gttttcttaa 4261 tctgagactc ccttcccttg ttttttaaag ataccgtgct tctccacatc ctcatccttc 4321 aaggagcata ttttgctctt aggatggtct ttgggattca agaatagaat aataaatcca 4381 aacttggtca ttcccatttt gaagagatgc aagagggccc agtgaggaca tccgcctccc 4441 tgaaagtggt gctagacaga gctgaggtca ttgtatctgt gtatccacat aggatttctc 4501 ttaattcagc ttgaattgat ggggagggag gtaagagtag ggtcagagtt actcatccct 4561 tttcaaagaa ttgtgggtgg aagtttgtaa aggccattca tttgattttc aaaatcaaag 4621 cgacagctct acttccactt ggccttagat ctctgctata ccctgccata gccttgatgc 4681 cactgggcac aagccacctg ccaaatacag gagtggcctc tcccagcctg gcatgatagg 4741 ggggtctgtg ccctcagatg tgttgacagc tgctcttctg aattgccaca cctgtgctac 4801 acttggaatt ctgtgctctg actctgcagg gtaggaccac gtgccatctc acacagaggt 4861 caaccgatga gcccactcac tcgtacatgc cttcttccac agtgggaagc atgatctggc 4921 aggggccgcc ctgtaggctg gggatgggct gctgtgtgaa tgttgacgtt cgtttcatgg 4981 agaaagggga ggtgaaagat tgaagagcag gttcctgtca atgttctgag ttcgagctgg 5041 aggtgtagat tgaatagtct acatggtctg tgagtgtgtg agatgaaccc ttccatcctt 5101 tgacacctgg ttgtatgtgt aggctaagaa ggaaggaccc tcctgtcagt gtgcaaagct 5161 gtaatctcat ggactagagg agagggggcc aaggggatgg acaggagaag tcatgcagaa 5221 tctaagcagg aatgcagata gaacacatct aggctctttt ccccaggaga gtgatgatgg 5281 agcatataga tctggctcaa attcagcctc catcacttac cagtcaggaa ccctggcgat 5341 atcactttaa ctttctgaac ctcagagtct tcacctataa gacggggaaa ataataccac 5401 cctttcaaga ttgttgagat aaataagtga tataaaacat gtaaagctta gttctggcca 5461 cagtgtagct actcaataaa tgataatact

1 ctcctctccg cgcggggcgg gctccgcgcc acgtgactcc gcggccgggc cgggacgcga

61 cgggacgcgc tgggaccggc gtcgggggtc gcggggacca tgcagcggag cctccctgcc

121 cttcgctatc ctgacgctgg tgaacgcccc gtacaagcga ggattttact gcggggatga

181 ctccatccgg tacccctacc gtccagatac catcacccac gggctcatgg ctggggtcac

241 catcacggcc accgtcatcc ttgtctcggc cggggaagcc tacctggtgt acacagaccg 301 gctctattct cgctcggact tcaacaacta cgtggctgct gtatacaagg tgctggggac

361 cttcctgttt ggggctgccg tgagccagtc tctgacagac ctggccaagt acatgattgg 421 gcgtctgagg cccaacttcc tagccgtctg cgaccccgac tggagccggg tcaactgctc 481 ggtctatgtg cagctggaga aggtgtgcag gggaaaccct gctgatgtca ccgaggccag 541 gttgtctttc tactcgggac actcttcctt tgggatgtac tgcatggtgt tcttggcgct 601 gtatgtgcag gcacgactct gttggaagtg ggcacggctg ctgcgaccca cagtccagtt 661 cttcctggtg gcctttgccc tctacgtggg ctacacccgc gtgtctgatt acaaacacca 721 ctggagcgat gtccttgttg gcctcctgca gggggcactg gtggctgccc tcactgtctg 781 ctacatctca gacttcttca aagcccgacc cccacagcac tgtctgaagg aggaggagct 841 ggaacggaag cccagcctgt cactgacgtt gaccctgggc gaggctgacc acaaccacta 901 tggatacccg cactcctcct cctgaggccg gaccccgccc aggcagggag ctgctgtgag 961 tccagctgag gcccacccag gtggtccctc cagccctggt taggcactga gggctctgga 1021 cgggctccag gaaccctggg ctgatgggag cagtgagcgg gctccgctgc cccctgccct 1081 gcactggacc aggagtctgg agatgcctgg gtagccctca gcatttggag gggaacctgt 1141 tcccgtcggt ccccaaatat ccccttcttt ttatggggtt aaggaaggga ccgagagatc 1201 agatagttgc tgttttgtaa aatgtaatgt atatgtggtt tttagtaaaa tagggcacct 1261 gtttcacaaa

1 gcgcgcctcg ccggcgcctc catcccggat ccttgctgca gcgtcagcgc cgccgcccgt 61 gcctttcctc ttcctcctcc tcctccttgg catccgcctc ttcttcctcc tgcgtcctcc 121 cccgctgcct ccgctgctcc cgacgcggag cccggagccc gcgccgagcc cctggcctcg 181 cggtgccatg ctgccccggc ggcggcgctg aaggatggcg acgccgctgc ctccgccctc 241 cccgcggcac ctgcggctgc tgcggctgct gctctccggc ctcgtcctcg gcgccgccct 301 gcgtggagcc gccgccggcc acccggatgt agccgcctgt cccgggagcc tggactgtgc 361 cctgaagagg cgggcaaggt gtcctcctgg tgcacatgcc tgtgggccct gccttcagcc 421 cttccaggag gaccagcaag ggctctgtgt gcccaggatg cgccggcctc caggcggggg 481 ccggccccag cccagactgg aagatgagat tgacttcctg gcccaggagc ttgcccggaa 541 ggagtctgga cactcaactc cgcccctacc caaggaccga cagcggctcc cggagcctgc 601 caccctgggc ttctcggcac gggggcaggg gctggagctg ggcctcccct ccactccagg 661 aacccccacg cccacgcccc acacctccat gggctcccct gtgtcatccg acccggtgca 721 catgtcgccc ctggagcccc ggggagggca aggcgacggc ctcgcccttg tgctgatcct 781 ggcgttctgt gtggccggtg cagccgccct ctccgtagcc tccctctgct ggtgcaggct 841 gcatcgtgag atccgcctga ctcagaaggc cgactacgcc actgcgaagg cccctggctc 901 acctgcagct ccccggatct cgcctgggga ccaacggctg gcacagagcg cggagatgta 961 ccactaccag caccaacggc aacagatgct gtgcctggag cggcataaag agccacccaa 1021 ggagctggac acggcctcct cggatgagga gaatgaggac ggagacttca cggtgtacga 1081 gtgcccgggc ctggccccga ccggggaaat ggaggtgcgc aaccctctgt tcgaccacgc 1141 cgcactgtcc gcgcccctgc cggcccccag ctcaccgcct gcactgccat gacctggagg 1201 cagacagacg cccacctgct ccccgacctc gaggcccccg gggaggggca gggcctggag 1261 cttcccacta aaaacatgtt ttgatgctgt gtgcttttgg ctgggcctcg ggctccaggc 1321 cctgggaccc cttgccaggg agacccccga acctttgtgc caggacacct cctggtcccc 1381 tgcacctctc ctgttcggtt tagaccccca aactggaggg ggcatggaga accgtagagc 1441 gcaggaacgg gtgggtaatt ctagagacaa aagccaatta aagtccattt cagaaaaaaa

1 gggcaacagt ctgcccacct gtggacacca gatcctggga gctcctggtt agcaagtgag

61 atctctggga tgtcagtgag gctggttgaa gaccagaggt aaactgcaga ggtcaccacc 121 cccaccatgt cccaggtgat gtccagccca ctgctggcag gaggccatgc tgtcagcttg

181 gcgccttgtg atgagcccag gaggaccctg cacccagcac ccagccccag cctgccaccc

241 cagtgttctt actacaccac ggaaggctgg ggagcccagg ccctgatggc ccccgtgccc

301 tgcatggggc cccctggccg actccagcaa gccccacagg tggaggccaa agccacctgc

361 ttcctgccgt cccctggtga gaaggccttg gggaccccag aggaccttga ctcctacatt 421 gacttctcac tggagagcct caatcagatg atcctggaac tggaccccac cttccagctg 481 cttcccccag ggactggggg ctcccaggct gagctggccc agagcaccat gtcaatgaga 541 aagaaggagg aatctgaagc cttggacata aagtacatcg aggtgacctc cgccagatca 601 aggtgccacg attggcccca gcactgctcc agcccctctg tcaccccgcc cttcggctcc 661 cctcgcagtg gtggcctcct cctttccaga gacgtccccc gagagacacg aagcagcagt 721 gagagcctca tcttctctgg gaaccagggc agggggcacc agcgccctct gcccccctca 781 gagggtctct cccctcgacc cccaaattcc cccagcatct caatcccttg catggggagc 841 aaggcctcga gcccccatgg tttgggctcc ccgctggtgg cttctccaag actggagaag 901 cggctgggag gcctggcccc acagcggggc agcaggatct ctgtgctgtc agccagccca 961 gtgtctgatg tcagctatat gtttggaagc agccagtccc tcctgcactc cagcaactcc 1021 agccatcagt catcttccag atccttggaa agtccagcca actcttcctc cagcctccac 1081 agccttggct cagtgtccct gtgtacaaga cccagtgact tccaggctcc cagaaacccc 1141 accctaacca tgggccaacc cagaacaccc cactctccac cactggccaa agaacatgcc 1201 agcatctgcc ccccatccat caccaactcc atggtggaca tacccattgt gctgatcaac 1261 ggctgcccag aaccagggtc ttctccaccc cagcggaccc caggacacca gaactccgtt 1321 caacctggag ctgcttctcc cagcaacccc tgtccagcca ccaggagcaa cagccagacc 1381 ctgtcagatg ccccctttac cacatgccca gagggtcccg ccagggacat gcagcccacc 1441 atgaagttcg tgatggacac atctaaatac tggtttaagc caaacatcac ccgagagcaa 1501 gcaatcgagc tgctgaggaa ggaggagcca ggggcttttg tcataaggga cagctcttca 1561 taccgaggct ccttcggcct ggccctgaag gtgcaggagg ttcccgcgtc tgctcagaat 1621 cgaccaggtg aggacagcaa tgacctcatc cgacacttcc tcatcgagtc gtctgccaaa 1681 ggagtgcatc tcaaaggagc agatgaggag ccctactttg ggagcctctc tgccttcgtg 1741 tgccagcatt ccatcatggc cctggccctg ccctgcaaac tcaccatccc acagagagaa 1801 ctgggaggtg cagatggggc ctcggactct acagacagcc cagcctcctg ccagaagaaa 1861 tctgcgggct gccacaccct gtacctgagc tcagtgagcg tggagaccct gactggagcc 1921 ctggccgtgc agaaagccat ctccaccacc tttgagaggg acatcctccc cacgcccacc 1981 gtggtccact tcgaagtcac agagcagggc atcactctga ctgatgtcca gaggaaggtg 2041 tttttccggc gccattaccc actcaccacc ctccgcttct gtggtatgga ccctgagcaa 2101 cggaagtggc agaagtactg caaaccctcc tggatctttg ggtttgtggc caagagccag 2161 acagagcctc aggagaacgt atgccacctc tttgcggagt atgacatggt ccagccagcc 2221 tcgcaggtca tcggcctggt gactgctctg ctgcaggacg cagaaaggat gtaggggaga 2281 gactgcctgt gcacctaacc aacacctcca ggggctcgct aaggagcccc cctccacccc 2341 ctgaatgggt gtggcttgtg gccatattga cagaccaatc tatgggacta gggggattgg 2401 catcaagttg acacccttga acctgctatg gccttcagca gtcaccatca tccagacccc 2461 ccgggcctca gtttcctcaa tcatagaaga agaccaatag acaagatcag ctgttcttag 2521 atgctggtgg gcatttgaac atgctcctcc atgattctga agcatgcaca cctctgaaga 2581 cccctgcatg aaaataacct ccaaggaccc tctgacccca tcgacctggg ccctgcccac 2641 acaacagtct gagcaagaga cctgcagccc ctgtttcgtg gcagacagca ggtgcctggc 2701 ggtgacccac ggggctcctg gcttgcagct ggtgatggtc aagaactgac tacaaaacag 2761 gaatggatag actctatttc cttccatatc tgttcctctg ttccttttcc cactttctgg 2821 gtggcttttt gggtccaccc agccaggatg ctgcaggcca agctgggtgt ggtatttagg 2881 gcagctcagc agggggaact tgtccccatg gtcagaggag acccagctgt cctgcacccc

2941 cttgcagatg agtatcaccc catcttttct ttccacttgg tttttatttt tatttttttt 3001 gagacagagt ctcactgtca cccaggctga actgcagtgg tgtgatctag gctcactgca 3061 acctccacct cccaggttca agcaattatc ctgcctcagg ctcccgagta gctgggatta 3121 caggcatgtg caactcaccc agctaatttt gtatttttag tagagacagg gtttcaccat 3181 gttggccagg ctggtcttga actcctgacc gcaggtaatc cacctgcttc ggcctcccaa 3241 agtgctggga ttacaggcgc aagccaccca gcccagcttc tttccattcc ttgataggcg 3301 agtattccaa agctggtatc gtagctgccc taatgttgca tattaggcgg cgggggcaga 3361 gataagggcc atctctctgt gattctgcct cagctcctgt cttgctgagc cctcccccaa 3421 cccacgctcc aacacacaca cacacacaca cacacacaca cacacacaca cacacacaca 3481 cacgcccctc tactgctatg tggcttcaac cagcctcaca gccacacggg ggaagcagag 3541 agtcaagaat gcaaagaggc cgcttcccta agaggcttgg aggagctggg ctctatccca 3601 cacccacccc caccccaccc ccacccagcc tccagaagct ggaaccattt ctcccgcagg 3661 cctgagttcc taaggaaacc accctaccgg ggtggaaggg agggtcaggg aagaaaccca 3721 ctcttgctct acgaggagca agtgcctgcc ccctcccagc agccagccct gccaaagttg 3781 cattatcttt ggccaaggct gggcctgacg gttatgattt cagccctggg cctgcaggag 3841 aggctgagat cagcccaccc agccagtggt cgagcactgc cccgccgcca aagtctgcag 3901 aatgtgagat gaggttctca aggtcacagg ccccagtccc agcctggggg ctggcagagg 3961 cccccatata ctctgctaca gctcctatca tgaaaaataa aatgt

1 ctctgcttcc ttacagcacc cccacctgcc agagctgatc ctccctaggc cctgcctaac

61 cttgagttgg cccccaatcc ctctggctgc agaagtcccc ttacccccaa tgagaggagg

121 ggcaggacca gatcttttga gagctgaggg ttgagggcat tgagccaaca cacagatttg

181 tcgcctctgt ccccgaagac acctgcaccc tccatgcgga gccaagatgg ggaatggaac

241 tgaggaagat tataactttg tcttcaaggt ggtgctgatc ggcgaatcag gtgtggggaa

301 gaccaatcta ctctcccgat tcacgcgcaa tgagttcagc cacgacagcc gcaccaccat

361 cggggttgag ttctccaccc gcactgtgat gttgggcacc gctgctgtca aggctcagat

421 ctgggacaca gctggcctgg agcggtaccg agccatcacc tcggcgtact atcgtggtgc

481 agtgggggcc ctcctggtgt ttgacctaac caagcaccag acctatgctg tggtggagcg

541 atggctgaag gagctctatg accatgctga agccacgatc gtcgtcatgc tcgtgggtaa

601 caaaagtgac ctcagccagg cccgggaagt gcccactgag gaggcccgaa tgttcgctga

661 aaacaatgga ctgctcttcc tggagacctc agccctggac tctaccaatg ttgagctagc

721 ctttgagact gtcctgaaag aaatctttgc gaaggtgtcc aagcagagac agaacagcat

781 ccggaccaat gccatcactc tgggcagtgc ccaggctgga caggagcctg gccctgggga

841 gaagagggcc tgttgcatca gcctctgacc ttggccagca ccacctgccc ccactggctt

901 tttggtgccc cttgtcccca cttcagcccc aggacctttc cttgcccttt ggttccagat

961 atcagactgt tccctgttca cagcaccctc agggtcttaa ggtcttcatg ccctatcaca

1021 aatacctctt ttatctgtcc acccctcaca gactaggacc ctcaaataaa gctgttttat

1081 atcaaaaaaa

1 gcccagcctg cctggagaaa agtgtctgct cctagccaag atctcctcat cacaaaagta

61 atgtgggcca tggagtcagg ccacctcctc tgggctctgc tgttcatgca gtccttgtgg

121 cctcaactga ctgatggagc cactcgagtc tactacctgg gcatccggga tgtgcagtgg 181 aactatgctc ccaagggaag aaatgtcatc acgaaccagc ctctggacag tgacatagtg

241 gcttccagct tcttaaagtc tgacaagaac cggatagggg gaacctacaa gaagaccatc

301 tataaagaat acaaggatga ctcatacaca gatgaagtgg cccagcctgc ctggttgggc

361 ttcctggggc cagtgttgca ggctgaagtg ggggatgtca ttcttattca cctgaagaat

421 tttgccactc gtccctatac catccaccct catggtgtct tctacgagaa ggactctgaa 481 ggttccctat acccagatgg ctcctctggg ccactgaaag ctgatgactc tgttcccccg

541 gggggcagcc atatctacaa ctggaccatt ccagaaggcc atgcacccac cgatgctgac

601 ccagcgtgcc tcacctggat ctaccattct catgtagatg ctccacgaga cattgcaact

661 ggcctaattg ggcctctcat cacctgtaaa agaggagccc tggatgggaa ctcccctcct

721 caacgccagg atgtagacca tgatttcttc ctcctcttca gtgtggtaga tgagaacctc 781 agctggcatc tcaatgagaa cattgccact tactgctcag atcctgcttc agtggacaaa

841 gaagatgaga catttcagga gagcaatagg atgcatgcaa tcaatggctt tgtttttggg

901 aatttacctg agctgaacat gtgtgcacag aaacgtgtgg cctggcactt gtttggcatg

961 ggcaatgaaa ttgatgtcca cacagcattt ttccatggac agatgctgac tacccgtgga

1021 caccacactg atgtggctaa catctttcca gccacctttg tgactgctga gatggtgccc 1081 tgggaacctg gtacctggtt aattagctgc caagtgaaca gtcactttcg agatggcatg

1141 caggcactct acaaggtcaa gtcttgctcc atggcccctc ctgtggacct gctcacaggc

1201 aaagttcgac agtacttcat tgaggcccat gagattcaat gggactatgg cccgatgggg

1261 catgatggga gtactgggaa gaatttgaga gagccaggca gtatctcaga taagtttttc

1321 cagaagagct ccagccgaat tgggggcact tactggaaag tgcgatatga agcctttcaa 1381 gatgagacat tccaagagaa gatgcatttg gaggaagata ggcatcttgg aatcctgggg

1441 ccagtgatcc gggctgaggt gggtgacacc attcaggtgg tcttctacaa ccgtgcctcc

1501 cagccattca gcatgcagcc ccatggggtc ttttatgaga aagactatga aggcactgtg

1561 tacaatgatg gctcatctta ccctggcttg gttgccaagc cctttgagaa agtaacatac

1621 cgctggacag tcccccctca tgccggtccc actgctcagg atcctgcttg tctcacttgg 1681 atgtacttct ctgctgcaga tcccataaga gacacaaatt ctggcctggt gggcccgctg

1741 ctggtgtgca gggctggtgc cttgggtgca gatggcaagc agaaaggggt ggataaagaa

1801 ttctttcttc tcttcactgt gttggatgag aacaagagct ggtacagcaa tgccaatcaa

1861 gcagctgcta tgttggattt ccgactgctt tcagaggata ttgagggctt ccaagactcc

1921 aatcggatgc atgccattaa tgggtttctg ttctctaacc tgcccaggct ggacatgtgc 1981 aagggtgaca cagtggcctg gcacctgctc ggcctgggca cagagactga tgtgcatgga

2041 gtcatgttcc agggcaacac tgtgcagctt cagggcatga ggaagggtgc agctatgctc

2101 tttcctcata cctttgtcat ggccatcatg cagcctgaca accttgggac atttgagatt

2161 tattgccagg caggcagcca tcgagaagca gggatgaggg caatctataa tgtctcccag

2221 tgtcctggcc accaagccac ccctcgccaa cgctaccaag ctgcaagaat ctactatatc 2281 atggcagaag aagtagagtg ggactattgc cctgaccgga gctgggaacg ggaatggcac

2341 aaccagtctg agaaggacag ttatggttac attttcctga gcaacaagga tgggctcctg

2401 ggttccagat acaagaaagc tgtattcagg gaatacactg atggtacatt caggatccct

2461 cggccaagga ctggaccaga agaacacttg ggaatcttgg gtccacttat caaaggtgaa

2521 gttggtgata tcctgactgt ggtattcaag aataatgcca gccgccccta ctctgtgcat 2581 gctcatggag tgctagaatc tactactgtc tggccactgg ctgctgagcc tggtgaggtg

2641 gtcacttatc agtggaacat cccagagagg tctggccctg ggcccaatga ctctgcttgt

2701 gtttcctgga tctattattc tgcagtggat cccatcaagg acatgtatag tggcctggtg

2761 gggcccttgg ctatctgcca aaagggcatc ctggagcccc atggaggacg gagtgacatg

2821 gatcgggaat ttgcattgtt gttct ' tgatt tttgatgaaa ataagtcttg gtatttggag

2881 gaaaatgtgg caacccatgg gtcccaggat ccaggcagta ttaacctaca ggatgaaact

2941 ttcttggaga gcaataaaat gcatgcaatc aatgggaaac tctatgccaa ccttaggggt 3001 cttaccatgt accaaggaga acgagtggcc tggtacatgc tggccatggg ccaagatgtg

3061 gatctacaca ccatccactt tcatgcagag agcttcctct atcggaatgg cgagaactac

3121 cgggcagatg tggtggatct gttcccaggg acttttgagg ttgtggagat ggtggccagc

3181 aaccctggga catggctgat gcactgccat gtgactgacc atgtccatgc tggcatggag

3241 accctcttca ctgttttttc tcgaacagaa cacttaagcc ctctcaccgt catcaccaaa 3301 gagactgaaa aagcagtgcc ccccagagac attgaagaag gcaatgtgaa gatgctgggc

3361 atgcagatcc ccataaagaa tgttgagatg ctggcctctg ttttggttgc cattagtgtc

3421 acccttctgc tcgttgttct ggctcttggt ggagtggttt ggtaccaaca tcgacagaga

3481 aagctacgac gcaataggag gtccatcctg gatgacagct tcaagcttct gtctttcaaa

3541 cagtaacatc tggagcctgg agatatcctc aggaagcaca tctgtagtgc actcccagca 3601 ggccatggac tagtcactaa ccccacactc aaaggggcat gggtggtgga gaagcagaag

3661 gagcaatcaa gcttatctgg atatttcttt ctttatttat tttacatgga aataatatga

3721 tttcactttt tctttagttt ctttgctcta cgtgggcacc tggcactaag ggagtacctt

3781 attatcctac atcgcaaatt tcaacagcta cattatattt ccttctgaca cttggaaggt

3841 attgaaattt ctagaaatgt atccttctca caaagtagag accaagagaa aaactcattg 3901 attgggtttc tacttctttc aaggactcag gaaatttcac tttgaactga ggccaagtga

3961 gctgttaaga taacccacac ttaaactaaa ggctaagaat ataggcttga tgggaaattg

4021 aaggtaggct gagtattggg aatccaaatt gaattttgat tctccttggc agtgaactac

4081 tttgaagaag tggtcaatgg gttgttgctg ccatgagcat gtacaacctc tggagctaga

4141 agctcctcag gaaagccagt tctccaagtt cttaacctgt ggcactgaaa ggaatgttga 4201 gttacctctt catgttttag acagcaaacc ctatccatta aagtacttgt tagaacactg

1 gcgggcggag gcggggcgcg gagaagtggc ggaggtggaa gcggaggcgt acccgcccct 61 ggggacgtca ttggtggcgg aggcaatggc cggcaaccag ctgtaagcga ggcacggaag

121 acatatgctt gtgagacaaa ggtgtctctg aaactatgga tggtacaaga acttcacttg

181 acattgaaga gtactcggat actgaggtac agaaaaacca agtactaact ctggaagaat

241 ggcaagacaa gtgggtgaac ggcaagactg cttttcatca ggaacaagga catcagctat

301 taaagaagca tttagatact ttccttaaag gcaagagtgg actgagggta ttttttcctc 361 tttgcggaaa agcggttgag atgaaatggt ttgcagaccg gggacacagt gtagttggtg

421 tggaaatcag tgaacttggg atacaagaat tttttacaga gcagaatctt tcttactcag

481 aagaaccaat caccgaaatt cctggaacca aagtatttaa gagttcttcg gggaacattt

541 cattgtactg ttgcagtatt tttgatcttc ccaggacaaa tattggcaaa tttgacatga

601 tttgggatag aggagcatta gttgccatca atccaggtga tcgcaaatgc tatgcagata 661 caatgttttc cctcctggga aagaagtttc agtatctcct gtgtgttctt tcttatgatc

721 caactaaaca tccaggtcca ccattttatg ttccacatgc tgaaattgaa aggttgtttg

781 gtaaaatatg caatatacgt tgtcttgaga aggttgatgc ttttgaagaa cgacataaaa

841 gttggggaat tgactgtctt tttgaaaagt tatatctact tacagaaaag taaatgagac

901 atagataaaa taaaatcaca ctgacatgtt tttgaggaat tgaaaattat gctaaagcct 961 gaaaatgtaa tggatgaatt tttaaaattg tttataaatc atatgataga tctttactaa

1021 aaatggcttt ttagtaaagc catttacttt ttctaaaaaa gttttagaag aaaaagatgt

1081 aactaaactt ttaaagtagc tcctttggag aggagattat gatgtgaaag attatgccta

1141 tgtgtcttgc agattgcaag atattttacc aatcagcatg tgttacctgt acaattaaaa

1201 aaatatttca aaatgcaatg catattaaat ataatacaca cagaaaaact ggcatttatt 1261 ttgttttatt tttttgagat ggagtttcgt tcttgttgcc caacctggag tgcaatggtg

1321 caatctcagc tcactgcaac ctctgcctcc caggttcagg tgattctcct gcctcagcct

1381 cctgagtagc tgggattaca ggtgtgcgcc accacgccca gctaattttt tgtattttta

1441 gtagagacag ggtttcacca tgttggtcag gctgatctcg agctcctgac ctcaggtgat

1501 ctacccacct cggcctccca aagtgctggg attacaggcg tgagccactg cacctggcct 1561 gacattcttt atgaaattta gaattgttga agaactataa catttcagta gggttcaagg

1621 tggtcccaaa agttatataa aagattagtt tttactataa acccttgtct tttactcaga

1681 tcctagcatc ccttttcaca tggtttctcc atgtatataa cagaatcaag aaacaaattt

1741 taattaaaca atctgtaaca gaatcaagaa acaaatacat tttaattaaa caatctatat

1801 ggaacaaaca ttcccaaatt ctaagaataa atttttcttt aagttttctc tgagtttggc 1861 aattgttgtt ttttataatt taatctgttt aaatcatcag gtcttataaa atataatgta

1921 cttagagctg gattcatggc tgtttattat gaaaggttag atttctcagt tcttctttaa

1981 ccacattttg ttatatcaga cagtcctcta taactctgta ctacccaaca actaaatggt

2041 ttagattgtt tagctcatgt taataggatg gttgtgtatt ataaaaaacg agttacgtgt

2101 gtgtgtgcac gcatgcacgc acatgtgctg gcttaaaggt tgttaatgca aggtttgggg 2161 tcccctttaa cactggtgaa agctacggta ctctccccag agatatgtct tgtcagcctc

2221 tctagttccc cttggcctgc atgtacaaac ttctacccta gaagctctct gccatcgatg

2281 tattctaata gatttgtaag gctattaatt tgaagcaact ccttgctcac agtgattctt

2341 gcttctctga gacctgctcc cagtcgatac tgtgggcttc agaagccatg actccccaac

2401 tctgcctgta tcaccggttg aatggacaac taacccgagc tggaccaaca caattctctc 2461 cagagacttt tgattttact tttatgtaga gacagggtct cactttgttg cccacgctga

2521 tgttgaactt gacgtgaggc ctcaagcagt cctcctgtct tggccaccca aagtgctagg

2581 attacaggta tgagccattg cgctggccct cttcataggc ttttggactt gggaatagaa

2641 aagcaacccc gtctctacta aaaatacaaa aaaattagcc aggcgtggtg gcacgtgcct

2701 gtaatcccag ctacttggga ggctgaggca ggagaatcac ttgaacctag gaggcggagg 2761 ttgcagtgag ctgagatcat gccactgcac gcaagcctgg gcaacagagc aagactctgt

2821 ctcaaaagaa agaaaaagaa aagaaaaaaa agaaaggcaa gttgactgct gaaaggggaa

2881 tctgtgtacg cctgggagct gtggggcagc cacattccag cacatggatc tgagaaacag

2941 aacgctgatc tgcagaaaga gatgagaacc aaagagaggc cacctgcgtc ctgggtccat

3001 tttcatcctc cctgaagccc agctgcccag ggtggggaga aacaccctgt gtccatggga

3061 tagagtcctt tccgcttgca gttgtgccca aagaatctta aatacaaatg agatatcctt

3121 aggtagttga tcatttatgt aatatgtgtc ttcactgggg aatactgact tcctaaaatc

3181 tcaagatgga agatatacca catgtaaatt attttagagc aattaaattg ttttcaggat

3241 tttccaaaaa

1 ggcctcgagg gacaggacgt gaagatagtt gggtttggag gcggccgcca ggcccaggcc 61 cggtggacct gccgccatgc aggacggtaa cttcctgctg tcggccctgc agcctgaggc

121 cggcgtgtgc tccctggcgc tgccctctga cctgcagctg gaccgccggg gcgccgaggg

181 gccggaggcc gagcggctgc gggcagcccg cgtccaggag caggtccgcg cccgcctctt

241 gcagctggga cagcagccgc ggcacaacgg ggccgctgag cccgagcctg aggccgagac 301 tgccagaggc acatccaggg ggcagtacca caccctgcag gctggcttca gctctcgctc

361 tcagggcctg agtggggaca agacctcggg cttccggccc atcgccaagc cggcctacag

421 cccagcctcc tggtcctccc gctccgccgt ggatctgagc tgcagtcgga ggctgagttc

481 agcccacaac gggggcagcg cctttggggc cgctgggtac gggggtgccc agcccacccc

541 tcccatgccc accaggcccg tgtccttcca tgagcgcggt ggggttggga gccgggccga 601 ctatgacaca ctctccctgc gctcgctgcg gctggggccc gggggcctgg acgaccgcta

661 cagcctggtg tctgagcagc tggagcccgc ggccacctcc acctacaggg cctttgcgta

721 cgagcgccag gccagctcca gctccagccg ggcagggggg ctggactggc ccgaggccac

781 tgaggtttcc ccgagccgga ccatccgtgc ccctgccgtg cggaccctgc agcgattcca

841 gagcagccac cggagccgcg gggtaggcgg ggcagtgccg ggggccgtcc tggagccagt 901 ggctcgagcg ccatctgtgc gcagcctcag cctcagcctg gctgactcgg gccacctgcc

961 ggacgtgcat gggttcaaca gctacggtag ccaccgaacc ctgcagagac tcagcagcgg

1021 ttttgatgac attgacctgc cctcagcagt caagtacctc atggcttcag accccaacct

1081 gcaggtgctg ggagcggcct acatccagca caagtgctac agcgatgcag ccgccaagaa

1141 gcaggcccgc agccttcagg ccgtgcctag gctggtgaag ctcttcaacc acgccaacca

1201 ggaagtgcag cgccatgcca caggtgccat gcgcaacctc atctacgaca acgctgacaa

1261 caagctggcc ctggtggagg agaacgggat cttcgagctg ctgcggacac tgcgggagca 1321 ggatgatgag cttcgcaaaa atgtcacagg gatcctgtgg aacctttcat ccagcgacca

1381 cctgaaggac cgcctggcca gagacacgct ggagcagctc acagacctgg tgttgagccc

1441 cctgtcgggg gctgggggtc cccccctcat ccagcagaac gcctcggagg cggagatctt

1501 ctacaacgcc accggcttcc tcaggaacct cagctcagcc tctcaggcca ctcgccagaa

1561 gatgcgggag tgccacgggc tggtggacgc cctggtcacc tctatcaacc acgccctgga 1621 cgcgggcaaa tgcgaggaca agagcgtgga gaacgcggtg tgcgtcctgc ggaacctgtc

1681 ctaccgcctc tacgacgaga tgccgccgtc cgcgctgcag cggctggagg gtcgcggccg

1741 cagggacctg gcgggggcgc cgccgggaga ggtcgtgggc tgcttcacgc cgcagagccg

1801 gcggctgcgc gagctgcccc tcgccgccga tgcgctcacc ttcgcggagg tgtccaagga

1861 ccccaagggc ctcgagtggc tgtggagccc ccagatcgtg gggctgtaca accggctgct 1921 gcagcgctgc gagctcaacc ggcacacgac ggaggcggcc gccggggcgc tgcagaacat

1981 cacggcaggc gaccgcaggt gggcgggggt gctgagccgc ctggccctgg agcaggagcg

2041 tattctgaac cccctgctag accgtgtcag gaccgccgac caccaccagc tgcgctcact

2101 gactggcctc atccgaaacc tgtctcggaa cgctaggaac aaggacgaga tgtccacgaa

2161 ggtggtgagc cacctgatcg agaagctgcc gggcagcgtg ggtgagaagt cgcccccagc 2221 cgaggtgctg gtcaacatca tagctgtgct caacaacctg gtggtggcca gccccatcgc

2281 tgcccgagac ctgctgtatt ttgacggact ccgaaagctc atcttcatca agaagaagcg

2341 ggacagcccc gacagtgaga agtcctcccg ggcagcatcc agcctcctgg ccaacctgtg

2401 gcagtacaac aagctccacc gtgacttccg ggcgaagggc tatcggaagg aggacttcct

2461 gggcccatag gtgaagcctt ctggaggaga aggtgacgtg gcccagcgtc caagggacag 2521 actcagctcc aggctgcttg gcagcccagc ctggaggaga aggctaatga cggaggggcc

2581 cctcgctggg gcccctgtgt gcatctttga gggtcctggg ccaccaggag gggcagggtc

2641 ttatagctgg ggacttggct tccgcagggc agggggtggg gcagggctca aggctgctct

2701 ggtgtatggg gtggtgaccc agtcacattg gcagaggtgg gggttggctg tggcctggca

2761 gtatcttggg atagccagca ctgggaataa agatggccat gaacagtcaa

1 agtgtttatc agaacttagc cagggccagc caagcaggca cagatgctct gctatgaaat

61 gccacgcagg cagagactga caagcggtag gaactgagct ttccccttgg actgctgctt

121 cctgctgtgt tcaggggagg gggtcacttt ctggcaactc tgctgctgct gctgctgctg

181 ctgctacttc agcttcctct ccactcaagg taagcaggct aagggagggc aggctgctag 241 ggaaagcttt gtaccatgaa caggatccga aagtttttcc gaggaagtgg gcgagtcttg

301 gcatttatct ttgtagcttc tgtcatctgg ctcctctttg acatggcagc tctccgcctc

361 tcattcagtg agatcaacac tcgggtcatc aaggaagaca ttgtgaggag ggagcggata

421 ggattcagag ttcagccaga ccaaggaaaa attttttaca gcagcataaa agagatgaaa

481 cctcccctaa ggggacatgg gaaaggggca tggggcaaag agaatgttag aaaaactgag 541 gagagtgtgc tcaaggttga ggtggacttg gaccaaaccc agagggaaag aaaaatgcag

601 aatgccctgg gaaggggcaa ggttgtgccg ttgtggcatc ctgcacatct gcagaccctc

661 cctgtgactc ctaacaagca gaagacagac gggagaggca ccaaacctga agcctcctct

721 caccagggga caccaaagca aacgacagct cagggggctc caaagacctc attcatagca

781 gcaaaaggaa ctcaggtagt caaaatatca gtacacatgg gacgtgtcag tttaaaacag 841 gagccccgga agagtcatag tcccagcagt gacacatcaa aactagcagc tgaaagggac

901 ttgaatgtga ccatcagtct tagtactgat agaccaaagc agcgatcaca ggcagtagca

961 aacgagaggg cacaccctgc cagcacagca gtgccgaagt ctggggaagc catggcctta

1021 aacaaaacta agactcagag caaagaagtc aatgcaaata aacacaaagc caatacgagt

1081 cttccttttc ctaagttcac tgtcaattca aatcgcttaa ggaagcaatc tattaatgag 1141 acacctttgg gaagtttgtc aaaggatgat ggagctagag gggctcatgg gaagaaactc

1201 aatttctctg aaagccatct tgtgattata accaaagagg aagagcaaaa ggcagacccc

1261 aaagaggtct ctaattctaa aaccaaaaca atatttccta aagtattggg taaaagccaa

1321 agtaaacaca tttccaggaa tagaagtgag atgtcttcct cttcacttgc tccacataga

1381 gtgccactgt cccaaactaa ccatgcttta actggagggc tagagccagc aaaaatcaac

1441 ataactgcca aagccccctc tacagaatac aaccagagtc atataaaagc ccttttacct

1501 gaagacagtg gaacgcacca ggtgttaaga attgatgtga cactttctcc aagggacccc 1561 aaagctccag ggcagtttgg gcgtcctgta gttgtccccc atggaaagga gaaggaggca

1621 gaaagaagat ggaaagaagg aaacttcaat gtctacctta gcgatttgat cccagtggat

1681 agagccattg aagacaccag acctgctgga tgtgcagagc agctagttca caataacctc

1741 ccaaccacca gtgtcatcat gtgctttgtg gatgaagtgt ggtccactct cctgagatct

1801 gttcacagtg tcatcaatcg ctctcctcca cacctcatca aggagattct gctggtagat 1861 gacttcagca ccaaagacta tctaaaagat aatttggata aatacatgtc ccagtttcca

1921 aaagttcgga ttcttcgcct caaagagaga catggcttaa taagggccag gctggcagga

1981 gcacagaatg caacaggtga tgtgttgaca tttttagatt ctcatgtgga atgtaacgtt

2041 ggttggttgg aacctcttct ggaaagagtt tatttaagta gaaagaaagt ggcctgtcca

2101 gtaatcgaag tcatcaatga taaggatatg agttacatga cagtggataa ctttcaaaga 2161 ggcatctttg tgtggcccat gaactttggt tggagaacaa ttcctccaga tgtcattgca

2221 aaaaacagaa ttaaagaaac tgatacaata aggtgccctg tcatggctgg tggattgttt

2281 tctattgaca aaagttactt ttttgaactt ggaacatacg accctggcct tgatgtttgg

2341 ggtggggaaa atatggagct ctcattcaag gtgtggatgt gtggtggtga aattgagatc

2401 attccctgct cccgagtggg ccatatattc agaaatgaca atccatattc cttccccaaa 2461 gaccggatga agacagtgga gcggaacttg gtgcgggttg ccgaggtctg gctggatgag

2521 tataaggagc tgttctatgg ccacggagac cacctcatcg accaagggct agatgttggc

2581 aacctcaccc agcaaaggga gctgcgaaag aaactgaagt gcaaaagttt caaatggtac

2641 ttggagaatg tctttcctga cttaagggct cccattgtga gagctagtgg tgtgcttatt

2701 aatgtggctt tgggtaaatg catttccatt gaaaacacta cagtcattct ggaagactgc 2761 gatgggagca aagagcttca acaatttaat tacacctggt taagacttat taaatgtgga

2821 gaatggtgta tagcccccat ccctgataaa ggagccgtaa ggctgcaccc ttgtgataac

2881 agaaacaaag ggctaaaatg gctgcataaa tcaacatcag tctttcatcc agaactggtg

2941 aatcacattg tttttgaaaa caatcagcaa ttattatgct tggaaggaaa tttttctcaa

3001 aagatcctga aagtagctgc ctgtgaccca gtgaagccat atcaaaagtg gaaatttgaa

3061 aaatattatg aagcctgaag tgtaactgat gtttttatat agtaaaccca ttaaatactg

3121 tgaaaataac a

1 ggggctgagg gtggagagag gaagggaagg aagaaaaggg gagccttcct ggccagggta 61 accggcacta agaggcctca ctccaagccc ccgaggagcc tgtggtgggg ctggagaccc 121 ggctcaggcc cctccaccac ccttaaagtc ctcagaaggt gggaactgaa ctggcacagg

181 atgggaaccg gctgtgcgct ggccacttga ttttgccagc tgccctgtaa ttcagctggt

241 gaggaaactg aggcacagac tgaggtagaa tgattcgcca gtcactcagc aagtcagcag

301 acggggagga ctgaatccca gcctgagagc accgaagctt gtatccctgc aataccgagc

361 cccaagcctg cgagccccgg tgcccatctc tgagttaggc cgtcttggaa gggttccctt 421 cctcctacaa gatggtgtgt gaggagcctt caatacgacc cggggtgtaa agtgtccaac

481 tctagtaggg gcctgatggc atccccgccg agtcccagga gagagagaga agaccccttc

541 ctggagtcca gggctcccgg gaagaaacac tggcatttgt ccctttgctt cggcttctgg

601 aggcagagac tctgagccca gggagagcct tctgcagccc catttcctca aaaatccaac

661 ctgcccaggt ggcgggtcat gagctgtgct caggaagctg gaatctgacc ctggtggcgt 721 cgggcccagt ctccatggca gccgagcatt tattacccgg gcctccaccc agcttggcag

781 actttagact tgaggctgga ggaaagggaa ctgaacgcgg ttctgggagc agcaagccca

841 cgggtagcag ccgaggcccc agaatggcca agtttctttc ccaagaccaa attaatgagt

901 acaaggaatg cttctccctg tatgacaagc agcagagggg gaagataaaa gccaccgacc

961 tcatggtggc catgaggtgc ctgggggcca gcccgacgcc aggggaggtg cagcggcacc 1021 tgcagaccca cgggatagac ggaaatggag agctggattt ctccactttt ctgaccatta

1081 tgcacatgca aataaaacaa gaagacccaa agaaagaaat tcttctagcc atgttgatgg

1141 tggacaagga gaagaaaggt tacgtcatgg cgtccgacct gcggtcaaaa ctcacgagtc

1201 tgggggagaa gctcacccac aaggaagtgg atgatctctt cagggaagca gatatcgaac

1261 ccaatggcaa agtgaagtat gatgaattta tccacaagat cacccttcct ggacgggact

1321 attgaaggag gagaatggga gagcctcccc tgggcctgaa aacttggagc aattaatttt

1381 ttttaaaaag tgttcttttc acttgggaga gatggcaaac acagtggcaa gacaacatta 1441 cccaactata gaagagaggc taactagcaa caataataga tgatttcagc catggtatga

1501 gtagatcttt aataaaagat ttgtattgat tttattaact accgtgagtc cggccctttc

1561 aagcatggaa ggagcctgcg gtttggagtc tggcctgggt tccagtcctg gctctgctgc

1621 ttcccactgt gactttgggc aaatcatttc actcctcaaa gcccccccac acaagctgga

1681 ttcccacttc ttacctcatg gagcctgttg aggaaggatt gagctgatga cttaagggca 1741 atctaccaag agacttattc tgtatttggg ggctagaacc atcttccata tttccaagat

1801 tttccaagat gaagccagtg ctagctgaga agcagcaatg aacagaaagc tgtaacactt

1861 atgacaacaa ttcttgcagt gccagaggcc catttacaaa ttctcatttc catctcaaca

1921 gatatagtga catagctcag gctattcatt cataaacaca gagtgtagag tgaaaacact

1981 agagtgaaaa cacatgctac aatgaggcag catcagctga gagcaggaag agcgatctac 2041 tttacacccc acaccaaagg aaaccagatg tgagctgcta aattgactgg ccttgcagag

2101 ctcaagaagg gggcttccaa tgctgtgaga attccgagct gttccctggg ctctgttaac

2161 aggcagagag gttccgggat ggtctgctca agtggcccac actggtcatt gccttaagcc

2221 acctccccag gacttacgga gagaaataag gggatgtaac cagcaatggc cagggtacaa

2281 cagccctgga aaacagtagt aggagcacta ggctttctgg gagtccatcc agctggagtg 2341 gctttgagtg agttacacag ctagaaggtg ccaggttggt gctgccagag attcagaggt

2401 gccatacact tgtcaaatct ggatcattcg tagtgccagc acagtcctaa aagggctgga

2461 gtaccacacc aacacaggta ggggtgcagg gcttcaagta caaagatttg catccatgta

2521 tgtatcaaaa gtgggttctc tgggctgtgg ctttgtctag tagtaccaca gtggctaaag

2581 tagaagaaaa ccaaatcaaa tgggatgtgt cttttgggag gatgtacaag acacaaatct 2641 ttcactaggc accgggcaca gggaaaactg cagggaacaa gagttgtagt gttagtgcaa

2701 ctgtctcaac gatgctgtgt ggcttcagac ccaaacaagg ccctgaggaa ggagactctc

2761 atttccccaa gcataactgc aaggagagga ggaattccta ggagccaaag agttttgtgg

2821 ggtgagggta aataaatggc ccaaatgcca actaggtgaa gttgtgacca tctggctggg

2881 aagcccaggt ccacacagtg taggagcaga tgttttgtgg ggtctgaggt ttacgagatt

2941 tggctgcctt aagaatacaa aaacagaaat gcagaatttc tggggctgct cctaggacca

3001 gaacaagtga agggtcctgg tgcttaaact tcattacctt catggtaaat ccaccagagg 3061 gccggttaga tgctggcccc gccgagagaa ctgctgtcac tttcaggcaa agctcaaagg

3121 tcctaggccc acagttcttt tgagctccag tcatggacat taggaagtaa atcctgcaca

3181 gccaacctgg aataccaaag attagatggg agatagatac caatgattta gatggcacag

3241 gaagagcaag ttctggatat aataaatgag ggtactttcc gtcaaagctt ttctatgtct

3301 atatttatca ctgaatagtc ccagtatggt tttaaagcaa gttttatgaa tctcatttgc 3361 ctaacaggaa tctgaaatat aacttgccaa aaacacacag ttggtgtgga atggtcatta

3421 gaacctgggg ctcctcttca cggactccct gctcattaag ggattcagtg gtccagagtc

3481 taagatccta ttaagtgttt gattcaaacc tctacccgag gaagggctgt taccttactc

3541 ctggtcctgg tttcaagctc attcctgaaa ttccagctgg tttctctagc acctagtgtt

3601 gtttacaaga aggccacggt gctcttagca ttcaaactgc agatactaaa cagatgctgt 3661 gatttattaa agagttagcc atatttcaac aagaaaggga aatgatggct atattcatta

3721 cttacctcaa agcatgctgc aagaaaatta gttagttact tgtcatgctt tgaaatctct

3781 ggatgaaagg tgctttggaa gcacaaacca ttatcacttg tctcataggg attgtcccct

3841 tgaacatcca gcagtgttat tttacagaag acaaattaac tgaaggcttt tcttttatta

3901 catctaaaga gctctacata aacaggtaac attcaatagg taaacaattt ttttccaatg 3961 catgtaataa atattttcac ttggtacttt tatacaaact gacattgtct actatacatt

4021 tttaaaagcc attttactgg tttggcatgc ggtatggaaa ttctaagaga gaaagtttta

4081 aggcaatgaa tcacagattt aagttcatgg aatttatggt aactttatct gtttatgtac

4141 attttcccct ttgttaaaca attaacagca gcacactctg ggaccaccag ctattttccc

4201 tctctttctg aaatctaagc tttgtattta attaaaaaac agaattcaac atctattgat 4261 aaaacaaaat tcttactaaa ataatttcaa atgtgcttta aaaagtcctg aagatcttga

4321 aagttttatg tgtttaaaat tgaaattgtc taaaaaaatg ctctttccac attaatttag

4381 ttaggatata ttttcactcc atttcagaca cttgactcaa aggaaaatct gccaaagaat

4441 ccgatttttc agagcttacg tgaatctttc ctcagtaaag atacagaatt gtgatcatgt

4501 ctaaataatt agtaaagcaa ttttaatgct caaaatagtc aaccaagtat ggcatggttc

4561 tggttcagat tttttttttt taagatgtat ccaataacac tcacgaagta attaaaagcc

4621 actttaaccc tgctaaaaaa

1 cattttataa tgaagcctgg tcaactctcc ttcggacagt ttacagtgtc cttgagacat

61 ccccggatat cctgctagaa gaagtgatcc ttgtagatga ctacagtgat agagagcacc

121 tgaaggagcg cttggccaat gagctttcgg gactgcccaa ggtgcgcctg atccgcgcca

181 acaagagaga gggcctggtg cgagcccggc tgctgggggc gtctgcggcg aggggcgatg 241 ttctgacctt cctggactgt cactgtgagt gccacgaagg gtggctggag ccgctgctgc

301 agaggatcca tgaagaggag tcggcagtgg tgtgcccggt gattgatgtg atcgactgga

361 acaccttcga atacctgggg aactccgggg agccccagat cggcggtttc gactggaggc

421 tggtgttcac gtggcacaca gttcctgaga gggagaggat acggatgcaa tcccccgtcg

481 atgtcatcag gtctccaaca atggctggtg ggctgtttgc tgtgagtaag aaatattttg 541 aatatctggg gtcttatgat acaggaatgg aagtttgggg aggagaaaac ctcgaatttt

601 cctttaggat ctggcagtgt ggtggggttc tggaaacaca cccatgttcc catgttggcc

661 atgttttccc caagcaagct ccctactccc gcaacaaggc tctggccaac agtgttcgtg

721 cagctgaagt atggatggat gaatttaaag agctctacta ccatcgcaac ccccgtgccc

781 gcttggaacc ttttggggat gtgacagaga ggaagcagct ccgggacaag ctccagtgta 841 aagacttcaa gtggttcttg gagactgtgt atccagaact gcatgtgcct gaggacaggc

901 ctggcttctt cgggatgctc cagaacaaag gactaacaga ctactgcttt gactataacc

961 ctcccgatga aaaccagatt gtgggacacc aggtcattct gtacctctgt catgggatgg

1021 gccagaatca gtttttcgag tacacgtccc agaaagaaat acgctataac acccaccagc

1081 ctgagggctg cattgctgtg gaagcaggaa tggataccct tatcatgcat ctctgcgaag 1141 aaactgcccc agagaatcag aagttcatct tgcaggagga tggatcttta tttcacgaac

1201 agtccaagaa atgtgtccag gctgcgagga aggagtcgag tgacagtttc gttccactct

1261 tacgagactg caccaactcg gatcatcaga aatggttctt caaagagcgc atgttatgaa 1321 gcctcgtgta tcaaggagcc catcgaagga gactgtggag ccaggactct gcccaacaaa

1381 gacttagcta agcagtgacc agaacccacc aaaaactagg ctgcattgct ttgaagaggc

1441 aatcattttg ccatttgtga aagttgtgtt ggatttagta aaaatgtgaa taagctttgt

1501 acttattttg agaacttttt aaatgttcca aaatacccta ttttcaaagg gtaatcgtaa

1561 gatgttaacc cttggtattt agaaaattaa aaccttataa tatttttcta tcaagatgta 1621 tattttacag tcgtgccttt tactctcatt agcaaaaaag ataaagattt tattttggta

1681 tttacaagaa ttcccaggta cgaagatatc tgcatgggtg gaaatcaggt tcaagcaacg

1741 tactttgcat taactgataa tacctcagct gcggggttaa agttttccca gtatagagag

1801 actgtcacta ggaacattgt attgatttat tcaggtcatt gagatcttct agatgtattt

1861 taaaaagaat gctttttggt tatgtgttgc taccacagtt aacactccat aatgttcatg 1921 tcagccaaag aggactaacc aaagctgaaa tctcagagaa caatttgctt tactaagctg

1981 agtcaacttg agagcgaact tctaacaatg ccgcactgta gtgtggctgg ttctaccact

2041 atgactttaa aacatgttta tatcattttt aatttttatg atacggtagt gtcagggaga

2101 aatgtaatgt tctatatgaa attccttttt caagtttgtt cattaataac agttattaat

2161 ttaaatcagc gttagagttt gtgctgctgc aactgctgtg aaaatttctc tgagtaattc 2221 tgatttgtga atgatcccag accaaccctg agattttgtc aacctgatta agtcaatatg

2281 aatgattaaa aagatgtgag

1 aaggctcctc agccgagcgc cgagcggtcg atcgccgtag ctcccgcagc ctgcgatctc 61 cagtctgtgg ctcctaccag ccattgtagg ccaataatcc gttatggagc atgcctttac

121 cccgttggag cccctgcttt ccactgggaa tttgaagtac tgccttgtaa ttcttaatca

181 gcctttggac aactattttc gtcatctttg gaacaaagct cttttaagag cctgtgccga

241 tggaggtgcc aaccgcttat atgatatcac cgaaggagag agagaaagct ttttgcctga

301 attcatcaat ggagactttg attctattag gcctgaagtc agagaatact atgctactaa

361 gggatgtgag ctcatttcaa ctcctgatca agaccacact gactttacta agtgccttaa 421 aatgctccaa aagaagatag aagaaaaaga cttaaaggtt gatgtgatcg tgacactggg

481 aggccttgct gggcgttttg accagattat ggcatctgtg aataccttgt tccaagcgac

541 tcacatcact ccttttccaa ttataataat ccaagaggaa tcgctgatct acctgctcca

601 accaggaaag cacaggttgc atgtagacac tggaatggag ggtgattggt gtggccttat

661 tcctgttgga cagccttgta tgcaggttac aaccacaggc ctcaagtgga acctcacaaa 721 tgatgtgctt gcttttggaa cattggtcag tacttccaat acctacgacg ggtctggtgt

781 tgtgactgtg gaaactgacc acccactcct ctggaccatg gccatcaaaa gctaacctgt

841 tgactggcat ccataagtgt gcctctgcct tatctcattt ctcaacagtt cattgctcaa

901 caagaacgat tcacctgggt ttgcaagaat ctaaacctct ctaggggaag cccactgggt

961 ttaaagatgt tagtgtttag ataatacagg taacattata aatgacagat ctcaatttta 1021 tagtagtggg aaagatacat gctaagaaag caaataagct ctattatatt cggttggaac

1081 ctaatgggaa tcattccact atacaattca gtactgatta ttcttcttac attattaatc

1141 attccattta tcctagaaaa ttgtttttaa tttgaatcag agaaaactgt tgaggttcct

1201 cttggagtct agaacatcct taaatgtcta acaacaaggg ctacctctga gtacctttta

1261 gtattagttt tctgtatatg atatatatta tcttatactg aaaaaaaatt cctttcagat 1321 tggggtgtta gaagtgcacc aggtcactct gaccttatta ctgtctttgg tattgtctta

1381 aataaatcaa gaatcattga cctaattgtt aaatttaaaa ataggtagtt agcaataggt

1441 ggaaagagaa atgatgtgaa agataaatga tgattcgtgg agccctactc acacattaac

1501 ccccaaattc aaaagtaaga atgcaaaagt ctagaggggg taacagtctg catcatcatc

1561 acaacctaaa tggagaaagc tgtgcagagg aaacttaagc ataaaaattg aattcgtttc 1621 tgacatacct tagactgaaa aactgttggt tcatccagaa gtgtattcat attaccagaa

1681 aatgagtttg tctatgggga tacatgaact tcatatacta aggagcctaa ctccaaagcc

1741 tgcgttctca tcccagtctg atattcacct aagtttccgg acccttttcc ttagctgtaa

1801 aatggaagcg gttggactga tggtgtctga ggttctttcc cacactgaaa ttctaaatat

1861 tgacacttag cagtcatagg gctgataata cacacagtta ctgacttagc ctaaacaacc

1921 tggtgcatcg aaatgtattc acctttcttt tgtaaagaga ccatcttcta tcttctttcc 1981 acctttctct gttttatgaa accaactgtt gacatacaaa ccatgattga aggagaacct 2041 gtccaacatg ttttatgtac acaaatccct atgttgctat aagaaaagtg aaagtaactg 2101 ttttcttctt ggtgctatga cagtgtgaga ctcaggttgt ctgtagagaa tgaaaggagc 2161 agtggcccgc gtgattgtgg catttaagga gcagtggccc atgtgactgt ggcattttcg 2221 gcacttttca ttactttctg cttgaccgga agttgaggct tagctatgtt tccatcttca 2281 gtttctgaag actagttata tattccttac tagaaatata ttcataatat ataaaagaaa 2341 tatatctgtg attttaaaat tttgctacca aagaatgcat gttctgtgtg ccctgaaaat 2401 gttaccagtg ttaataaatg gatacttatc aaaaaagaaa

1 acacatctgc tcctgctctc tctcctccag cgaccctagc catgagaacc ctcaccatcc

61 tcactgctgt tctcctcgtg gccctccagg ccaaggctga gccactccaa gctgaggatg 121 atccactgca ggcaaaagct tatgaggctg atgcccagga gcagcgtggg gcaaatgacc 181 aggactttgc cgtctccttt gcagaggatg caagctcaag tcttagagct ttgggctcaa 241 caagggcttt cacttgccat tgcagaaggt cctgttattc aacagaatat tcctatggga 301 cctgcactgt catgggtatt aaccacagat tctgctgcct ctgagggatg agaacagaga 361 gaaatatatt cataatttac tttatgacct agaaggaaac tgtcgtgtgt cccatacatt 421 gccatcaact ttgtttcctc atctcaaata aagtcctttc agcaaaaaaa aaaaa

1 gcgctaggta gagcgccggg acctgtgaca gggctggtag cagcgcagag gaaaggcggc 61 ttttagccag gtatttcagt gtctgtagac aagatggaat catctccatt taatagacgg

121 caatggacct cactatcatt gagggtaaca gccaaagaac tttctcttgt caacaagaac

181 aagtcatcgg ctattgtgga aatattctcc aagtaccaga aagcagctga agaaacaaac

241 atggagaaga agagaagtaa caccgaaaat ctctcccagc actttagaaa ggggaccctg

301 actgtgttaa agaagaagtg ggagaaccca gggctgggag cagagtctca cacagactct 361 ctacggaaca gcagcactga gattaggcac agagcagacc atcctcctgc tgaagtgaca

421 agccacgctg cttctggagc caaagctgac caagaagaac aaatccaccc cagatctaga

481 ctcaggtcac ctcctgaagc cctcgttcag ggtcgatatc cccacatcaa ggacggtgag

541 gatcttaaag accactcaac agaaagtaaa aaaatggaaa attgtctagg agaatccagg

601 catgaagtag aaaaatcaga aatcagtgaa aacacagatg cttcgggcaa aatagagaaa 661 tataatgttc cgctgaacag gcttaagatg atgtttgaga aaggtgaacc aactcaaact

721 aagattctcc gggcccaaag ccgaagtgca agtggaagga agatctctga aaacagctat

781 tctctagatg acctggaaat aggcccaggt cagttgtcat cttctacatt tgactcggag

841 aaaaatgaga gtagacgaaa tctggaactt ccacgcctct cagaaacctc tataaaggat

901 cgaatggcca agtaccaggc agctgtgtcc aaacaaagca gctcaaccaa ctatacaaat 961 gagctgaaag ccagtggtgg cgaaatcaaa attcataaaa tggagcaaaa ggagaatgtg

1021 cccccaggtc ctgaggtctg catcacccat caggaagggg aaaagatttc tgcaaatgag

1081 aatagcctgg cagtccgttc cacccctgcc gaagatgact cccgtgactc ccaggttaag

1141 agtgaggttc aacagcctgt ccatcccaag ccactaagtc cagattccag agcctccagt

1201 ctttctgaaa gttctcctcc caaagcaatg aagaagtttc aggcacctgc aagagagacc 1261 tgcgtggaat gtcagaagac agtctatcca atggagcgtc tcttggccaa ccagcaggtg

1321 tttcacatca gctgcttccg ttgctcctat tgcaacaaca aactcagtct aggaacatat

1381 gcatctttac atggaagaat ctattgtaag cctcacttca atcaactctt taaatctaag

1441 ggcaactatg atgaaggctt tgggcacaga ccacacaagg atctatgggc aagcaaaaat

1501 gaaaacgaag agattttgga gagaccagcc cagcttgcaa atgcaaggga gacccctcac 1561 agcccagggg tagaagatgc ccctattgct aaggtgggtg tcctggctgc aagtatggaa

1621 gccaaggcct cctctcagca ggagaaggaa gacaagccag ctgaaaccaa gaagctgagg

1681 atcgcctggc caccccccac tgaacttgga agttcaggaa gtgccttgga ggaagggatc

1741 aaaatgtcaa agcccaaatg gcctcctgaa gacgaaatca gcaagcccga agttcctgag

1801 gatgtcgatc tagatctgaa gaagctaaga cgatcttctt cactgaagga aagaagccgc 1861 ccattcactg tagcagcttc atttcaaagc acctctgtca agagcccaaa aactgtgtcc

1921 ccacctatca ggaaaggctg gagcatgtca gagcagagtg aagagtctgt gggtggaaga

1981 gttgcagaaa ggaaacaagt ggaaaatgcc aaggcttcta agaagaatgg gaatgtggga

2041 aaaacaacct ggcaaaacaa agaatctaaa ggagagacag ggaagagaag taaggaaggt

2101 catagtttgg agatggagaa tgagaatctt gtagaaaatg gtgcagactc cgatgaagat 2161 gataacagct tcctcaaaca acaatctcca caagaaccca agtctctgaa ttggtcgagt

2221 tttgtagaca acacctttgc tgaagaattc actactcaga atcagaaatc ccaggatgtg

2281 gaactctggg agggagaagt ggtcaaagag ctctctgtgg aagaacagat aaagagaaat

2341 cggtattatg atgaggatga ggatgaagag tgacaaattg caatgatgct gggccttaaa

2401 ttcatgttag tgttagcgag ccactgccct ttgtcaaaat gtgatgcaca taagcaggta 2461 tcccagcatg aaatgtaatt tacttggaag taactttgga aaagaattcc ttcttaaaat

2521 caaaaacaaa acaaaaaaac acaaaaaaca cattctaaat actagagata actttactta

2581 aattcttcat tttagcagtg atgatatgcg taagtgctgt aaggcttgta actggggaaa

2641 tattccacct gataatagcc cagattctac tgtattccca aaaggcaata ttaaggtaga

2701 tagatgatta gtagtatatt gttacacact attttggaat tagagaacat acagaaggaa 2761 tttaggggct taaacattac gactgaatgc actttagtat aaagggcaca gtttgtatat

2821 ttttaaatga ataccaattt aattttttag tatttacctg ttaagagatt atttagtctt

2881 taaatttttt aggttaattt tcttgctgtg atatatatga ggaatttact actttatgtc

2941 ctgctctcta aactacatcc tgaactcgac gtcctgaggt ataatacaac agagcacttt

3001 ttgaggcaat tgaaaaacca acctacactc ttcggtgctt agagagatct gctgtctccc

3061 aaataagctt ttgtatctgc cagtgaattt actgtactcc aaatgattgc tttcttttct

3121 ggtgatatct gtgcttctca taattactga aagctgcaat attttagtaa taccttcggg 3181 atcactgtcc cccatcttcc gtgttagagc aaagtgaaga gtttaaagga ggaagaagaa

3241 agaactgtct tacaccactt gagctcagac ctctaaaccc tgtatttccc ttatgatgtc

3301 ccctttttga gacactaatt tttaaatact tactagctct gaaatatatt gatttttatc

3361 acagtattct cagggtgaaa ttaaaccaac tataggcctt tttcttggga tgattttcta

3421 gtcttaaggt ttggggacat tataaacttg agtacatttg ttgtacacag ttgatattcc 3481 aaattgtatg gatgggaggg agaggtgtct taagctgtag gcttttcttt gtactgcatt

3541 tatagagatt tagctttaat attttttaga gatgtaaaac attctgcttt cttagtctta

3601 cctagtctga aacattttta ttcaataaag attttaatta aaatttgaaa

1 gacagtcgcg gatcctgtga cacctccggg cagcccggca cttgttgctc ccacgacctg 61 ttgtcattcc cttaacccgg ctttccccgt ggccccccgc ctcctcccgg cttcgctcct

121 tttcatgtga gcatctggga cactgatctc tcagaccccg ctgctcgggc tggagaatag

181 atggttttgt gaaaaattaa acaccgccct gaagaggagc cccgctgggc agcggcagga

241 gcgcagagtg ctggcccagg tgctgcagag gtggcgcctc cccggcccgg gacggtagcc

301 ccgggcgcca acggcatgac agactcggcg acagctaacg gggacgacag ggaccccgag 361 atcgagctct ttgtgaaggc tggaatcgat ggagaaagca tcggcaactg tcctttctct

421 cagcgcctct tcatgatcct ctggctgaaa ggagtcgtgt tcaatgtcac cactgtggat

481 ctgaaaagaa agccagctga cctgcacaac ctagcccccg gcacgcaccc gcccttcctg

541 accttcaacg gggacgtgaa gacagacgtc aataagatcg aggagttcct ggaggagacc

601 ttgacccctg aaaagtaccc caaactggct gcaaaacacc gggaatccaa cacagcgggc 661 atcgacatct tttccaagtt ttctgcctac atcaaaaata ccaagcagca gaacaatgct

721 gctcttgaaa gaggcctaac caaggctcta aagaaattgg atgactacct gaacacccct

781 ctaccagagg agattgacgc caacacttgt ggggaagaca aggggtcccg gcgcaagttc

841 ctggatgggg atgagctgac cctggctgac tgcaatctgt tgcccaagct ccatgtggtc 901 aagattgtgg ccaagaaata ccgcaactat gatatcccgg ctgagatgac aggcctgtgg

961 cggtacctca agaacgccta tgcccgtgat gagttcacca acacctgtgc agctgacagt

1021 gagatcgagt tggcctacgc tgatgtcgcc aaacgcctca gccgatcctg agcacagcca

1081 ttttgcccca tccccgctgc agaaggactc aaccactccc ctaagactcc agcttcatag

1141 actcctctgt atcactgcct tgaggcgcac tttttataat caagcctcat cttgctggta 1201 tcatgggaac tccagcctgc tatctttcat gaaggtcagc accatccctg gcctcctcac

1261 ataggaatct agcagaaatg atagacacag tccacctttc ggccggccag cctgatctgg

1321 gctcagcatg tttggggtca gtcagtgttg gagagcccac atatgggatt gccactagct

1381 tcttctgcca atatcaaaat accttctcag atgctttaga aacatgcaac accaactcct

1441 tttctaccct cctctccgtc catacctaca aggccaagga caaacgccat cttcatcctt 1501 cttagaaaga gatctattac cccattaggg gagacagaga gagtgaatgg aggagtaccg

1561 agctggctat ggacttgggt gtctggcaaa cacagcttca gtctcactac ttctgacact

1621 ctggttattg ggcactaagg gccagactgg aaagtcactt gagacacatt ctcagtttgt

1681 tgcagtgcca ggaatgctgc gctgctgctg ctgcgcacct ggcccatgct gtccctggct

1741 tccatgccgt ccaggccctg ccagaaaagg aaattggcat gcaattctaa actgcagtga 1801 ctgggatggg aggggagggg agcagtgttg atgccaaaat acccacgggg tctaccagcc

1861 atggggtttg cttgcttagg agtagttgtt tcagaggtga ttacaggcct gggtttgact

1921 gtgcttacca atgagtggtt tttgagctat gagaaagtgg atgggagtgg gaggaggaga

1981 gatgggtgaa gacaaaagag ttctttatga gcctcgatgt tccctggtaa acttttaaaa

2041 aggccttctc tcatgatcta agtcttggac tggtggcatc atgtaactgc taaccttaca 2101 gtaaaaaccc aagaatgggt caaaaatgtc ttcccagttt ctccaagctg cttctggaat

2161 gcaggtctgt cggctgggtg ctctccagca gctgctcctg cctgattcaa ctgtagcctg

2221 taatgggtaa aagccacatt taggaggtgg tctgatcata gaacacctta ggaagaaagt

2281 ccatgagact ttctgactag gaaaccatgt ggtttgaact tgaagaaaaa tgtagaccca

2341 tctgggttaa ttttcctaca atctgactca actgccaggt gaaaaaaaaa aggaaaaatt

2401 tttaagctaa tatttcactc ttttgtcatt ctccttaagt ttcatctcct aaaaagctta

2461 cccagcctga gcttggggac ctgtgcagag gaaactaaga aaaatgcact catcaactcc 2521 ttctcccagt gaacgcccgg tgagaaaatc catttgccac aggcccttac cttcaacaat

2581 cccccttcta tagtgttcgc tggtaaaggg tgaggctccc aagtgctgga aagcccctgg

2641 acttggctca tttctcagca agggcaggat agcacgggtc ctttccatag aaatatcaac

2701 aaattctaac ccaagcaatc cctggaccta cctgcctcca gggatctctg aagaaaaaaa

2761 gtaacccatt gatcaaatca gaggagagga agcaggaggt ctcctagagc ccattgagga 2821 agaggaactt tctcagtagg acactttata agcctgagaa agctttgaaa aggcggaatg

2881 agttgattca tttccacctc aaaaggaacc tttccaggtc cccctggaaa ttgtgccctg

2941 gagatgttta acaaggagaa ctggtgagga aagagtcctt ttttactgta gggaaaagcc

3001 ccaaactggc ctcctggggg atgagggctg aaatgatccc gaaggccttt taattagtgt

3061 gaaatcctgc tgtactcaga aatccttccc cgaatttaca gcacaggcag gatgacctaa 3121 gaggcagttt acttccctga gacccacagt tgggctgttc tggaaacaca tctgtgaatc

3181 atagccaatt gccacagaga aaacagaacc aagcctccgg tgaggccact ccaccccaga

3241 gaagtctgca gaattccaag gactcggatt ggatgttcag aattcagcaa ctggaaagtc

3301 cttaaaaaca aacaggccaa accaaatcaa tattgctgtt tctagatgtc ccttctgtgg

3361 ttgagctagt tttacagaga taaatatatt aagacaagga ggtgggggtg ttatatgatc 3421 aatgatagcc atttgaaaga gagggaggag tacagaagga aggcacttct gggtacttaa

3481 ttcagaaatt tctttatatt tcagcactgg attatcatat aatgcaagtg actatggact

3541 aagagttagt tatggtgtct tatgactaga tttattatgg tatattaaag taacaataat

3601 attaatatta ccttcctttt tttttttgtt tcaaaagaga tctttctcca gatgcttcag

3661 cctgtctggc cttcttatca tatgtgcagc acatcatgtc tcagcaacag tgtggtgagg 3721 tccttaggtg tcccaagaac aactcaggga gcacgggagg gtctgcagtt gggaccccac

3781 aactatacag ctatagggta ggaggcttcc ttttcattgg tcctgaatga atacaaatcg

3841 ctcagaaagc attttggtgg cacagaaagg ggatgtattt gtgttgagat cttattttat

3901 tttgtattta tttatcttct ttgacttgca cagcactatt gggggtgggg gaagcagggt

3961 agtgggagac gaaggcagaa gcaagagtca aactcagaat gactgagttg aattcactgt

4021 ctagtcagca atgcctgctt ctgagtttgg cccagagaga aggtattgag taagatttta

4081 ataactgtaa aaagtaagct ggataagtaa aatcatgatg gatccaaagc acagtttctt 4141 catctcctga taaagaaagt caaatgcttg ataaattcag agtcacagat gtgagcatag

4201 ctatattctt ttaaacgaga ggtagagtga cctagcacta agcaaatgag ctgaaatgtc

4261 ggaaacagag tccatcagct tatttggcca cacgatccca aactagtttt atcttgggaa

4321 atggccctgt cctcagcatt cccttcttgt gctggtgggg ccagtgaagt cttgatctta

4381 tcagaaaaag gccacaccaa gtgcgagttt tcccaggctg actttccagg cccttatcaa 4441 atgaaacaac agaagctctt cacagttctg tgccccatgg ccactccaca gacagacaat

4501 accaagcatc ttagaactgt cataagatag gtcatgcctg aaatagatct tgaccatatg

4561 agagtcccag aaatcagcaa ggcctggaca aatagaacta agagagaggc agaggcagga

4621 agctgcgggt ctatcttgta aagagtttag catcactgtg agagtgtgtg tctaaaatta

4681 aattaaacta gaagcagcag gtgagtattt ggtaagtact tctgtgactc gcctcaattc 4741 ccactggcca ggggccatct caactgcacg gtgaatcaag atgctggtgt catcctcctt

4801 ggaaaaagga aatgttaact catggttaaa actaagtaca atgattccca agggatcact

4861 ttcttatttt tttaaatgac attaaggaga atcttaagaa agcatcagag aaagacatgt

4921 gcatgtgaag caccctgatt ctgatgttag gaaaacttaa gcgaacagga cctgctgcac

4981 acagccccat tgtcttctat ccatttctct ttatcattca aatcaagcaa catgtgccct 5041 cctcatcaac acacattctt cccctttgtc agtatgcatc tcccagctta gtgtcaggat

5101 actttcgatt cataattatg tatgatccaa agtgtgcata atttcattta acgttaaaga

5161 aatagatcca attcctttct tgcaaccaaa aataaataaa atacgttgcc tcaatataag

5221 gtttgggcta ttctgtgttt ctatagaagc aatctgtttt tggtaaaatg tacttttaag

5281 gatccagtca tctgaagtat tttatgtaga gttagagatt tcacaatatt gactatacat 5341 atatttaaaa tataaattat ccagctgatg tttgaatttg tcttactttc ctggccacct

5401 cgttgtccta ttttataagc tggggagtta actagcttaa caaaagatgc ttagcttttg

5461 taaaagaaca agtgtttcat tttacaaaga cactccaaat gatagttact tgattttctc

5521 gagaccttta actatggtga tgaataacag gacttgcttt caagccttaa taaatgtaaa

5581 atgcctttta atgaagatac agctgagtgt tttcctcatg aatctgaacc aattaccaat

5641 ttgtgttcca gtcttgattg gtattgactg attcaaataa agttggttta ttttcaaata

5701 tta

1 gcttttgtgg cggcgcccgc gctcgcaggc cactctctgc tgtcgcccgt cccgcgcgct

61 cctccgaccc gctccgctcc gctccgctcg gccccgcgcc gcccgtcaac atgatccgct

121 gcggcctggc ctgcgagcgc tgccgctgga tcctgcccct gctcctactc agcgccatcg

181 ccttcgacat catcgcgctg gccggccgcg gctggttgca gtctagcgac cacggccaga 241 cgtcctcgct gtggtggaaa tgctcccaag agggcggcgg cagcgggtcc tacgaggagg

301 gctgtcagag cctcatggag tacgcgtggg gtagagcagc ggctgccatg ctcttctgtg

361 gcttcatcat cctggtgatc tgtttcatcc tctccttctt cgccctctgt ggaccccaga

421 tgcttgtctt cctgagagtg attggaggtc tccttgcctt ggctgctgtg ttccagatca

481 tctccctggt aatttacccc gtgaagtaca cccagacctt cacccttcat gccaaccctg 541 ctgtcactta catctataac tgggcctacg gctttgggtg ggcagccacg attatcctga

601 ttggctgtgc cttcttcttc tgctgcctcc ccaactacga agatgacctt ctgggcaatg

661 ccaagcccag gtacttctac acatctgcct aacttgggaa tgaatgtggg agaaaatcgc

721 tgctgctgag atggactcca gaagaagaaa ctgtttctcc aggcgacttt gaacccattt

781 tttggcagtg ttcatattat taaactagtc aaaaatgcta aaataatttg ggagaaaata 841 ttttttaagt agtgttatag tttcatgttt atcttttatt atgttttgtg aagttgtgtc

901 ttttcactaa ttacctatac tatgccaata tttcctatct atccataaca tttatactac

961 atttgtaaga gaatatgcac gtgaaactta acactttata aggtaaaaat gaggtttcca

1021 agatttaata atctgatcaa gttcttgtta tttccaaata gaatggactc ggtctgttaa

1081 gggctaagga gaagaggaag ataaggttaa aagttgttaa tgaccaaaca ttctaaaaga 1141 aatgcaaaaa aaaagtttat tttcaagcct tcgaactatt taaggaaagc aaaatcattt

1201 cctaaatgca tatcatttgt gagaatttct cattaatatc ctgaatcatt cattttagct

1261 aaggcttcat gttgactcga tatgtcatct aggaaagtac tatttcatgg tccaaacctg

1321 ttgccatagt tggtaaggct ttcctttaag tgtgaaatat ttagatgaaa ttttctcttt

1381 taaagttctt tatagggtta gggtgtggga aaatgctata ttaataaatc tgtagtgttt 1441 tgtgtttata tgttcagaac cagagtagac tggattgaaa gatggactgg gtctaattta

1501 tcatgactga tagatctgtt aagttgtgta gtaaagcatt aggagggtca ttcttgtcac

1561 aaaagtgcca ctaaaacagc ctcaggagaa taaatgactt gcttttctaa atctcaggtt

1621 tatctgggct ctatcatata gacaggcttc tgatagtttg caactgtaag cagaaaccta

1681 catatagtta aaatcctggt ctttcttggt aaacagattt taaatgtctg atataaaaca 1741 tgccacagga gaattcgggg atttgagttt ctctgaatag catatatatg atgcatcgga

1801 taggtcatta tgatttttta ccatttcgac ttacataatg aaaaccaatt cattttaaat

1861 atcagattat tattttgtaa gttgtggaaa aagctaattg tagttttcat tatgaagttt

1921 tcccaataaa ccaggtattc t

1 aggaagagcc gcgggcccgg cggctgaggc caccccggcg gcggctggag agcgaggagg 61 agcgggtggc cccgcgctgc gcccgccctc gcctcacctg gcgcaggtgg acacctgcgc 121 aggtgtgtgc cctccggccc ctgaagcatg gccagcagcg gcatggctga cagcgccaac

181 cacctgccct tctttttcgg caacatcacc cgggaggagg cagaagatta cctggtccag

241 gggggcatga gtgatgggct ttatttgctg cgccagagcc gcaactacct gggtggcttc

301 gccctgtccg tggcccacgg gaggaaggca caccactaca ccatcgagcg ggagctgaat

361 ggcacctacg ccatcgccgg tggcaggacc catgccagcc ccgccgacct ctgccactac 421 cactcccagg agtctgatgg cctggtctgc ctcctcaaga agcccttcaa ccggccccaa

481 ggggtgcagc ccaagactgg gccctttgag gatttgaagg aaaacctcat cagggaatat

541 gtgaagcaga catggaacct gcagggtcag gctctggagc aggccatcat cagtcagaag

601 cctcagctgg agaagctgat cgctaccaca gcccatgaaa aaatgccttg gttccatgga

661 aaaatctctc gggaagaatc tgagcaaatt gtcctgatag gatcaaagac aaatggaaag 721 ttcctgatcc gagccagaga caacaacggc tcctacgccc tgtgcctgct gcacgaaggg

781 aaggtgctgc actatcgcat cgacaaagac aagacaggga agctctccat ccccgaggga

841 aagaagttcg acacgctctg gcagctagtc gagcattatt cttataaagc agatggtttg 901 ttaagagttc ttactgtccc atgtcaaaaa atcggcacac agggaaatgt taattttgga

961 ggccgtccac aacttccagg ttcccatcct gcgacttggt cagcgggtgg aataatctca

1021 agaatcaaat catactcctt cccaaagcct ggccacagaa agtcctcccc tgcccaaggg

1081 aaccggcaag agagtactgt gtcattcaat ccgtatgagc cagaacttgc accctgggct

1141 gcagacaaag gcccccagag agaagcccta cccatggaca cagaggtgta cgagagcccc 1201 tacgcggacc ctgaggagat caggcccaag gaggtttacc tggaccgaaa gctgctgacg

1261 ctggaagaca aagaactggg ctctggtaat tttggaactg tgaaaaaggg ctactaccaa

1321 atgaaaaaag ttgtgaaaac cgtggctgtg aaaatactga aaaacgaggc caatgacccc

1381 gctcttaaag atgagttatt agcagaagca aatgtcatgc agcagctgga caacccgtac

1441 atcgtgcgca tgatcgggat atgcgaggcc gagtcctgga tgctagttat ggagatggca 1501 gaacttggtc ccctcaataa gtatttgcag cagaacagac atgtcaagga taagaacatc

1561 atagaactgg ttcatcaggt ttccatgggc atgaagtact tggaggagag caattttgtg

1621 cacagagatc tggctgcaag aaatgtgttg ctagttaccc aacattatgc caagatcagt

1681 gatttcggac tctccaaagc actgcgtgct gatgaaaact actacaaggc ccagacccat

1741 ggaaagtggc ctgtcaagtg gtacgctccg gaatgcatca actactacaa gttctccagc 1801 aaaagcgatg tctggagctt tggagtgttg atgtgggaag cattctccta tgggcagaag

1861 ccatatcgag ggatgaaagg aagtgaagtc accgctatgt tagagaaagg agagcggatg

1921 gggtgccctg cagggtgtcc aagagagatg tacgatctca tgaatctgtg ctggacatac

1981 gatgtggaaa acaggcccgg attcgcagca gtggaactgc ggctgcgcaa ttactactat

2041 gacgtggtga actaaccgct cccgcacctg tcggtggctg cctttgatca caggagcaat 2101 cacaggaaaa tgtatccaga ggaattgatt gtcagccacc tccctctgcc agtcgggaga

2161 gccaggcttg gatggaacat gcccacaact tgtcacccaa agcctgtccc aggactcacc

2221 ctccacaaag caaaggcagt cccgggagaa aagacggatg gcaggatcca aggggctagc

2281 tggatttgtt tgttttcttg tctgtgtgat tttcatacag gttattttta cgatctgttt

2341 ccaaatccct ttcatgtctt tccacttctc tgggtcccgg ggtgcatttg ttactcatcg

2401 ggcccaggga cattgcagag tggcctagag cactctcacc ccaagcggcc ttttccaaat

2461 gcccaaggat gccttagcat gtgactcctg aagggaaggc aaaggcagag gaatttggct

2521 gcttctacgg ccatgagact gatccctggc cactgaaaag ctttcctgac aataaaaatg

2581 ttttgaggct ttaaaaagaa aatcaagttt gaccagtgca gtttctaagc atgtagccag

2641 ttaaggaaag aaagaaaaaa

1 ggtggcctct gtggccgtcc aggctagcgg cggcccgcag gcggcgggga gaaagactct 61 ctcacctggt cttgcggctg tggccaccgc cggccagggg tgtggagggc gtgctgccgg

121 agacgtccgc cgggctctgc agttccgccg ggggtcgggc agctatggag ccgcggccca

181 cggcgccctc ctccggcgcc ccgggactgg ccggggtcgg ggagacgccg tcagccgctg

241 cgctggccgc agccagggtg gaactgcccg gcacggctgt gccctcggtg ccggaggatg

301 ctgcgcccgc gagccgggac ggcggcgggg tccgcgatga gggccccgcg gcggccgggg 361 acgggctggg cagacccttg gggcccaccc cgagccagag ccgtttccag gtggacctgg

421 tttccgagaa cgccgggcgg gccgctgctg cggcggcggc ggcggcggcg gcagcggcgg

481 cggctggtgc tggggcgggg gccaagcaga cccccgcgga cggggaagcc agcggcgaga

541 gcgagccggc taaaggcagc gaggaagcca agggccgctt ccgcgtgaac ttcgtggacc

601 cagctgcctc ctcgtcggct gaagacagcc tgtcagatgc tgccggggtc ggagtcgacg 661 ggcccaacgt gagcttccag aacggcgggg acacggtgct gagcgagggc agcagcctgc

721 actccggcgg cggcggcggc agtgggcacc accagcacta ctattatgat acccacacca

781 acacctacta cctgcgcacc ttcggccaca acaccatgga cgctgtgccc aggatcgatc

841 actaccggca cacagccgcg cagctgggcg agaagctgct ccggcctagc ctggcggagc

901 tccacgacga gctggaaaag gaaccttttg aggatggctt tgcaaatggg gaagaaagta 961 ctccaaccag agatgctgtg gtcacgtata ctgcagaaag taaaggagtc gtgaagtttg

1021 gctggatcaa gggtgtatta gtacgttgta tgttaaacat ttggggtgtg atgcttttca

1081 ttagattgtc atggattgtg ggtcaagctg gaataggtct atcagtcctt gtaataatga

1141 tggccactgt tgtgacaact atcacaggat tgtctacttc agcaatagca actaatggat 1201 ttgtaagagg aggaggagca tattatttaa tatctagaag tctagggcca gaatttggtg

1261 gtgcaattgg tctaatcttc gcctttgcca acgctgttgc agttgctatg tatgtggttg

1321 gatttgcaga aaccgtggtg gagttgctta aggaacattc catacttatg atagatgaaa

1381 tcaatgatat ccgaattatt ggagccatta cagtcgtgat tcttttaggt atctcagtag

1441 ctggaatgga gtgggaagca aaagctcaga ttgttctttt ggtgatccta cttcttgcta 1501 ttggtgattt cgtcatagga acatttatcc cactggagag caagaagcca aaagggtttt

1561 ttggttataa atctgaaata tttaatgaga actttgggcc cgattttcga gaggaagaga

1621 ctttcttttc tgtatttgcc atcttttttc ctgctgcaac tggtattctg gctggagcaa

1681 atatctcagg tgatcttgca gatcctcagt cagccatacc caaaggaaca ctcctagcca

1741 ttttaattac tacattggtt tacgtaggaa ttgcagtatc tgtaggttct tgtgttgttc 1801 gagatgccac tggaaacgtt aatgacacta tcgtaacaga gctaacaaac tgtacttctg

1861 cagcctgcaa attaaacttt gatttttcat cttgtgaaag cagtccttgt tcctatggcc

1921 taatgaacaa cttccaggta atgagtatgg tgtcaggatt tacaccacta atttctgcag

1981 gtatattttc agccactctt tcttcagcat tagcatccct agtgagtgct cccaaaatat

2041 ttcaggctct atgtaaggac aacatctacc cagctttcca gatgtttgct aaaggttatg 2101 ggaaaaataa tgaacctctt cgtggctaca tcttaacatt cttaattgca cttggattca

2161 tcttaattgc tgaactgaat gttattgcac caattatctc aaacttcttc cttgcatcat

2221 atgcattgat caatttttca gtattccatg catcacttgc aaaatctcca ggatggcgtc

2281 ctgcattcaa atactacaac atgtggatat cacttcttgg agcaattctt tgttgcatag

2341 taatgttcgt cattaactgg tgggctgcat tgctaacata tgtgatagtc cttgggctgt 2401 atatttatgt tacctacaaa aaaccagatg tgaattgggg atcctctaca caagccctga

2461 cttacctgaa tgcactgcag cattcaattc gtctttctgg agtggaagac cacgtgaaaa

2521 actttaggcc acagtgtctt gttatgacag gtgctccaaa ctcacgtcca gctttacttc

2581 atcttgttca tgatttcaca aaaaatgttg gtttgatgat ctgtggccat gtacatatgg

2641 gtcctcgaag acaagccatg aaagagatgt ccatcgatca agccaaatat cagcgatggc

2701 ttattaagaa caaaatgaag gcattttatg ctccagtaca tgcagatgac ttgagagaag

2761 gtgcacagta tttgatgcag gctgctggtc ttggtcgtat gaagccaaac acacttgtcc 2821 ttggatttaa gaaagattgg ttgcaagcag atatgaggga tgtggatatg tatataaact

2881 tatttcatga tgcttttgac atacaatatg gagtagtggt tattcgccta aaagaaggtc

2941 tggatatatc tcatcttcaa ggacaagaag aattattgtc atcacaagag aaatctcctg

3001 gcaccaagga tgtggtagta agtgtggaat atagtaaaaa gtccgattta gatacttcca

3061 aaccactcag tgaaaaacca attacacaca aagttgagga agaggatggc aagactgcaa 3121 ctcaaccact gttgaaaaaa gaatccaaag gccctattgt gcctttaaat gtagctgacc

3181 aaaagcttct tgaagctagt acacagtttc agaaaaaaca aggaaagaat actattgatg

3241 tctggtggct ttttgatgat ggaggtttga ccttattgat accttacctt ctgacgacca

3301 agaaaaaatg gaaagactgt aagatcagag tattcattgg tggaaagata aacagaatag

3361 accatgaccg gagagcgatg gctactttgc ttagcaagtt ccggatagac ttttctgata 3421 tcatggttct aggagatatc aataccaaac caaagaaaga aaatattata gcttttgagg

3481 aaatcattga gccatacaga cttcatgaag atgataaaga gcaagatatt gcagataaaa

3541 tgaaagaaga tgaaccatgg cgaataacag ataatgagct tgaactttat aagaccaaga

3601 cataccggca gatcaggtta aatgagttat taaaggaaca ttcaagcaca gctaatatta

3661 ttgtcatgag tctcccagtt gcacgaaaag gtgctgtgtc tagtgctctc tacatggcat 3721 ggttagaagc tctatctaag gacctaccac caatcctcct agttcgtggg aatcatcaga

3781 gtgtccttac cttctattca taaatgttct atacagtgga cagccctcca gaatggtact

3841 tcagtgccta gtgtagtaac tgaaatcttc aatgacacat taacatcaca atggcgaatg

3901 gtgacttttc tttcacgatt tcattaattt gaaagcacac aggaaagttg ctccattgat

3961 aacgtgtatg gagacttcgg ttttagtcaa ttccatatct caatcttaat ggtgattctt 4021 ctctgttgaa ctgaagtttg tgagagtagt tttcctttgc tacttgaata gcaataaaag

4081 cgtgttaact ttttgattga tgaaagaagt acaaaaagcc tttagccttg aggtgccttc

4141 tgaaattaac caaatttcat ccatatatcc tcttttataa acttatagaa tgtcaaactt

4201 tgccttcaac tgtttttatt tctagtctct tccactttaa aacaaaatga acactgcttg

4261 tcttcttcca ttgaccattt agtgttgagt actgtatgtg ttttgttaat tctataaagg

4321 tatctgttag atattaaagg tgagaattag ggcaggttaa tcaaaaatgg ggaaggggaa

4381 atggtaacca aaaagtaacc ccatggtaag gtttatatga gtatatgtga atatagagct 4441 aggaaaaaaa gcccccccaa ataccttttt aacccctctg attggctatt attactatat

4501 ttattattat ttattgaaac cttagggaag attgaagatt catcccatac ttctatatac

4561 catgcttaaa aatcacgtca ttctttaaac aaaaatactc aagatcattt atatttattt

4621 ggagagaaaa ctgtcctaat ttagaatttc cctcaaatct gagggacttt taagaaatgc

4681 taacagattt ttctggagga aatttagaca aaacaatgtc atttagtaga atatttcagt 4741 atttaagtgg aatttcagta tactgtacta tcctttataa gtcattaaaa taatgtttca

4801 tcaaatggtt aaatggacca ctggtttctt agagaaatgt ttttaggctt aattcattca

4861 attgtcaagt acacttagtc ttaatacact caggtttgaa cagattattc tgaatattaa

4921 aatttaatcc attcttaata ttttaaaact tttgttaaga aaaactgcca gtttgtgctt

4981 ttgaaatgtc tgttttgaca tcatagtcta gtaaaatttt gacagtgcat atgtactgtt 5041 actaaaagct ttatatgaaa ttattaatgt gaagtttttc atttataatt caaggaagga

5101 tttcctgaaa acatttcaag ggatttatgt ctacatattt gtgtgtgtgt gtgtatatat

5161 atgtaatatg catacacaga tgcatatgtg tatatataat gaaatttatg ttgctggtat

5221 tttgcatttt aaagtgatca agattcatta ggcaaacttt ggtttaagta aacatatgtt

5281 caaaatcaga ttaacagata caggtttcat agagaacaaa ggtgatcatt tgaagggcat 5341 gctgtaattt cacacaattt tccagttcaa aaatggagaa tacttcgcct aaaatactgt

5401 taagtgggtt aattgataca agtttctgtg gtggaaaatt tatgcaggtt ttcacgaatc

5461 cttttttttt tttttttttt tttttgagac ggagtcttgc tctgttgcca cgctggaatg

5521 cagtaacgtg atcttggctc actgcgacct ccacctcccc agttcaagcg attctcctgc

5581 ctcagcctcc ctagtagctg ggactacggg tgcacgccac catgcccagc taatttttgt 5641 attttgagta gagacagggt ttcaccgtgt tggctaggat ggtgtctatc tcttgacctt

5701 gtgatccacc cgcctcagcc tcccagagtg ctgggattac aggtgcgagc cactgcgcct

5761 ggctggtttt catgaatctt gatagacatc tataacgtta ttattttcag tggtgtgcag

5821 catttttgct tcatgagtat gacctaggta tagagatctg ataacttgaa ttcagaatat

5881 taagaaaatg aagtaactga ttttctaaaa aaaaaaaaaa aaaaaatttc tacattataa

5941 ctcacagcat tgttccattg caggttttgc aatgtttggg ggtaaagaca gtagaaatat 6001 tattcagtaa acaataatgt gtgaactttt aagatggata atagggcatg gactgagtgc 6061 tgctatcttg aaatgtgcac aggtacactt accttttttt tttttttttt taagtttttc 6121 ccattcagga aaacaacatt gtgatctgta ctacaggaac caaatgtcat gcgtcataca 6181 tgtgggtata aagtacataa aatatatcta actattcata atgtggggtg ggtaatactg 6241 tctgtgaaat aatgtaagaa gcttttcact taaaaaaaat gcattacttt cacttaacac 6301 tagacaccag gtcgaaaatt ttcaaggtta tagtacttat ttcaacaatt cttagagatg 6361 ctagctagtg ttgaagctaa aaatagcttt atttatgctg aattgtgatt tttttatgcc 6421 aaattttttt tagttctaat cattgatgat agcttggaaa taaataatta tgccatggca 6481 tttgacagtt cattattcct ataagaatta aattgagttt agagagaatg gtggtgttga 6541 gctgattatt aacagttact gaaatcaaat atttatttgt tacattattc catttgtatt 6601 ttaggtttcc ttttacattc tttttatatg cattctgaca ttacatattt tttaagacta 6661 tggaaataat ttaaagattt aagctctggt ggatgattat ctgctaagta agtctgaaaa 6721 tgtaatattt tgataatact gtaatatacc tgtcacacaa atgcttttct aatgttttaa 6781 ccttgagtat tgcagttgct gctttgtaca gaggttactg caataaagga agtggattca 6841 ttaaacctat ttaatgtcca

1 cgcaaagcaa gtgggcacaa ggagtatggt tctaacgtga ttggggtcat gaagacgttg

61 ctgttggact tggctttgtg gtcactgctc ttccagcccg 99tggctgtc ctttagttcc 121 caggtgagtc agaactgcca caatggcagc tatgaaatca gcgtcctgat gatgggcaac 181 tcagcctttg cagagcccct gaaaaacttg gaagatgcgg tgaatgaggg gctggaaata 241 gtgagaggac gtctgcaaaa tgctggccta aatgtgactg tgaacgctac tttcatgtat 301 tcggatggtc tgattcataa ctcaggcgac tgccggagta gcacctgtga aggcctcgac 361 ctactcagga aaatttcaaa tgcacaacgg atgggctgtg tcctcatagg gccctcatgt 421 acatactcca ccttccagat gtaccttgac acagaattga gctaccccat gatctcagct

481 ggaagttttg gattgtcatg tgactataaa gaaaccttaa ccaggctgat gtctccagct

541 agaaagttga tgtacttctt ggttaacttt tggaaaacca acgatctgcc cttcaaaact 601 tattcctgga gcacttcgta tgtttacaag aatggtacag aaactgagga ctgtttctgg

661 taccttaatg ctctggaggc tagcgtttcc tatttctccc acgaactcgg ctttaaggtg

721 gtgttaagac aagataagga gtttcaggat atcttaatgg accacaacag gaaaagcaat

781 gtgattatta tgtgtggtgg tccagagttc ctctacaagc tgaagggtga ccgagcagtg

841 gctgaagaca ttgtcattat tctagtggat cttttcaatg accagtactt ggaggacaat 901 gtcacagccc ctgactatat gaaaaatgtc cttgttctga cgctgtctcc tgggaattcc

961 cttctaaata gctctttctc caggaatcta tcaccaacaa aacgagactt tgctcttgcc

1021 tatttgaatg gaatcctgct ctttggacat atgctgaaga tatttcttga aaatggagaa

1081 aatattacca cccccaaatt tgctcatgct ttcaggaatc tcacttttga agggtatgac

1141 ggtccagtga ccttggatga ctggggggat gttgacagta ccatggtgct tctgtatacc 1201 tctgtggaca ccaagaaata caaggttctt ttgacctatg atacccacgt aaataagacc

1261 tatcctgtgg atatgagccc cacattcact tggaagaact ctaaacttcc taatgatatt

1321 acaggccggg gccctcagat cctgatgatt gcagtcttca ccctcactgg agctgtggtg

1381 ctgctcctgc tcgtcgctct cctgatgctc agaaaatata gaaaagatta tgaacttcgt

1441 cagaaaaaat ggtcccacat tcctcctgaa aatatctttc ctctggagac caatgagacc 1501 aatcatgtta gcctcaagat cgatgatgac aaaagacgag atacaatcca gagactacga

1561 cagtgcaaat acgacaaaaa gcgagtgatt ctcaaagatc tcaagcacaa tgatggtaat

1621 ttcactgaaa aacagaagat agaattgaac aagttgcttc agattgacta ttacaacctg

1681 accaagttct acggcacagt gaaacttgat accatgatct tcggggtgat agaatactgt

1741 gagagaggat ccctccggga agttttaaat gacacaattt cctaccctga tggcacattc 1801 atggattggg agtttaagat ctctgtcttg tatgacattg ctaagggaat gtcatatctg

1861 cactccagta agacagaagt ccatggtcgt ctgaaatcta ccaactgcgt agtggacagt

1921 agaatggtgg tgaagatcac tgattttggc tgcaattcca ttttacctcc aaaaaaggac

1981 ctgtggacag ctccagagca cctccgccaa gccaacatct ctcagaaagg agatgtgtac

2041 agctatggga tcatcgcaca ggagatcatt ctgcggaaag aaaccttcta cactttgagc

2101 tgtcgggacc ggaatgagaa gattttcaga gtggaaaatt ccaatggaat gaaacccttc

2161 cgcccagatt tattcttgga aacagcagag gaaaaagagc tagaagtgta cctacttgta 2221 aaaaactgtt gggaggaaga tccagaaaag agaccagatt tcaaaaaaat tgagactaca

2281 cttgccaaga tatttggact ttttcatgac caaaaaaatg aaagctatat ggataccttg

2341 atccgacgtc tacagctata ttctcgaaac ctggaacatc tggtagagga aaggacacag

2401 ctgtacaagg cagagaggga cagggctgac agacttaact ttatgttgct tccaaggcta

2461 gtggtaaagt ctctgaagga gaaaggcttt gtggagccgg aactatatga ggaagttaca 2521 atctacttca gtgacattgt aggtttcact actatctgca aatacagcac ccccatggaa

2581 gtggtggaca tgcttaatga catctataag agttttgacc acattgttga tcatcatgat

2641 gtctacaagg tggaaaccat cggtgatgcg tacatggtgg ctagtggttt gcctaagaga

2701 aatggcaatc ggcatgcaat agacattgcc aagatggcct tggaaatcct cagcttcatg

2761 gggacctttg agctggagca tcttcctggc ctcccaatat ggattcgcat tggagttcac 2821 tctggtccct gtgctgctgg agttgtggga atcaagatgc ctcgttattg tctatttgga

2881 gatacggtca acacagcctc taggatggaa tccactggcc tccctttgag aattcacgtg

2941 agtggctcca ccatagccat cctgaagaga actgagtgcc agttccttta tgaagtgaga

3001 ggagaaacat acttaaaggg aagaggaaat gagactacct actggctgac tgggatgaag

3061 gaccagaaat tcaacctgcc aacccctcct actgtggaga atcaacagcg tttgcaagca 3121 gaattttcag acatgattgc caactcttta cagaaaagac aggcagcagg gataagaagc

3181 caaaaaccca gacgggtagc cagctataaa aaaggcactc tggaatactt gcagctgaat

3241 accacagaca aggagagcac ctatttttaa acctaaatga ggtataagga ctcacacaaa

3301 ttaaaataca gctgcactga ggcagcgacc tcaagtgtcc tgaaagctta cattttcctg

3361 agacctcaat gaagcagaaa tgtacttagg cttggctgcc ctgtctggaa catggacttt 3421 cttgcatgaa tcagatgtgt gttctcagtg aaataactac cttccactct ggaaccttat

3481 tccagcagtt gttccaggga gcttctacct ggaaaagaaa agaaatgaat agactatcta

3541 gaacttgaga agattttatt cttatttcat ttattttttg tttgtttatt tttatcgttt

3601 ttgtttactg gctttccttc tgtattcata agatttttta aattgtcata attatatttt

3661 aaatacccat cttcattaaa gtatatttaa ctcataattt ttgcagaaaa tatgctatat 3721 attaggcaag aataaaagct aaagg

1 cttcaggtca gggagaatgt ataaatgtcc attgccatcg aggttctgct atttttgaga 61 agctgaagca actccaagga cacagttcac agaaatttgg ttctcagccc caaaatactg

121 attgaattgg agacaattac aaggactctc tggccaaaaa cccttgaaga ggccccgtga

181 aggaggcagt gaggagcttt tgattgctga cctgtgtcgt accaccccag aatgtgcact

241 gggggctgtg ccagatgcct gggggggacc ctcattcccc ttgctttttt tggcttcctg

301 gctaacatcc tgttattttt tcctggagga aaagtgatag atgacaacga ccacctttcc 361 caagagatct ggtttttcgg aggaatatta ggaagcggtg tcttgatgat cttccctgcg

421 ctggtgttct tgggcctgaa gaacaatgac tgctgtgggt gctgcggcaa cgagggctgt

481 gggaagcgat ttgcgatgtt cacctccacg atatttgctg tggttggatt cttgggagct

541 ggatactcgt ttatcatctc agccatttca atcaacaagg gtcctaaatg cctcatggcc

601 aatagtacat ggggctaccc cttccacgac ggggattatc tcaatgatga ggccttatgg 661 aacaagtgcc gagagcctct caatgtggtt ccctggaatc tgaccctctt ctccatcctg

721 ctggtcgtag gaggaatcca gatggttctc tgcgccatcc aggtggtcaa tggcctcctg

781 gggaccctct gtggggactg ccagtgttgt ggctgctgtg ggggagatgg acccgtttaa

841 acctccgaga tgagctgctc agactctaca gcatgacgac tacaatttct tttcataaaa

901 cttcttctct tcttggaatt attaattcct atctgcttcc tagctgataa agcttagaaa 961 aggcagttat tccttctttc caaccagctt tgctcgagtt agaattttgt tattttcaaa

1021 taaaaaatag tttggccact taacaaattt gatttataaa tctttcaaat tagttccttt

1081 ttagaattta ccaacaggtt caaagcatac ttttcatgat ttttttatta caaatgtaaa

1141 atgtataaag tcacatgtac tgccatacta cttctttgta tataaagatg tttatatctt

1201 tggaagtttt acataaatca aaggaagaaa gcacatttaa aatgagaaac taagaccaat 1261 ttctgttttt aagaggaaaa agaatgattg atgtatccta agtattgtta tttgttgtct

1321 ttttttgctg ccttgcttga gttgcttgtg actgatcttt tgaggctgtc atcatggcta

1381 gggttctttt atgtatgtta aattaaaacc tgaattcaga ggtaacgt

1 ctggagagcc tgctgcccgc ccgcccgtaa aatggtcccc tcggctggac agctcgccct 61 gttcgctctg ggtattgtgt tggctgcgtg ccaggccttg gagaacagca cgtccccgct

121 gagtgcagac ccgcccgtgg ctgcagcagt ggtgtcccat tttaatgact gcccagattc

181 ccacactcag ttctgcttcc atggaacctg caggtttttg gtgcaggagg acaagccagc

241 atgtgtctgc cattctgggt acgttggtgc acgctgtgag catgcggacc tcctggccgt

301 ggtggctgcc agccagaaga agcaggccat caccgccttg gtggtggtct ccatcgtggc 361 cctggctgtc cttatcatca catgtgtgct gatacactgc tgccaggtcc gaaaacactg

421 tgagtggtgc cgggccctca tctgccggca cgagaagccc agcgccctcc tgaagggaag

481 aaccgcttgc tgccactcag aaacagtggt ctgaagagcc cagaggagga gtttggccag

541 gtggactgtg gcagatcaat aaagaaaggc ttcttcagga cagcactgcc agagatgcct

601 gggtgtgcca cagaccttcc tacttggcct gtaatcacct gtgcagcctt ttgtgggcct 661 tcaaaactct gtcaagaact ccgtctgctt ggggttattc agtgtgacct agagaagaaa

721 tcagcggacc acgatttcaa gacttgttaa aaaagaactg caaagagacg gactcctgtt

781 cacctaggtg aggtgtgtgc agcagttggt gtctgagtcc acatgtgtgc agttgtcttc

841 tgccagccat ggattccagg ctatatattt ctttttaatg ggccacctcc ccacaacaga

901 attctgccca acacaggaga tttctatagt tattgttttc tgtcatttgc ctactgggga 961 agaaagtgaa ggaggggaaa ctgtttaata tcacatgaag accctagctt taagagaagc

1021 tgtatcctct aaccacgaga ctctcaacca gcccaacatc ttccatggac acatgacatt

1081 gaagaccatc ccaagctatc gccacccttg gagatgatgt cttatttatt agatggataa

1141 tggttttatt tttaatctct taagtcaatg taaaaagtat aaaacccctt cagacttcta

1201 cattaatgat gtatgtgttg ctgactgaaa agctatactg attagaaatg tctggcctct 1261 tcaagacagc taaggcttgg gaaaagtctt ccagggtgcg gagatggaac cagaggctgg

1321 gttactggta ggaataaagg taggggttca gaaatggtgc cattgaagcc acaaagccgg

1381 taaatgcctc aatacgttct gggagaaaac ttagcaaatc catcagcagg gatctgtccc

1441 ctctgttggg gagagaggaa gagtgtgtgt gtctacacag gataaaccca atacatattg

1501 tactgctcag tgattaaatg ggttcacttc ctcgtgagcc ctcggtaagt atgtttagaa 1561 atagaacatt agccacgagc cataggcatt tcaggccaaa tccatgaaag ggggaccagt

1621 catttatttt ccattttgtt gcttggttgg tttgttgctt tatttttaaa aggagaagtt

1681 taactttgct atttattttc gagcactagg aaaactattc cagtaatttt tttttcctca

1741 tttccattca ggatgccggc tttattaaca aaaactctaa caagtcacct ccactatgtg

1801 ggtcttcctt tcccctcaag agaaggagca attgttcccc tgacatctgg gtccatctga 1861 cccatggggc ctgcctgtga gaaacagtgg gtcccttcaa atacatagtg gatagctcat

1921 ccctaggaat tttcattaaa atttggaaac agagtaatga agaaataata tataaactcc

1981 ttatgtgagg aaatgctact aatatctgaa aagtgaaaga tttctatgta ttaactctta

2041 agtgcaccta gcttattaca tcgtgaaagg tacatttaaa atatgttaaa ttggcttgaa

2101 attttcagag aattttgtct tcccctaatt cttcttcctt ggtctggaag aacaatttct 2161 atgaattttc tctttatttt ttttttataa ttcagacaat tctatgaccc gtgtcttcat

2221 ttttggcact cttatttaac aatgccacac ctgaagcact tggatctgtt cagagctgac

2281 cccctagcaa cgtagttgac acagctccag gtttttaaat tactaaaata agttcaagtt

2341 tacatccctt gggccagata tgtgggttga ggcttgactg tagcatcctg cttagagacc

2401 aatcaatgga cactggtttt tagacctcta tcaatcagta gttagcatcc aagagacttt 2461 gcagaggcgt aggaatgagg ctggacagat ggcggaacga gaggttccct gcgaagactt

2521 gagatttagt gtctgtgaat gttctagttc ctaggtccag caagtcacac ctgccagtgc

2581 cctcatcctt atgcctgtaa cacacatgca gtgagaggcc tcacatatac gcctccctag

2641 aagtgccttc caagtcagtc ctttggaaac cagcaggtct gaaaaagagg ctgcatcaat

2701 gcaagcctgg ttggaccatt gtccatgcct caggatagaa cagcctggct tatttgggga 2761 tttttcttct agaaatcaaa tgactgataa gcattggctc cctctgccat ttaatggcaa

2821 tggtagtctt tggttagctg caaaaatact ccatttcaag ttaaaaatgc atcttctaat

2881 ccatctctgc aagctccctg tgtttccttg ccctttagaa aatgaattgt tcactacaat

2941 tagagaatca tttaacatcc tgacctggta agctgccaca cacctggcag tggggagcat

3001 cgctgtttcc aatggctcag gagacaatga aaagccccca tttaaaaaaa taacaaacat

3061 tttttaaaag gcctccaata ctcttatgga gcctggattt ttcccactgc tctacaggct

3121 gtgacttttt ttaagcatcc tgacaggaaa tgttttcttc tacatggaaa gatagacagc 3181 agccaaccct gatctggaag acagggcccc ggctggacac acgtggaacc aagccaggga

3241 tgggctggcc attgtgtccc cgcaggagag atgggcagaa tggccctaga gttcttttcc

3301 ctgagaaagg agaaaaagat gggattgcca ctcacccacc cacactggta agggaggaga

3361 atttgtgctt ctggagcttc tcaagggatt gtgttttgca ggtacagaaa actgcctgtt

3421 atcttcaagc caggttttcg agggcacatg ggtcaccagt tgctttttca gtcaatttgg 3481 ccgggatgga ctaatgaggc tctaacactg ctcaggagac ccctgccctc tagttggttc

3541 tgggctttga tctcttccaa cctgcccagt cacagaagga ggaatgactc aaatgcccaa

3601 aaccaagaac acattgcaga agtaagacaa acatgtatat ttttaaatgt tctaacataa

3661 gacctgttct ctctagccat tgatttacca ggctttctga aagatctagt ggttcacaca

3721 gagagagaga gagtactgaa aaagcaactc ctcttcttag tcttaataat ttactaaaat 3781 ggtcaacttt tcattatctt tattataata aacctgatgc ttttttttag aactccttac

3841 tctgatgtct gtatatgttg cactgaaaag gttaatattt aatgttttaa tttattttgt

3901 gtggtaagtt aattttgatt tctgtaatgt gttaatgtga ttagcagtta ttttccttaa

3961 tatctgaatt atacttaaag agtagtgagc aatataagac gcaattgtgt ttttcagtaa

4021 tgtgcattgt tattgagttg tactgtacct tatttggaag gatgaaggaa tgaacctttt 4081 tttcctaaaa

1 gaatagtcta ccccccttgc actctacctg acacagctgc agcctgcaat tcactcgcac 61 tgcctgggat tgcactggat ccgtgtgctc agaacaaggt gaacgcccag ctgcagccat

121 gaagatctgt agcctcaccc tgctctcctt cctcctactg gctgctcagg tgctcctggt

181 ggaggggaaa aaaaaagtga agaatggact tcacagcaaa gtggtctcag aacaaaagga

241 cactctgggc aacacccaga ttaagcagaa aagcaggccc gggaacaaag gcaagtttgt

301 caccaaagac caagccaact gcagatgggc tgctactgag caggaggagg gcatctctct

361 caaggttgag tgcactcaat tggaccatga attttcctgt gtctttgctg gcaatccaac

421 ctcatgccta aagctcaagg atgagagagt ctattggaaa caagttgccc ggaatctgcg 481 ctcacagaaa gacatctgta gatattccaa gacagctgtg aaaaccagag tgtgcagaaa

541 ggattttcca gaatccagtc ttaagctagt cagctccact ctatttggga acacaaagcc

601 caggaaggag aaaacagaga tgtcccccag ggagcacatc aaaggcaaag agaccacccc

661 ctctagccta gcagtgaccc agaccatggc caccaaagct cccgagtgtg tggaggaccc

721 agatatggca aaccagagga agactgccct ggagttctgt ggagagactt ggagctctct 781 ctgcacattc ttcctcagca tagtgcagga cacgtcatgc taatgaggtc aaaagagaac

841 gggttccctt aagagatgtc atgtcgtaag tccctctgta tactttaaag ctctctacag

901 tccccccaaa atatgaactt ttgtgcttag tgagtgcaac gaaatattta aacaagtttt

961 gtattttttg cttttgtgtt ttggaatttg ccttattttt cttggatgcg atgttcagag

1021 gctgtttcct gcagcatgta tttccatggc ccacacagct atgtgtttga gcagcgaaga 1081 gtctttgagc tgaatgagcc agagtgataa tttcagtgca acgaactttc tgctgaatta

1141 atggtaataa aactctgggt gtttttcaga aatacattca

1 gctgggccac agcctggtcc tgccgctgcg cccgcccgcc atggtgtccc gggaccaggc 61 tcacctgggc cccaagtatg tgggcctctg ggacttcaag tcccggacgg acgaggagct

121 gagcttccgc gcgggggacg tcttccacgt ggccaggaag gaggagcagt ggtggtgggc

181 cacgctgctg gacgaggcgg gtggggccgt ggcccagggc tatgtgcccc acaactacct

241 ggccgagagg gagacggtgg agtcggaacc gtggttcttt ggctgcatct cccgctcgga 301 agctgtgcgt cggctgcagg ccgagggcaa cgccacgggc gccttcctga tcagggtcag

361 cgagaagccg agtgccgact acgtcctgtc ggtgcgggac acgcaggctg tgcggcacta

421 caagatctgg cggcgtgccg ggggccggct gcacctgaac gaggcggtgt ccttcctcag

481 cctgcccgag cttgtgaact accacagggc ccagagcctg tcccacggcc tgcggctggc

541 cgcgccctgc cggaagcacg agcctgagcc cctgccccat tgggatgact gggagaggcc

601 gagggaggag ttcacgctct gcaggaagct ggggtccggc tactttgggg aggtcttcga

661 ggggctctgg aaagaccggg tccaggtggc cattaaggtg atttctcgag acaacctcct 721 gcaccagcag atgctgcagt cggagatcca ggccatgaag aagctgcggc acaaacacat

781 cctggcgctg tacgccgtgg tgtccgtggg ggaccccgtg tacatcatca cggagctcat

841 ggccaagggc agcctgctgg agctgctccg cgactctgat gagaaagtcc tgcccgtttc

901 ggagctgctg gacatcgcct ggcaggtggc tgagggcatg tgttacctgg agtcgcagaa

961 ttacatccac cgggacctgg ccgccaggaa catcctcgtc ggggaaaaca ccctctgcaa 1021 agttggggac ttcgggttag ccaggcttat caaggaggac gtctacctct cccatgacca

1081 caatatcccc tacaagtgga cggcccctga agcgctctcc cgaggccatt actccaccaa

1141 atccgacgtc tggtcctttg ggattctcct gcatgagatg ttcagcaggg gtcaggtgcc

1201 ctacccaggc atgtccaacc atgaggcctt cctgagggtg gacgccggct accgcatgcc

1261 ctgccctctg gagtgcccgc ccagcgtgca caagctgatg ctgacatgct ggtgcaggga 1321 ccccgagcag agaccctgct tcaaggccct gcgggagagg ctctccagct tcaccagcta

1381 cgagaacccg acctgagctg ctgtggagcg ggcatggccg ggccctgctg aggaggggcc

1441 tgggcagagg gcctggacct gggatcaagg cccacgcgct tccctggggt ttactgaggt

1501 gatgggtgca ggaaaggttc acaaatgtgg agtgtctgcg tccaatacac gcgtgtgctc

1561 ctctccttac tccatcgtgt gtgccttggg tctcagctgc tgacacgcag cctgctctgg 1621 agcctgcaga tgagatccgg gagactgaca cgaagccagc agaggtcaga ggggactctg

1681 accacagccc gctctctggc tgtctgtctg cagtgcccgg ctgagggtgg gaggcaaaca

1741 cgccttgttc ctgctcttcc cagttcagct tggtgggaga aagtcattcg cgtggctcgg

1801 gacgctcatg taaatttggt tttggtgctc aagggttctt tcctcccagg ggcaggtgtt

1861 tctttcctgt ttgtcttgtg tcttgagagc ttggccttat gaccagtgag aactctctcc 1921 ctggtctctg ccagcccaag catcactgcc cgaggcgcca gctcagtttc accgtccacg

1981 tccacaaggg gcttttccca ccttcacctt tgtcgctggg tcagtgctgg aaagcgcccc

2041 tcactcctgc gctgacaagg gcccttctct actgtctgtg gggtggttcc gggctggggg

2101 ggctgcctcc tttgcacctg attttgaagg tgtctctttc atccatggtt aagtcataaa

2161 aagcttattg gttttggttt tgactcacct gaaagttttt ttggtttaaa agaagaatag

2221 gcggggcacg gtggctcatg cctgtaatcc cagcactttg ggaggctgag gcaggtggat

2281 cacgaggtca ggagatcgac accatcctgg ctaacacggt gaaaccccgt ctctactaaa

2341 aaatacaaaa aattagctgg gtgtggtggt gggggtgggc gcctgtagtc ccagctacgt

2401 gggaggctga ggcagcagac tggtgtgaac ccgggaggtg gagcttgcag tgagccgaga

2461 tcgcgccact gcactccagc ctgggcgaca gagcgagact ccatctcaaa

1 acaggcacag gtgaggaact caactcaaac tcctctctct gggaaaacgc ggtgcttgct

61 cctcccggag tggccttggc agggtgttgg agccctcggt ctgccccgtc cggtctctgg

121 ggccaaggct gggtttccct catgtatggc aagagctcta ctcgtgcggt gcttcttctc

181 cttggcatac agctcacagc tctttggcct atagcagctg tggaaattta tacctcccgg 241 gtgctggagg ctgttaatgg gacagatgct cggttaaaat gcactttctc cagctttgcc

301 cctgtgggtg atgctctaac agtgacctgg aattttcgtc ctctagacgg gggacctgag

361 cagtttgtat tctactacca catagatccc ttccaaccca tgagtgggcg gtttaaggac

421 cgggtgtctt gggatgggaa tcctgagcgg tacgatgcct ccatccttct ctggaaactg

481 cagttcgacg acaatgggac atacacctgc caggtgaaga acccacctga tgttgatggg 541 gtgatagggg agatccggct cagcgtcgtg cacactgtac gcttctctga gatccacttc

601 ctggctctgg ccattggctc tgcctgtgca ctgatgatca taatagtaat tgtagtggtc

661 ctcttccagc attaccggaa aaagcgatgg gccgaaagag ctcataaagt ggtggagata

721 aaatcaaaag aagaggaaag gctcaaccaa gagaaaaagg tctctgttta tttagaagac

781 acagactaac aattttagat ggaagctgag atgatttcca agaacaagaa ccctagtatt 841 tcttgaagtt aatggaaact tttctttggc ttttccagtt gtgacccgtt ttccaaccag

901 ttctgcagca tattagattc tagacaagca acacccctct ggagccagca cagtgctcct

961 ccatatcacc agtcatacac agcctcatta ttaaggtctt atttaatttc agagtgtaaa

1021 ttttttcaag tgctcattag gttttataaa caagaagcta catttttgcc cttaagacac

1081 tacttacagt gttatgactt gtatacacat atattggtat caaaagggat aaaagccaat

1141 ttgtctgtta catttccttt cacgtatttc ttttagcagc acttctgcta ctaaagttaa

1201 tgtgtttact ctctttcctt cccacattct caattaaaag gtgagctaag cctcctcggt 1261 gtttctgatt aacagtaaat cctaaattca aactgttaaa tgacattttt atttttatgt

1321 ctctccttaa ctatgagaca catcttgttt tactgaattt ctttcaatat tccaggtgat

1381 agatttttgt tgttttgtta attaatccaa gatttacaat agcacaacgc taaatcacac

1441 agtaactaca aaaggttaca tagatatgaa aagattggca gaggccattg caggatgaat

1501 cacttgtcac ttttcttctg tgctgggaaa aataatcaac aatgtgggtc tttcatgagc 1561 agtgacggat agtttagctt actatgtttc ccccccaatt caatgatcta taacaacaga

1621 gcaaagtcta tgctcatttg cagactggaa tcattaagta atttaataaa aaaattgtga

1681 aacagcatat tacaagtttg aaaattcagg gctggtgaaa aaaatcaact ctaaatgatg

1741 ataattttgt acagttttat ataaaactct gagaactaga agaaattatt aacttttttt

1801 cttttttaat tctaattcac ttgtttattt tgggggagga agactttggt atggagcaaa 1861 gaaataccaa aactacttta aatggaataa aaccaacttt attctttttt tcccccatac

1921 tggtagataa agcaaacttt ataagtgggc tattgaaaga aaagttacaa gcttaagata

1981 cagaagcatt tgttcaaagg atagaaagca tctaaaagtt taggctcaag atcaatcttt

2041 acagattgat attttcagtt tttaatcgac tggactgcag atgttttttc ttttaacaaa

2101 ctggaatttt caaacagatt atctgtattt aaatgtatag accttgatat ttttccaata 2161 ctatttttta aaaaattgta tgatttacat atgaacctca gttctgaaat tcattacata

2221 tctgtctcat tctgcctttt atactgtcta aaaaagcaaa gttttaaagt gcaattttaa

2281 aactgtaaat tacatctgaa ggctatatat cctttaatca cattttatat tttttcttca

2341 caattctaac ctttgaaaat attataactg gatatttctt caaacagatg tcctggatga

2401 tggtccataa gaataatgaa gaagtagtta aaaatgtatg gacagttttt ccggcaaaat 2461 ttgtagctta tgtcttggct aaatagtcaa ggggtaatat gggcctgttg tttagtgtct

2521 ccttcctaaa gagcactttt gtattgtaat ttatttttta ttatgcttta aacactatgt

2581 aaataaacct ttagtaataa agaattatca gttataaaaa

1 attaaggact cggggcagga ggggcagaag ttgcgcgcag gccggcgggc gggagcggac 61 accgaggccg gcgtgcaggc gtgcgggtgt gcgggagccg ggctcggggg gatcggaccg

121 agagcgagaa gcgcggcatg gagctccagg cagcccgcgc ctgcttcgcc ctgctgtggg

181 gctgtgcgct ggccgcggcc gcggcggcgc agggcaagga agtggtactg ctggactttg

241 ctgcagctgg aggggagctc ggctggctca cacacccgta tggcaaaggg tgggacctga

301 tgcagaacat catgaatgac atgccgatct acatgtactc cgtgtgcaac gtgatgtctg 361 gcgaccagga caactggctc cgcaccaact gggtgtaccg aggagaggct gagcgtatct

421 tcattgagct caagtttact gtacgtgact gcaacagctt ccctggtggc gccagctcct

481 gcaaggagac tttcaacctc tactatgccg agtcggacct ggactacggc accaacttcc

541 agaagcgcct gttcaccaag attgacacca ttgcgcccga tgagatcacc gtcagcagcg

601 acttcgaggc acgccacgtg aagctgaacg tggaggagcg ctccgtgggg ccgctcaccc 661 gcaaaggctt ctacctggcc ttccaggata tcggtgcctg tgtggcgctg ctctccgtcc

721 gtgtctacta caagaagtgc cccgagctgc tgcagggcct ggcccacttc cctgagacca

781 tcgccggctc tgatgcacct tccctggcca ctgtggccgg cacctgtgtg gaccatgccg

841 tggtgccacc ggggggtgaa gagccccgta tgcactgtgc agtggatggc gagtggctgg

901 tgcccattgg gcagtgcctg tgccaggcag gctacgagaa ggtggaggat gcctgccagg 961 cctgctcgcc tggatttttt aagtttgagg catctgagag cccctgcttg gagtgccctg

1021 agcacacgct gccatcccct gagggtgcca cctcctgcga gtgtgaggaa ggcttcttcc

1081 gggcacctca ggacccagcg tcgatgcctt gcacacgacc cccctccgcc ccacactacc

1141 tcacagccgt gggcatgggt gccaaggtgg agctgcgctg gacgccccct caggacagcg

1201 ggggccgcga ggacattgtc tacagcgtca cctgcgaaca gtgctggccc gagtctgggg 1261 aatgcgggcc gtgtgaggcc agtgtgcgct actcggagcc tcctcacgga ctgacccgca

1321 ccagtgtgac agtgagcgac ctggagcccc acatgaacta caccttcacc gtggaggccc

1381 gcaatggcgt ctcaggcctg gtaaccagcc gcagcttccg tactgccagt gtcagcatca

1441 accagacaga gccccccaag gtgaggctgg agggccgcag caccacctcg cttagcgtct

1501 cctggagcat ccccccgccg cagcagagcc gagtgtggaa gtacgaggtc acttaccgca 1561 agaagggaga ctccaacagc tacaatgtgc gccgcaccga gggtttctcc gtgaccctgg

1621 acgacctggc cccagacacc acctacctgg tccaggtgca ggcactgacg caggagggcc

1681 agggggccgg cagcaaggtg cacgaattcc agacgctgtc cccggaggga tctggcaact

1741 tggcggtgat tggcggcgtg gctgtcggtg tggtcctgct tctggtgctg gcaggagttg

1801 gcttctttat ccaccgcagg aggaagaacc agcgtgcccg ccagtccccg gaggacgttt 1861 acttctccaa gtcagaacaa ctgaagcccc tgaagacata cgtggacccc cacacatatg

1921 aggaccccaa ccaggctgtg ttgaagttca ctaccgagat ccatccatcc tgtgtcactc

1981 ggcagaaggt gatcggagca ggagagtttg gggaggtgta caagggcatg ctgaagacat

2041 cctcggggaa gaaggaggtg ccggtggcca tcaagacgct gaaagccggc tacacagaga

2101 agcagcgagt ggacttcctc ggcgaggccg gcatcatggg ccagttcagc caccacaaca 2161 tcatccgcct agagggcgtc atctccaaat acaagcccat gatgatcatc actgagtaca

2221 tggagaatgg ggccctggac aagttccttc gggagaagga tggcgagttc agcgtgctgc

2281 agctggtggg catgctgcgg ggcatcgcag ctggcatgaa gtacctggcc aacatgaact

2341 atgtgcaccg tgacctggct gcccgcaaca tcctcgtcaa cagcaacctg gtctgcaagg

2401 tgtctgactt tggcctgtcc cgcgtgctgg aggacgaccc cgaggccacc tacaccacca 2461 gtggcggcaa gatccccatc cgctggaccg ccccggaggc catttcctac cggaagttca

2521 cctctgccag cgacgtgtgg agctttggca ttgtcatgtg ggaggtgatg acctatggcg

2581 agcggcccta ctgggagttg tccaaccacg aggtgatgaa agccatcaat gatggcttcc

2641 ggctccccac acccatggac tgcccctccg ccatctacca gctcatgatg cagtgctggc

2701 agcaggagcg tgcccgccgc cccaagttcg ctgacatcgt cagcatcctg gacaagctca 2761 ttcgtgcccc tgactccctc aagaccctgg ctgactttga cccccgcgtg tctatccggc

2821 tccccagcac gagcggctcg gagggggtgc ccttccgcac ggtgtccgag tggctggagt

2881 ccatcaagat gcagcagtat acggagcact tcatggcggc cggctacact gccatcgaga

2941 aggtggtgca gatgaccaac gacgacatca agaggattgg ggtgcggctg cccggccacc

3001 agaagcgcat cgcctacagc ctgctgggac tcaaggacca ggtgaacact gtggggatcc

3061 ccatctgagc ctcgacaggg cctggagccc catcggccaa gaatacttga agaaacagag

3121 tggcctccct gctgtgccat gctgggccac tggggacttt atttatttct agttctttcc 3181 tccccctgca acttccgctg aggggtctcg gatgacaccc tggcctgaac tgaggagatg

3241 accagggatg ctgggctggg ccctctttcc ctgcgagacg cacacagctg agcacttagc

3301 aggcaccgcc acgtcccagc atccctggag caggagcccc gccacagcct tcggacagac

3361 atataggata ttcccaagcc gaccttccct ccgccttctc ccacatgagg ccatctcagg

3421 agatggaggg cttggcccag cgccaagtaa acagggtacc tcaagcccca tttcctcaca 3481 ctaagagggc agactgtgaa cttgactggg tgagacccaa agcggtccct gtccctctag

3541 tgccttcttt agaccctcgg gccccatcct catccctgac tggccaaacc cttgctttcc

3601 tgggcctttg caagatgctt ggttgtgttg aggtttttaa atatatattt tgtactttgt

3661 ggagagaatg tgtgtgtgtg gcagggggcc ccgccagggc tggggacaga gggtgtcaaa

3721 cattcgtgag ctggggactc agggaccggt gctgcaggag tgtcctgccc atgc.cccagt 3781 cggccccatc tctcatcctt ttggataagt ttctattctg tcagtgttaa agattttgtt

3841 ttgttggaca tttttttcga atcttaattt attatttttt ttatatttat tgttagaaaa

3901 tgacttattt ctgctctgga ataaagttgc agatgattca aaccgaaaaa

1 aacgggctca ttcagcggtc gcgagctgcc cgcgaggggg agcggccgga cggagagcgc

61 gacccgtccc gggggtgggg ccgggcgcag cggcgagagg aggcgaaggt ggctgcggta

121 gcagcagcgc ggcagcctcg gacccagccc ggagcgcagg gcggccgctg caggtccccg

181 ctcccctccc cgtgcgtccg cccatggccg ccgccgggca gctgtgcttg ctctacctgt 241 cggcggggct cctgtcccgg ctcggcgcag ccttcaactt ggacactcgg gaggacaacg

301 tgatccggaa atatggagac cccgggagcc tcttcggctt ctcgctggcc atgcactggc

361 aactgcagcc cgaggacaag cggctgttgc tcgtgggggc cccgcgggca gaagcgcttc

421 cactgcagag agccaacaga acgggagggc tgtacagctg cgacatcacc gcccgggggc

481 catgcacgcg gatcgagttt gataacgatg ctgaccccac gtcagaaagc aaggaagatc

541 agtggatggg ggtcaccgtc cagagccaag gtccaggggg caaggtcgtg acatgtgctc

601 accgatatga aaaaaggcag catgttaata cgaagcagga atcccgagac atctttgggc 661 ggtgttatgt cctgagtcag aatctcagga ttgaagacga tatggatggg ggagattgga

721 gcttttgtga tgggcgattg agaggccatg agaaatttgg ctcttgccag caaggtgtag

781 cagctacttt tactaaagac tttcattaca ttgtatttgg agccccgggt acttataact

841 ggaaagggat tgttcgtgta gagcaaaaga ataacacttt ttttgacatg aacatctttg

901 aagatgggcc ttatgaagtt ggtggagaga ctgagcatga tgaaagtctc gttcctgttc 961 ctgctaacag ttacttaggt ttttctttgg actcagggaa aggtattgtt tctaaagatg

1021 agatcacttt tgtatctggt gctcccagag ccaatcacag tggagccgtg gttttgctga

1081 agagagacat gaagtctgca catctcctcc ctgagcacat attcgatgga gaaggtctgg

1141 cctcttcatt tggctatgat gtggcggtgg tggacctcaa caaggatggg tggcaagata

1201 tagttattgg agccccacag tattttgata gagatggaga agttggaggt gcagtgtatg 1261 tctacatgaa ccagcaaggc agatggaata atgtgaagcc aattcgtctt aatggaacca

1321 aagattctat gtttggcatt gcagtaaaaa atattggaga tattaatcaa gatggctacc

1381 cagatattgc agttggagct ccgtatgatg acttgggaaa ggtttttatc tatcatggat

1441 ctgcaaatgg aataaatacc aaaccaacac aggttctcaa gggtatatca ccttattttg

1501 gatattcaat tgctggaaac atggaccttg atcgaaattc ctaccctgat gttgctgttg 1561 gttccctctc agattcagta actattttca gatcccggcc tgtgattaat attcagaaaa

1621 ccatcacagt aactcctaac agaattgacc tccgccagaa aacagcgtgt ggggcgccta

1681 gtgggatatg cctccaggtt aaatcctgtt ttgaatatac tgctaacccc gctggttata

1741 atccttcaat atcaattgtg ggcacacttg aagctgaaaa agaaagaaga aaatctgggc

1801 tatcctcaag agttcagttt cgaaaccaag gttctgagcc caaatatact caagaactaa 1861 ctctgaagag gcagaaacag aaagtgtgca tggaggaaac cctgtggcta caggataata

1921 tcagagataa actgcgtccc attcccataa ctgcctcagt ggagatccaa gagccaagct

1981 ctcgtaggcg agtgaattca cttccagaag ttcttccaat tctgaattca gatgaaccca

2041 agacagctca tattgatgtt cacttcttaa aagagggatg tggagacgac aatgtatgta

2101 acagcaacct taaactagaa tataaatttt gcacccgaga aggaaatcaa gacaaatttt

2161 cttatttacc aattcaaaaa ggtgtaccag aactagttct aaaagatcag aaggatattg

2221 ctttagaaat aacagtgaca aacagccctt ccaacccaag gaatcccaca aaagatggcg 2281 atgacgccca tgaggctaaa ctgattgcaa cgtttccaga cactttaacc tattctgcat

2341 atagagaact gagggctttc cctgagaaac agttgagttg tgttgccaac cagaatggct

2401 cgcaagctga ctgtgagctc ggaaatcctt ttaaaagaaa ttcaaatgtc actttttatt

2461 tggttttaag tacaactgaa gtcacctttg acaccccaga tctggatatt aatctgaagt

2521 tagaaacaac aagcaatcaa gataatttgg ctccaattac agctaaagca aaagtggtta 2581 ttgaactgct tttatcggtc tcgggagttg ctaaaccttc ccaggtgtat tttggaggta

2641 cagttgttgg cgagcaagct atgaaatctg aagatgaagt gggaagttta atagagtatg

2701 aattcagggt aataaactta ggtaaacctc ttacaaacct cggcacagca accttgaaca

2761 ttcagtggcc aaaagaaatt agcaatggga aatggttgct ttatttggtg aaagtagaat

2821 ccaaaggatt ggaaaaggta acttgtgagc cacaaaagga gataaactcc ctgaacctaa 2881 cggagtctca caactcaaga aagaaacggg aaattactga aaaacagata gatgataaca

2941 gaaaattttc tttatttgct gaaagaaaat accagactct taactgtagc gtgaacgtga

3001 actgtgtgaa catcagatgc ccgctgcggg ggctggacag caaggcgtct cttattttgc

3061 gctcgaggtt atggaacagc acatttctag aggaatattc caaactgaac tacttggaca

3121 ttctcatgcg agccttcatt gatgtgactg ctgctgccga aaatatcagg ctgccaaatg 3181 caggcactca ggttcgagtg actgtgtttc cctcaaagac tgtagctcag tattcgggag

3241 taccttggtg gatcatccta gtggctattc tcgctgggat cttgatgctt gctttattag

3301 tgtttatact atggaagtgt ggtttcttca agagaaataa gaaagatcat tatgatgcca

3361 catatcacaa ggctgagatc catgctcagc catctgataa agagaggctt acttctgatg

3421 catagtattg atctacttct gtaattgtgt ggattcttta aacgctctag gtacgatgac 3481 agtgttcccc gataccatgc tgtaaggatc cggaaagaag agcgagagat caaagatgaa

3541 aagtatattg ataaccttga aaaaaaacag tggatcacaa agtggaacga aaatgaaagc

3601 tactcatagc gggggcctaa aaaaaaaaag cttcacagta cccaaactgc tttttccaac

3661 tcagaaattc aatttggatt taaaagcctg ctcaatccct gaggactgat ttcagagtga

3721 ctacacacag tacgaaccta cagttttaac tgtggatatt gttacgtagc ctaaggctcc

3781 tgttttgcac agccaaattt aaaactgttg gaatggattt ttctttaact gccgtaattt

3841 aactttctgg gttgccttta tttttggcgt ggctgactta catcatgtgt tggggaaggg 3901 cctgcccagt tgcactcagg tgacatcctc cagatagtgt agctgaggag gcacctacac

3961 tcacctgcac taacagagtg gccgtcctaa cctcgggcct gctgcgcaga cgtccatcac

4021 gttagctgtc ccacatcaca agactatgcc attggggtag ttgtgtttca acggaaagtg

4081 ctgtcttaaa ctaaatgtgc aatagaaggt gatgttgcca tcctaccgtc ttttcctgtt

4141 tcctagctgt gtgaatacct gctcacgtca aatgcataca agtttcattc tccctttcac 4201 taaaacacac aggtgcaaca gacttgaatg ctagttatac ttatttgtat atggtattta 4261 ttttttcttt tctttacaaa ccattttgtt attgactaac aggccaaaga gtctccagtt

4321 tacccttcag gttggtttaa tcaatcagaa ttagagcatg ggaggtcatc actttgacct

4381 aaattattta ctgcaaaaag aaaatcttta taaatgtacc agagagagtt gttttaataa

4441 cttatctata aactataacc tctccttcat gacagcctcc accccacaac ccaaaaggtt 4501 taagaaatag aattataact gtaaagatgt ttatttcagg cattggatat tttttacttt

4561 agaagcctgc ataatgtttc tggatttcat actgtaacat tcaggaattc ttggagaaaa

4621 tgggtttatt cactgaactc tagtgcggtt tactcactgc tgcaaatact gtatattcag

4681 gacttgaaag aaatggtgaa tgcctatggt ggatccaaac tgatccagta taagactact

4741 gaatctgcta ccaaaacagt taatcagtga gtcgatgttc tattttttgt tttgtttcct 4801 cccctatctg tattcccaaa aattactttg gggctaattt aacaagaact ttaaattgtg

4861 ttttaattgt aaaaatggca gggggtggaa ttattactct atacattcaa cagagactga

4921 atagatatga aagctgattt tttttaatta ccatgcttca caatgttaag ttatatgggg

4981 agcaacagca aacaggtgct aatttgtttt ggatatagta taagcagtgt ctgtgttttg

5041 aaagaataga acacagtttg tagtgccact gttgttttgg gggggctttt ttcttttcgg 5101 aaatcttaaa ccttaagata ctaaggacgt tgttttggtt gtactttgga attcttagtc

5161 acaaaatata ttttgtttac aaaaatttct gtaaaacagg ttataacagt gtttaaagtc

5221 tcagtttctt gcttggggaa cttgtgtccc taatgtgttt agattgctag attgctaagg

5281 agctgatact ttgacagtgt ttttagacct gtgttactaa aaaaaagatg aatgtcctga

5341 aaagggtgtt gggagggtgg ttcaacaaag aaacaaagat gttatggtgt ttagatttat

5401 ggttgttaaa aatgtcatct caagtcaagt cactggtctg tttgcatttg atacattttt 5461 gtactaacta gcattgtaaa attatttcat gattagaaat tacctgtgga tatttgtata 5521 aaagtgtgaa ataaattttt tataaaagtg ttcattgttt cgtaacacag cattgtatat 5581 gtgaagcaaa ctctaaaatt ataaatgaca acctgaatta tctatttcat caaaccaaag 5641 ttcagtgttt ttatttttgg tgtctcatgt aatctcagat cagccaaaga tactagtgcc 5701 aaagcaatgg gattcggggt ttttttctgt tttcgctcta tgtaggtgat cctcaagtct 5761 ttcattttcc ttctttatga ttaaaagaaa cctacaggta tttaacaacc

1 gccaccacgt gtgtccctgc gcccggtggc caccgactca gtccctcgcc gaccagtctg

61 ggcagcggag gagggtggtt ggcagtggct ggaagcttcg ctatgggaag ttgttccttt 121 gctctctcgc gcccagtcct cctccctggt tctcctcagc cgctgtcgga ggagagcacc 181 cggagacgcg ggctgcagtc gcggcggctt ctccccgcct gggcggccgc gccgctgggc 241 aggtgctgag cgcccctaga gcctcccttg ccgcctccct cctctgcccg gccgcagcag 301 tgcacatggg gtgttggagg tagatgggct cccggcccgg gaggcggcgg tggatgcggc 361 gctgggcaga agcagccgcc gattccagct gccccgcgcg ccccgggcgc ccctgcgagt 421 ccccggttca gccatgggga cctctccgag cagcagcacc gccctcgcct cctgcagccg 481 catcgcccgc cgagccacag ccacgatgat cgcgggctcc cttctcctgc ttggattcct 541 tagcaccacc acagctcagc cagaacagaa ggcctcgaat ctcattggca cataccgcca 601 tgttgaccgt gccaccggcc aggtgctaac ctgtgacaag tgtccagcag gaacctatgt 661 ctctgagcat tgtaccaaca caagcctgcg cgtctgcagc agttgccctg tggggacctt 721 taccaggcat gagaatggca tagagaaatg ccatgactgt agtcagccat gcccatggcc 781 aatgattgag aaattacctt gtgctgcctt gactgaccga gaatgcactt gcccacctgg 841 catgttccag tctaacgcta cctgtgcccc ccatacggtg tgtcctgtgg gttggggtgt 901 gcggaagaaa gggacagaga ctgaggatgt gcggtgtaag cagtgtgctc ggggtacctt 961 ctcagatgtg ccttctagtg tgatgaaatg caaagcatac acagactgtc tgagtcagaa

1021 cctggtggtg atcaagccgg ggaccaagga gacagacaac gtctgtggca cactcccgtc

1081 cttctccagc tccacctcac cttcccctgg cacagccatc tttccacgcc ctgagcacat 1141 ggaaacccat gaagtccctt cctccactta tgttcccaaa ggcatgaact caacagaatc

1201 caactcttct gcctctgtta gaccaaaggt actgagtagc atccaggaag ggacagtccc

1261 tgacaacaca agctcagcaa gggggaagga agacgtgaac aagaccctcc caaaccttca

1321 ggtagtcaac caccagcaag gcccccacca cagacacatc ctgaagctgc tgccgtccat

1381 ggaggccact gggggcgaga agtccagcac gcccatcaag ggccccaaga ggggacatcc 1441 tagacagaac ctacacaagc attttgacat caatgagcat ttgccctgga tgattgtgct

1501 tttcctgctg ctggtgcttg tggtgattgt ggtgtgcagt atccggaaaa gctcgaggac

1561 tctgaaaaag gggccccggc aggatcccag tgccattgtg gaaaaggcag ggctgaagaa

1621 atccatgact ccaacccaga accgggagaa atggatctac tactgcaatg gccatggtat

1681 cgatatcctg aagcttgtag cagcccaagt gggaagccag tggaaagata tctatcagtt 1741 tctttgcaat gccagtgaga gggaggttgc tgctttctcc aatgggtaca cagccgacca

1801 cgagcgggcc tacgcagctc tgcagcactg gaccatccgg ggccccgagg ccagcctcgc

1861 ccagctaatt agcgccctgc gccagcaccg gagaaacgat gttgtggaga agattcgtgg

1921 gctgatggaa gacaccaccc agctggaaac tgacaaacta gctctcccga tgagccccag

1981 cccgcttagc ccgagcccca tccccagccc caacgcgaaa cttgagaatt ccgctctcct 2041 gacggtggag ccttccccac aggacaagaa caagggcttc ttcgtggatg agtcggagcc

2101 ccttctccgc tgtgactcta catccagcgg ctcctccgcg ctgagcagga acggttcctt

2161 tattaccaaa gaaaagaagg acacagtgtt gcggcaggta cgcctggacc cctgtgactt

2221 gcagcctatc tttgatgaca tgctccactt tctaaatcct gaggagctgc gggtgattga

2281 agagattccc caggctgagg acaaactaga ccggctattc gaaattattg gagtcaagag 2341 ccaggaagcc agccagaccc tcctggactc tgtttatagc catcttcctg acctgctgta

2401 gaacataggg atactgcatt ctggaaatta ctcaatttag tggcagggtg gttttttaat

2461 tttcttctgt ttctgatttt tgttgtttgg ggtgtgtgtg tgtgtttgtg tgtgtgtgtg

2521 tgtgtgtgtg tgtgtgtgtg tttaacagag aatatggcca gtgcttgagt tctttctcct

2581 tctctctctc tctttttttt ttaaataact cttctgggaa gttggtttat aagcctttgc

2641 caggtgtaac tgttgtgaaa tacccaccac taaagttttt taagttccat attttctcca

2701 ttttgccttc ttatgtattt tcaagattat tctgtgcact ttaaatttac ttaacttacc 2761 ataaatgcag tgtgactttt cccacacact ggattgtgag gctcttaact tcttaaaagt

2821 ataatggcat cttgtgaatc ctataagcag tctttatgtc tcttaacatt cacacctact

2881 ttttaaaaac aaatattatt actattttta ttattgtttg tcctttataa attttcttaa

2941 agattaagaa aatttaagac cccattgagt tactgtaatg caattcaact ttgagttatc

3001 ttttaaatat gtcttgtata gttcatattc atggctgaaa cttgaccaca ctattgctga 3061 ttgtatggtt ttcacctgga caccgtgtag aatgcttgat tacttgtact cttcttatgc

3121 taatatgctc tgggctggag aaatgaaatc ctcaagccat caggatttgc tatttaagtg

3181 gcttgacaac tgggccacca aagaacttga acttcacctt ttaggatttg agctgttctg

3241 gaacacattg ctgcactttg gaaagtcaaa atcaagtgcc agtggcgccc tttccataga

3301 gaatttgccc agctttgctt taaaagatgt cttgtttttt atatacacat aatcaatagg 3361 tccaatctgc tctcaaggcc ttggtcctgg tgggattcct tcaccaatta ctttaattaa

3421 aaatggctgc aactgtaaga acccttgtct gatatatttg caactatgct cccatttaca

3481 aatgtacctt ctaatgctca gttgccaggt tccaatgcaa aggtggcgtg gactcccttt

3541 gtgtgggtgg ggtttgtggg tagtggtgaa ggaccgatat cagaaaaatg ccttcaagtg

3601 tactaattta ttaataaaca ttaggtgttt gttaaaaaaa

1 agtgccccag gagctatgac aagcaaagga acatacttgc ctggagatag cctttgcgat 61 atttaaatgt ccgtggatac agaaatctct gcaggcaagt tgctccagag catattgcag

121 gacaagcctg taacgaatag ttaaattcac ggcatctgga ttcctaatcc ttttccgaaa

181 tggcaggtgt gagtgcctgt ataaaatatt ctatgtttac cttcaacttc ttgttctggc

241 tatgtggtat cttgatccta gcattagcaa tatgggtacg agtaagcaat gactctcaag 301 caatttttgg ttctgaagat gtaggctcta gctcctacgt tgctgtggac atattgattg

361 ctgtaggtgc catcatcatg attctgggct tcctgggatg ctgcggtgct ataaaagaaa

421 gtcgctgcat gcttctgttg tttttcatag gcttgcttct gatcctgctc ctgcaggtgg

481 cgacaggtat cctaggagct gttttcaaat ctaagtctga tcgcattgtg aatgaaactc

541 tctatgaaaa cacaaagctt ttgagcgcca caggggaaag tgaaaaacaa ttccaggaag 601 ccataattgt gtttcaagaa gagtttaaat gctgcggttt ggtcaatgga gctgctgatt

661 ggggaaataa ttttcaacac tatcctgaat tatgtgcctg tctagataag cagagaccat

721 gccaaagcta taatggaaaa caagtttaca aagagacctg tatttctttc ataaaagact

781 tcttggcaaa aaatttgatt atagttattg gaatatcatt tggactggca gttattgaga

841 tactgggttt ggtgttttct atggtcctgt attgccagat cgggaacaaa tgaatctgtg 901 gatgcatcaa cctatcgtca gtcaaacccc tttaaaatgt tgctttggct ttgtaaattt

961 aaatatgtaa gtgctatata agtcaggagc agctgtcttt ttaaaatgtc tcggctagct

1021 agaccacaga tatcttctag acatattgaa cacatttaag atttgaggga tataagggaa

1081 aatgatatga atgtgtattt ttactcaaaa taaaagtaac tgtttacgtt

1 attctctccc cagcttgctg agccctttgc tcccctggcg actgcctgga cagtcagcaa

61 ggaattgtct cccagtgcat tttgccctcc tggctgccaa ctctggctgc taaagcggct 121 gccacctgct gcagtctaca cagcttcggg aagaggaaag gaacctcaga ccttccagat

181 cgcttcctct cgcaacaaac tatttgtcgc aggaataaag atggctgctg aaccagtaga 241 agacaattgc atcaactttg tggcaatgaa atttattgac aatacgcttt actttatagc 301 tgaagatgat gaaaacctgg aatcagatta ctttggcaag cttgaatcta aattatcagt 361 cataagaaat ttgaatgacc aagttctctt cattgaccaa ggaaatcggc ctctatttga 421 agatatgact gattctgact gtagagataa tgcaccccgg accatattta ttataagtat

481 gtataaagat agccagccta gaggtatggc tgtaactatc tctgtgaagt gtgagaaaat 541 ttcaactctc tcctgtgaga acaaaattat ttcctttaag gaaatgaatc ctcctgataa 601 catcaaggat acaaaaagtg acatcatatt ctttcagaga agtgtcccag gacatgataa 661 taagatgcaa tttgaatctt catcatacga aggatacttt ctagcttgtg aaaaagagag

721 agaccttttt aaactcattt tgaaaaaaga ggatgaattg ggggatagat ctataatgtt

781 cactgttcaa aacgaagact agctattaaa atttcatgcc gggcgcagtg gctcacgcct

841 gtaatcccag ccctttggga ggctgaggcg ggcagatcac cagaggtcag gtgttcaaga

901 ccagcctgac caacatggtg aaacctcatc tctactaaaa atacaaaaaa ttagctgagt

961 gtagtgacgc atgccctcaa tcccagctac tcaagaggct gaggcaggag aatcacttgc

1021 actccggagg tagaggttgt ggtgagccga gattgcacca ttgcgctcta gcctgggcaa

1081 caacagcaaa actccatctc aaaaaataaa ataaataaat aaacaaataa aaaattcata

1141 atgtg

1 gagggagggg ccgccgggga agaggaggag gaaggaaaga aagaaagcga gggagggaaa

61 gaggaggaag gaagatgcga gaaggcagag gaggagggag ggagggaagg agcgcggagc 121 ccggcccgga agctaggagc cattccgtag tgccatcccg agcaacgcac tgctgcagct 181 tccctgagcc tttccagcaa gtttgttcaa gattggctgt caagaatcat ggactgttat 241 tatatgcctt gttttctgtc aagacaccat gattcctggt aaccgaatgc tgatggtcgt 301 tttattatgc caagtcctgc taggaggcgc gagccatgct agtttgatac ctgagacggg 361 gaagaaaaaa gtcgccgaga ttcagggcca cgcgggagga cgccgctcag ggcagagcca 421 tgagctcctg cgggacttcg aggcgacact tctgcagatg tttgggctgc gccgccgccc 481 gcagcctagc aagagtgccg tcattccgga ctacatgcgg gatctttacc ggcttcagtc 541 tggggaggag gaggaagagc agatccacag cactggtctt gagtatcctg agcgcccggc 601 cagccgggcc aacaccgtga ggagcttcca ccacgaagaa catctggaga acatcccagg 661 gaccagtgaa aactctgctt ttcgtttcct ctttaacctc agcagcatcc ctgagaacga 721 ggcgatctcc tctgcagagc ttcggctctt ccgggagcag gtggaccagg gccctgattg 781 ggaaaggggc ttccaccgta taaacattta tgaggttatg aagcccccag cagaagtggt 841 gcctgggcac ctcatcacac gactactgga cacgagactg gtccaccaca atgtgacacg

901 gtgggaaact tttgatgtga gccctgcggt ccttcgctgg acccgggaga agcagccaaa

961 ctatgggcta gccattgagg tgactcacct ccatcagact cggacccacc agggccagca

1021 tgtcaggatt agccgatcgt tacctcaagg gagtgggaat tgggcccagc tccggcccct

1081 cctggtcacc tttggccatg atggccgggg ccatgccttg acccgacgcc ggagggccaa

1141 gcgtagccct aagcatcact cacagcgggc caggaagaag aataagaact gccggcgcca

1201 ctcgctctat gtggacttca gcgatgtggg ctggaatgac tggattgtgg ccccaccagg

1261 ctaccaggcc ttctactgcc atggggactg cccctttcca ctggctgacc acctcaactc

1321 aaccaaccat gccattgtgc agaccctggt caattctgtc aattccagta tccccaaagc

1381 ctgttgtgtg cccactgaac tgagtgccat ctccatgctg tacctggatg agtatgataa

1441 ggtggtactg. aaaaattatc aggagatggt agtagaggga tgtgggtgcc gctgagatca

1501 ggcagtcctt gaggatagac agatatacac accacacaca cacaccacat acaccacaca

1561 cacacgttcc catccactca cccacacact acacagactg cttccttata gctggacttt

1621 tatttaaaaa aaaaaaaaaa aaaatggaaa aaatccctaa acattcacct tgaccttatt

1681 tatgacttta cgtgcaaatg ttttgaccat attgatcata tattttgaca aaatatattt

1741 ataactacgt attaaaagaa aaaaataaaa tgagtcatta ttttaaaggt

1 ccagatcata ccctgctggg caaaggagga agagccagag gatccagacg ccttggagga

61 cttggaacac ctgtaacagg acaaggagtt ctgctcaggc acgtggccac agaaaactac 121 ttaggaagcc tgtggtgaga acaacaacag tgcctgagaa tcccacggct ctggggaagt 181 gagccccgag gatgaggctg ctcgcctggc tgattttcct ggctaactgg ggaggtgcca 241 gggctgaacc agggaagttc tggcacatcg ctgacctgca ccttgaccct gactacaagg 301 tatccaaaga ccccttccag gtgtgcccat cagctggatc ccagccagtg cccgacgcag

361 gcccctgggg tgactacctc tgtgattctc cctgggccct catcaactcc tccatctatg

421 ccatgaagga gattgagcca gagccagact tcattctctg gactggtgat gacacgcctc

481 atgtgcccga tgagaaactg ggagaggcag ctgtactgga aattgtggaa cgcctgacca 541 agctcatcag agaggtcttt ccagatacta aagtctatgc tgctttggga aatcatgatt

601 ttcaccccaa aaaccagttc ccagctggaa gtaacaacat ctacaatcag atagcagaac

661 tatggaaacc ctggcttagt aatgagtcca tcgctctctt caaaaaaggt gccttctact

721 gtgagaagct gccgggtccc agcggggctg ggcgaattgt ggtcctcaac accaatctgt

781 actataccag caatgcgctg acagcagaca tggcggaccc tggccagcag ttccagtggc 841 tggaagatgt gctgaccgat gcatccaaag ctggggacat ggtgtacatt gtcggccacg

901 tgcccccggg gttctttgag aagacgcaaa acaaggcatg gttccgggag ggcttcaatg

961 aaaaatacct gaaggtggtc cggaagcatc atcgcgtcat agcagggcag ttcttcgggc

1021 accaccacac cgacagcttt cggatgctct atgatgatgc aggtgtcccc ataagcgcca

1081 tgttcatcac acctggagtc accccatgga aaaccacatt acctggagtg gtcaatgggg 1141 ccaacaatcc agccatccgg gtgttcgaat atgaccgagc cacactgagc ctgaaggaca

1201 tggtgaccta cttcatgaac ctgagccagg cgaatgctca ggggacgccg cgctgggagc

1261 tcgagtacca gctgaccgag gcctatgggg tgccggacgc cagcgcccac tccatgcaca

1321 cagtgctgga ccgcatcgct ggcgaccaga gcacactgca gcgctactac gtctataact

1381 cagtcagcta ctctgctggg gtctgcgacg aggcctgcag catgcagcac gtgtgtgcca 1441 tgcgccaggt ggacattgac gcttacacca cctgtctgta tgcctctggc accacgcccg

1501 tgccccagct cccgctgctg ctgatggccc tgctgggcct gtgcacgctc gtgctgtgac

1561 ctgccaggct caccttcttc ctggtaacgg gtaacggggg cagcgcccag gatcacccag

1621 agctgggcct tccaccattt cctccgcgcc tgaggagtga actgaaatag gacaaccgaa

1681 tcaggaagcg aagccccagg agctgcagcc atccgtgatc gcgccactgc actccagcct 1741 gggcgacaaa gccagactct ctccaaaaac aaaccagaaa cagaaaagaa atgacgaccc

1801 aagacccccc tacaagcata cttcttttgc gtattatgtt ttactcacaa aacaaagctc

1861 atcatgcgtt tgaaaaaaaa

1 cgcgagctaa gcaggaggcg gaggcggagg cggagggcga ggggcgggga gcgccgcctg 61 gagcgcggca ggtcatattg aacattccag atacctatca ttactcgatg ctgttgataa

121 cagcaagatg gctttgaact cagggtcacc accagctatt ggaccttact atgaaaacca

181 tggataccaa ccggaaaacc cctatcccgc acagcccact gtggtcccca ctgtctacga

241 ggtgcatccg gctcagtact acccgtcccc cgtgccccag tacgccccga gggtcctgac

301 gcaggcttcc aaccccgtcg tctgcacgca gcccaaatcc ccatccggga cagtgtgcac 361 ctcaaagact aagaaagcac tgtgcatcac cttgaccctg gggaccttcc tcgtgggagc

421 tgcgctggcc gctggcctac tctggaagtt catgggcagc aagtgctcca actctgggat

481 agagtgcgac tcctcaggta cctgcatcaa cccctctaac tggtgtgatg gcgtgtcaca

541 ctgccccggc ggggaggacg agaatcggtg tgttcgcctc tacggaccaa acttcatcct

601 tcagatgtac tcatctcaga ggaagtcctg gcaccctgtg tgccaagacg actggaacga 661 gaactacggg cgggcggcct gcagggacat gggctataag aataattttt actctagcca

721 aggaatagtg gatgacagcg gatccaccag ctttatgaaa ctgaacacaa gtgccggcaa

781 tgtcgatatc tataaaaaac tgtaccacag tgatgcctgt tcttcaaaag cagtggtttc

841 tttacgctgt atagcctgcg gggtcaactt gaactcaagc cgccagagca ggatcgtggg

901 cggtgagagc gcgctcccgg gggcctggcc ctggcaggtc ag . cctgcacg tccagaacgt 961 ccacgtgtgc ggaggctcca tcatcacccc cgagtggatc gtgacagccg cccactgcgt

1021 ggaaaaacct cttaacaatc catggcattg gacggcattt gcggggattt tgagacaatc

1081 tttcatgttc tatggagccg gataccaagt agaaaaagtg atttctcatc caaattatga

1141 ctccaagacc aagaacaatg acattgcgct gatgaagctg cagaagcctc tgactttcaa

1201 cgacctagtg aaaccagtgt gtctgcccaa cccaggcatg atgctgcagc cagaacagct 1261 ctgctggatt tccgggtggg gggccaccga ggagaaaggg aagacctcag aagtgctgaa

1321 cgctgccaag gtgcttctca ttgagacaca gagatgcaac agcagatatg tctatgacaa

1381 cctgatcaca ccagccatga tctgtgccgg cttcctgcag gggaacgtcg attcttgcca

1441 gggtgacagt ggagggcctc tggtcacttc gaagaacaat atctggtggc tgatagggga 1501 tacaagctgg ggttctggct gtgccaaagc ttacagacca ggagtgtacg ggaatgtgat

1561 ggtattcacg gactggattt atcgacaaat gagggcagac ggctaatcca catggtcttc

1621 gtccttgacg tcgttttaca agaaaacaat ggggctggtt ttgcttcccc gtgcatgatt

1681 tactcttaga gatgattcag aggtcacttc atttttatta aacagtgaac ttgtctggct

1741 ttggcactct ctgccattct gtgcaggctg cagtggctcc cctgcccagc ctgctctccc 1801 taaccccttg tccgcaaggg gtgatggccg gctggttgtg ggcactggcg gtcaagtgtg

1861 gaggagaggg gtggaggctg ccccattgag atcttcctgc tgagtccttt ccaggggcca

1921 attttggatg agcatggagc tgtcacctct cagctgctgg atgacttgag atgaaaaagg

1981 agagacatgg aaagggagac agccaggtgg cacctgcagc ggctgccctc tggggccact

2041 tggtagtgtc cccagcctac ctctccacaa ggggattttg ctgatgggtt cttagagcct 2101 tagcagccct ggatggtggc cagaaataaa gggaccagcc cttcatgggt ggtgacgtgg

2161 tagtcacttg taaggggaac agaaacattt ttgttcttat ggggtgagaa tatagacagt

2221 gcccttggtg cgagggaagc aattgaaaag gaacttgccc tgagcactcc tggtgcaggt

2281 ctccacctgc acattgggtg gggctcctgg gagggagact cagccttcct cctcatcctc

2341 cctgaccctg ctcctagcac cctggagagt gcacatgccc cttggtcctg gcagggcgcc 2401 aagtctggca ccatgttggc ctcttcaggc ctgctagtca ctggaaattg aggtccatgg

2461 gggaaatcaa ggatgctcag tttaaggtac actgtttcca tgttatgttt ctacacattg

2521 ctacctcagt gctcctggaa acttagcttt tgatgtctcc aagtagtcca ccttcattta

2581 actctttgaa actgtatcac ctttgccaag taagagtggt ggcctatttc agctgctttg

2641 acaaaatgac tggctcctga cttaacgttc tataaatgaa tgtgctgaag caaagtgccc 2701 atggtggcgg cgaagaagag aaagatgtgt tttgttttgg actctctgtg gtcccttcca

2761 atgctgtggg tttccaacca ggggaagggt cccttttgca ttgccaagtg ccataaccat

2821 gagcactact ctaccatggt tctgcctcct ggccaagcag gctggtttgc aagaatgaaa

2881 tgaatgattc tacagctagg acttaacctt gaaatggaaa gtcttgcaat cccatttgca

2941 ggatccgtct gtgcacatgc ctctgtagag agcagcattc ccagggacct tggaaacagt

3001 tggcactgta aggtgcttgc tccccaagac acatcctaaa aggtgttgta atggtgaaaa

3061 cgtcttcctt ctttattgcc ccttcttatt tatgtgaaca actgtttgtc tttttttgta 3121 tcttttttaa actgtaaagt tcaattgtga aaatgaatat catgcaaata aattatgcga 3181 tttttttttc aaagcaaaaa

1 gtagggagcc agcccctggg cgcggcctgc agggtaccgg caaccgcccg ggtaagcggg 61 ggcaggacaa ggccggagcc tgtgtccgcc cggcagccgc ccgcagctgc agagagtccc

121 gctgcgtctc cgccgcgtgc gccctcctcg accagcagac ccgcgctgcg ctccgccgct

181 gacatgtgtg ccgctcagat gccgcccctg gcgcacatct tccgagggac gttcgtccac

241 tccacctgga cctgccccat ggaggtgctg cgggatcacc tcctcggcgt gagcgacagc 301 ggcaaaatag tgtttttaga agaagcatct caacaggaaa aactggccaa agaatggtgc

361 ttcaagccgt gtgaaataag agaactgagc caccatgagt tcttcatgcc tgggctggtt

421 gatacacaca tccatgcctc tcagtattcc tttgctggaa gtagcataga cctgccactc

481 ttggagtggc tgaccaagta cacatttcct gcagaacaca gattccagaa catcgacttt

541 gcagaagaag tatataccag agttgtcagg agaacactaa agaatggaac aaccacagct 601 tgttactttg caacaattca cactgactca tctctgctcc ttgccgacat tacagataaa

661 tttggacagc gggcatttgt gggcaaagtt tgcatggatt tgaatgacac ttttccagaa

721 tacaaggaga ccactgagga atcgatcaag gaaactgaga gatttgtgtc agaaatgctc

781 caaaagaact attctagagt gaagcccata gtgacaccac gtttttccct ctcctgctct

841 gagactttga tgggtgaact gggcaacatt gctaaaaccc gtgatttgca cattcagagc 901 catataagtg aaaatcgtga tgaagttgaa gctgtgaaaa acttataccc cagttataaa

961 aactacacat ctgtgtatga taaaaacaat cttttgacaa ataagacagt gatggcacac

1021 ggctgctacc tctctgcaga agaactgaac gtattccatg aacgaggagc atccatcgca

1081 cactgtccca attctaattt atcgctcagc agtggatttc taaatgtgct agaagtcctg

1141 aaacatgaag tcaagatagg gctgggtaca gacgtggctg gtggctattc atattccatg

1201 cttgatgcaa tcagaagagc agtgatggtt tccaatatcc ttttaattaa taaggtaaat

1261 gagaaaagcc tcaccctcaa agaagtcttc agactagcta ctcttggagg aagccaagcc 1321 ctggggctgg atggtgagat tggaaacttt gaagtgggca aggaatttga tgccatcctg

1381 atcaacccca aagcatccga ctctcccatt gacctgtttt atggggactt ttttggtgat

1441 atttctgagg ctgttatcca gaagttcctc tatctaggag atgatcgaaa tattgaagag

1501 gtttatgtgg gcggaaagca ggtggttccg ttttccagct cagtgtaaga ccctcgggcg

1561 tctacaaagt tctcctggga ttagcgtggt tctgcatctc ccttgtgccc aggtggagtt 1621 agaaagtcaa aaaatagtac cttgttcttg ggatgactat ccctttctgt gtctagttac

1681 agtattcact tgacaaatag ttcgaaggaa gttgcactaa ttctcaactc tggttgagag

1741 ggttcataaa tttcatgaaa atatctccct ttggagctgc tcagacttac tttaagctca

1801 aacagaaggg aatgctatta ctggtggtgt tcctacggta agacttaagc aaagcctttt

1861 tcatatttga aaatgtggaa agaaaagatg ttcctaaaag gttagatatt ttgagctaat 1921 aattgcaaaa attagaagac tgaaaatgga cccatgagag tatattttta tgagggagca

1981 aaagttagac tgagaacaaa cgttagaaaa tcacttcaga ttgtgtttga aaattatata

2041 ctgagcatac taatttaaaa agagaacttg ttgaaattta aaacgtgttt ctaggttgac

2101 cttgtgtttt agaaatttgc acttaatgga atttgcattt cagagatgtg ttagtgttgt

2161 gctttgcctt ctttggcgat gaatgtcaga aattgaatgc cacatgcttt cataatatag 2221 ttttgtgctt caaagtgttt gacagaagtt gggtattaaa gatttaaagt ctcttaggaa

2281 tattattcat gtaactccat ggcataaata gttgtatttt tgtgtacttt aaaatcaact

2341 tataactgtg agatgttatt gcttccattt tattagaaga gaaacaaatt ccatgcttta

2401 tggaatttat gtagactgga gtcttcgtga actggggcaa atgctggcat ccaggagccg

2461 ccaatactaa caggacaggt tccattgcca tggcctattc cacccaaaca atatgttgta 2521 gtttctggaa attccatact cagatatcag tctgctagaa ctttaaaatg aaggacaaat

2581 cctgttaaag aaatattgtt aaaaatcttt aaaccctgtg tattgaaagc actctatttt

2641 ctaattttat ccagttttct gtttaactcc ttataatgtt taggatatta aaattttagg

2701 ataatgaaga gtacataatg tcctacttaa tatttatgtt aataggactt aattcttact

2761 agacatctag gaacattaca aagcaaagac tatttttatg cttccataac ctagaattaa

2821 aaccaaatta tgaccttatg ataaatcttt aagtattggt gtgaatgtta tttaaattct

2881 atatttttct tatttaatta caaatactat aaatgagcaa ggaaaaggaa tagactttct 2941 taatatatta taacactcat tcctagagct taggggtgac tctttaatat taccttatag

3001 tagaaacttt atgtaatata gctaactccg tatttacaga acaaaaaaac acagttcccc

3061 ctcctgtagt ataaatttta ttttcacata cttagctaat ttagcagtaa ttggcccagt

3121 tttttcccta atagaaatac ttttagattt gattatgtat acatgacacc taaagaggga

3181 acaaaagtta gttttatttt tttaataaac aacagagttt gttttgtgag ataagtatct 3241 tagtaaaccc aatttccagt cttagtctgt atttccaata tttctaattc ctgagccacg

3301 tcaaagatgc cttgccaaat ttctccccat ttctctacgg ggctagcaaa aatcttcagc

3361 tttatcactc aacccctgcc aaaggaactt gattacatgg tgtctaacca aatgagcagg

3421 cttaggaatt tagatgagat gtgtaagatt cacttacagg cagtagctgc ttctagcatt

3481 tgcaagatcc tacactttta ccttctttaa gggtgtacat tttgatgttg aacatcagtt 3541 ttcatgtaga cttaggactc atgtgcagta aatataaata agtgtagcat cagaagcagt

3601 aggaatggcc gtatacaacc atcctgttaa acatttaaat ttagctctga tagtgtgtta

3661 agacctgaat atctttccta gtaaaaatag gatgtgttga aatatttata tgtactttga

3721 tctctccaca tcacttataa cttatgtgtt ttatttctcc aagtgcggtg ttcctgaatg

3781 ttatgtatgc ttttttttct gtaccacagg cattatctat acctggggcc agattttctg 3841 cactttgaaa tgttgccttt gcctaatgta ggttgacttt ctgaattgtg gagaggcact

3901 tttccaagcc aatcttattt gtcacttttt gttttaatat cttgctctct gacaggaaag

3961 aaacaattca cttaccagcc tcctcacccc atcctccacc atttccttaa tgttccatgg

4021 tattttcaac ggaatacact ttgaaaggta aaaacaattc aaaagtatcg attatcataa

4081 attcacaaaa tatttttgca accagaacac aaaagcaggc tagtcagcta aggtaaattt 4141 cattttcaaa cgagagggaa acatgggaag taaaagatta ggatgtgaaa ggttgtccta

4201 aacagaccaa ggagactgtt ccctaattta ttctcttggc tggttctctc attgaattat •

4261 cagaccccaa gaggagatat tggaacaggc tcccttcatg ccaagggtct ttctaagtta

4321 atactgtgag cattgagccc ccattaaaac tcttttttac ttcagaaaga attttacagg

4381 ttaaagggaa agaaatggtg ggaaactctc cccgtaatgc ttagccaact ttaaagtgta

4441 cccttcaata tccccattgg caactgcagc tgagatctta gagaggaaat ataaccggtg

4501 tgagatctag caatgcattt tgaatcttca ctccctacca ggctcttcct atttttaatc

4561 tcttcacctc agaactagac atatggagag ctttaaaggc aagctggaag gcacattgta

4621 tcaattctac cttgtgctat acgtaggaga gatccaaaat ttggatgctt ctggagactc

4681 ttagacatct tttcattgtt gtccattttt aaagttgatg attgctggaa acattcacac

4741 gcttaaaagc aatggtgtga gttattaatg ggtaaactaa gaagtgttat aggcaatgac

4801 ttgaaatggt ttttaaattg tatggattgt taagaattgt tgaaaaaaaa tttttttttt

4861 ttggacagct tcaaggagat gttagcaatt tcagatatac tagccagttt aggtatgact

4921 ttggaagtgc agaaacagaa ggatactgtt agaaaatcct aacattggtc tccgtgcatg

4981 tgttcacacc tggtctcact gcctttcctt cccacagacc tgagtgtgaa agactgagag

5041 ttgaggagtt actttgtgga tcttgtccaa atttagtgaa atgtggaagt caaccagacc

5101 aatgatggaa ttaaatgtaa attccaagag ggctttcaca gtccacaggg ttcaaatgac

5161 ttgggtaaca gaagttattc ttagcttacc tgttatgtga cagtgattta cctgtccatt

5221 tccaacccaa aagcctgtca gaaagcattc tttagagaaa accactttac atttgttgtt

5281 aaactcctga tcgctactct taagaatata catgtatgta ttcataggaa cattttttct

5341 caatatttgt atgattcgct tactgttatt gtgctgagtg agctcctgtg tgcttcagac

5401 aaaaataaat gagactttgt gtttacgtta

1 ggatcctcta gggtcccagc tcgcctcgat ggagctcctc ccgccgctgc ctcagtcctt

61 cctgttgctg ctgctgttgc ctgccaagcc cgcggcgggc gaggactggc agtgcccgcg

121 caccccctac gcggcctctc gcgactttga cgtgaagtac gtggtgccca gcttctccgc

181 cggaggcctg gtacaggcca tggtgaccta cgagggcgac agaaatgaga gtgctgtgtt

241 tgtagccata cgcaatcgcc tgcatgtgct tgggcctgac ctgaagtctg tccagagcct

301 ggccacgggc cctgctggag accctggctg ccagacgtgt gcagcctgtg gcccaggacc 361 ccacggccct cccggtgaca cagacacaaa ggtgctggtg ctggatcccg cgctgcctgc

421 gctggtcagt tgtggctcca gcctgcaggg ccgctgcttc ctgcatgacc tagagcccca

481 agggacagcc gtgcatctgg cagcgccagc ctgcctcttc tcagcccacc ataaccggcc

541 cgatgactgc cccgactgtg tggccagccc attgggcacc cgtgtaactg tggttgagca

601 aggccaggcc tcctatttct acgtggcatc ctcactggac gcagccgtgg ctggcagctt 661 cagcccacgc tcagtgtcta tcaggcgtct caaggctgac gcctcgggat tcgcaccggg

721 ctttgtggcg ttgtcagtgc tgcccaagca tcttgtctcc tacagtattg aatacgtgca

781 cagcttccac acgggagcct tcgtatactt cctgactgta cagccggcca gcgtgacaga

841 tgatcctagt gccctgcaca cacgcctggc acggcttagc gccactgagc cagagttggg

901 tgactatcgg gagctggtcc tcgactgcag atttgctcca aaacgcaggc gccggggggc 961 cccagaaggc ggacagccct accctgtgct gcaggtggcc cactccgctc cagtgggtgc

1021 ccaacttgcc actgagctga gcatcgccga gggccaggaa gtactatttg gggtctttgt

1081 gactggcaag gatggtggtc ctggcgtggg ccccaactct gtcgtctgtg ccttccccat

1141 tgacctgctg gacacactaa ttgatgaggg tgtggagcgc tgttgtgaat ccccagtcca

1201 tccaggcctc cggcgaggcc tcgacttctt ccagtcgccc agtttttgcc ccaacccgcc 1261 tggcctggaa gccctcagcc ccaacaccag ctgccgccac ttccctctgc tggtcagtag

1321 cagcttctca cgtgtggacc tattcaatgg gctgttggga ccagtacagg tcactgcatt

1381 gtatgtgaca cgccttgaca acgtcacagt ggcacacatg ggcacaatgg atgggcgtat

1441 cctgcaggtg gagctggtca ggtcactaaa ctacttgctg tatgtgtcca acttctcact

1501 gggtgacagt gggcagcccg tgcagcggga tgtcagtcgt cttggggacc acctactctt 1561 tgcctctggg gaccaggttt tccaggtacc tatccgaggc cctggctgcc gccacttcct

1621 gacctgtggg cgttgcctaa gggcatggca tttcatgggc tgtggctggt gtgggaacat

1681 gtgcggccag cagaaggagt gtcctggctc ctggcaacag gaccactgcc cacctaagct

1741 tactgagttc cacccccaca gtggacctct aaggggcagt acaaggctga ccctgtgtgg

1801 ctccaacttc taccttcacc cttctggtct ggtgcctgag ggaacccatc aggtcactgt

1861 gggccaaagt ccctgccggc cactgcccaa ggacagctca aaactcagac cagtgccccg

1921 gaaagacttt gtagaggagt ttgagtgtga actggagccc ttgggcaccc aggcagtggg 1981 gcctaccaac gtcagcctca ccgtgactaa catgccaccg ggcaagcact tccgggtaga

2041 cggcacctcc gtgctgagag gcttctcttt catggagcca gtgctgatag cagtgcaacc

2101 cctctttggc ccacgggcag gaggcacctg tctcactctt gaaggccaga gtctgtctgt

2161 aggcaccagc cgggctgtgc tggtcaatgg gactgagtgt ctgctagcac gggtcagtga

2221 ggggcagctt ttatgtgcca caccccctgg ggccacggtg gccagtgtcc cccttagcct 2281 gcaggtgggg ggtgcccagg tacctggttc ctggaccttc cagtacagag aagaccctgt

2341 cgtgctaagc atcagcccca actgtggcta catcaactcc cacatcacca tctgtggcca

2401 gcatctaact tcagcatggc acttagtgct gtcattccat gacgggctta gggcagtgga

2461 aagcaggtgt gagaggcagc ttccagagca gcagctgtgc cgccttcctg aatatgtggt

2521 ccgagacccc cagggatggg tggcagggaa tctgagtgcc cgaggggatg gagctgctgg 2581 ctttacactg cctggctttc gcttcctacc cccaccccat ccacccagtg ccaacctagt

2641 tccactgaag cctgaggagc atgccattaa gtttgagtat attgggctgg gcgctgtggc

2701 tgactgtgtg ggtatcaacg tgaccgtggg tggtgagagc tgccagcacg agttccgggg

2761 ggacatggtt gtctgccccc tgcccccatc cctgcagctt ggccaggatg gtgccccatt

2821 gcaggtctgc gtagatggtg aatgtcatat cctgggtaga gtggtgcggc cagggccaga 2881 tggggtccca cagagcacgc tccttggtat cctgctgcct ttgctgctgc ttgtggctgc

2941 actggcgact gcactggtct tcagctactg gtggcggagg aagcagctag ttcttcctcc

3001 caacctgaat gacctggcat ccctggacca gactgctgga gccacacccc tgcctattct

3061 gtactcgggc tctgactaca gaagtggcct tgcactccct gccattgatg gtctggattc

3121 caccacttgt gtccatggag catccttctc cgatagtgaa gatgaatcct gtgtgccact 3181 gctgcggaaa gagtccatcc agctaaggga cctggactct gcgctcttgg ctgaggtcaa

3241 ggatgtgctg attccccatg agcgggtggt cacccacagt gaccgagtca ttggcaaagg

3301 ccactttgga gttgtctacc acggagaata catagaccag gcccagaatc gaatccaatg

3361 tgccatcaag tcactaagtc gcatcacaga gatgcagcag gtggaggcct tcctgcgaga

3421 ggggctgctc atgcgtggcc tgaaccaccc gaatgtgctg gctctcattg gtatcatgtt

3481 gccacctgag ggcctgcccc atgtgctgct gccctatatg tgccacggtg acctgctcca

3541 gttcatccgc tcacctcagc ggaaccccac cgtgaaggac ctcatcagct ttggcctgca 3601 ggtagcccgc ggcatggagt acctggcaga gcagaagttt gtgcacaggg acctggctgc

3661 gcggaactgc atgctggacg agtcattcac agtcaaggtg gctgactttg gtttggcccg

3721 cgacatcctg gacagggagt actatagtgt tcaacagcat cgccacgctc gcctacctgt

3781 gaagtggatg gcgctggaga gcctgcagac ctatagattt accaccaagt ctgatgtgtg

3841 gtcatttggt gtgctgctgt gggaactgct gacacggggt gccccaccat accgccacat 3901 tgaccctttt gaccttaccc acttcctggc ccagggtcgg cgcctgcccc agcctgagta

3961 ttgccctgat tctctgtacc aagtgatgca gcaatgctgg gaggcagacc cagcagtgcg

4021 acccaccttc agagtactag tgggggaggt ggagcagata gtgtctgcac tgcttgggga

4081 ccattatgtg cagctgccag caacctacat gaacttgggc cccagcacct cgcatgagat

4141 gaatgtgcgt ccagaacagc cgcagttctc acccatgcca gggaatgtac gccggccccg 4201 gccactctca gagcctcctc ggcccacttg acttagttct tgggctggac ctgcttagct

4261 gccttgagct aaccccaagg ctgcctctgg gccatgccag gccagagcag tggccctcca

4321 ccttgttcct gccctttaac tttcagaggc aataggtaaa tgggcccatt aggtccctca

4381 ctccacagag tgagccagtg agggcagtcc tgcaacatgt atttatggag tgcctgctgt

4441 ggaccctgtc ttctgggcac agtggactca gcagtgacca caccaacact gacccttgaa 4501 ccaataaagg aacaaatgac tattaaagca caaaaaaaaa a

1 gcgctgcccg cctcgtcccc acccccccaa cccccgcgcc cgccctcgga cagtccctgc

61 tcgcccgcgc gctgcagccc catctcctag cggcagccca ggcgcggagg gagcgagtcc

121 gccccgaggt aggtccagga cgggcgcaca gcagcagccg aggctggccg ggagagggag

181 gaagaggatg gcagggccac gccccagccc atgggccagg ctgctcctgg cagccttgat

241 cagcgtcagc ctctctggga ccttggcaaa ccgctgcaag aaggccccag tgaagagctg

301 cacggagtgt gtccgtgtgg ataaggactg cgcctactgc acagacgaga tgttcaggga

361 ccggcgctgc aacacccagg cggagctgct ggccgcgggc tgccagcggg agagcatcgt

421 ggtcatggag agcagcttcc aaatcacaga ggagacccag attgacacca ccctgcggcg

481 cagccagatg tccccccaag gcctgcgggt ccgtctgcgg cccggtgagg agcggcattt

541 tgagctggag gtgtttgagc cactggagag ccccgtggac ctgtacatcc tcatggactt

601 ctccaactcc atgtccgatg atctggacaa cctcaagaag atggggcaga acctggctcg

661 ggtcctgagc cagctcacca gcgactacac tattggattt ggcaagtttg tggacaaagt

721 cagcgtcccg cagacggaca tgaggcctga gaagctgaag gagccctggc ccaacagtga

781 cccccccttc tccttcaaga acgtcatcag cctgacagaa gatgtggatg agttccggaa

841 taaactgcag ggagagcgga tctcaggcaa cctggatgct cctgagggcg gcttcgatgc

901 catcctgcag acagctgtgt gcacgaggga cattggctgg cgcccggaca gcacccacct

961 gctggtcttc tccaccgagt cagccttcca ctatgaggct gatggcgcca acgtgctggc

1021 tggcatcatg agccgcaacg atgaacggtg ccacctggac accacgggca cctacaccca

1081 gtacaggaca caggactacc cgtcggtgcc caccctggtg cgcctgctcg ccaagcacaa

1141 catcatcccc atctttgctg tcaccaacta ctcctatagc tactacgaga agcttcacac

1201 ctatttccct gtctcctcac tgggggtgct gcaggaggac tcgtccaaca tcgtggagct

1261 gctggaggag gccttcaatc ggatccgctc caacctggac atccgggccc tagacagccc

1321 ccgaggcctt cggacagagg tcacctccaa gatgttccag aagacgagga ctgggtcctt

1381 tcacatccgg cggggggaag tgggtatata ccaggtgcag ctgcgggccc ttgagcacgt

1441 ggatgggacg cacgtgtgcc agctgccgga ggaccagaag ggcaacatcc atctgaaacc

1501 ttccttctcc gacggcctca agatggacgc gggcatcatc tgtgatgtgt gcacctgcga 1561 gctgcaaaaa gaggtgcggt cagctcgctg cagcttcaac ggagacttcg tgtgcggaca

1621 gtgtgtgtgc agcgagggct ggagtggcca gacctgcaac tgctccaccg gctctctgag

1681 tgacattcag ccctgcctgc gggagggcga ggacaagccg tgctccggcc gtggggagtg

1741 ccagtgcggg cactgtgtgt gctacggcga aggccgctac gagggtcagt tctgcgagta

1801 tgacaacttc cagtgtcccc gcacttccgg gttcctctgc aatgaccgag gacgctgctc 1861 catgggccag tgtgtgtgtg agcctggttg gacaggccca agctgtgact gtcccctcag

1921 caatgccacc tgcatcgaca gcaatggggg catctgtaat ggacgtggcc actgtgagtg

1981 tggccgctgc cactgccacc agcagtcgct ctacacggac accatctgcg agatcaacta

2041 ctcggcgatc cacccgggcc tctgcgagga cctacgctcc tgcgtgcagt gccaggcgtg

2101 gggcaccggc gagaagaagg ggcgcacgtg tgaggaatgc aacttcaagg tcaagatggt 2161 ggacgagctt aagagagccg aggaggtggt ggtgcgctgc tccttccggg acgaggatga

2221 cgactgcacc tacagctaca ccatggaagg tgacggcgcc cctgggccca acagcactgt

2281 cctggtgcac aagaagaagg actgccctcc gggctccttc tggtggctca tccccctgct

2341 cctcctcctc ctgccgctcc tggccctgct actgctgcta tgctggaagt actgtgcctg

2401 ctgcaaggcc tgcctggcac ttctcccgtg ctgcaaccga ggtcacatgg tgggctttaa 2461 ggaagaccac tacatgctgc gggagaacct gatggcctct gaccacttgg acacgcccat

2521 gctgcgcagc gggaacctca agggccgtga cgtggtccgc tggaaggtca ccaacaacat

2581 gcagcggcct ggctttgcca ctcatgccgc cagcatcaac cccacagagc tggtgcccta

2641 cgggctgtcc ttgcgcctgg cccgcctttg caccgagaac ctgctgaagc ctgacactcg

2701 ggagtgcgcc cagctgcgcc aggaggtgga ggagaacctg aacgaggtct acaggcagat 2761 ctccggtgta cacaagctcc agcagaccaa gttccggcag cagcccaatg ccgggaaaaa

2821 gcaagaccac accattgtgg acacagtgct gatggcgccc cgctcggcca agccggccct

2881 gctgaagctt acagagaagc aggtggaaca gagggccttc cacgacctca aggtggcccc

2941 cggctactac accctcactg cagaccagga cgcccggggc atggtggagt tccaggaggg

3001 cgtggagctg gtggacgtac gggtgcccct ctttatccgg cctgaggatg acgacgagaa

3061 gcagctgctg gtggaggcca tcgacgtgcc cgcaggcact gccaccctcg gccgccgcct

3121 ggtaaacatc accatcatca aggagcaagc cagagacgtg gtgtcctttg agcagcctga 3181 gttctcggtc agccgcgggg accaggtggc ccgcatccct gtcatccggc gtgtcctgga

3241 cggcgggaag tcccaggtct cctaccgcac acaggatggc accgcgcagg gcaaccggga

3301 ctacatcccc gtggagggtg agctgctgtt ccagcctggg gaggcctgga aagagctgca

3361 ggtgaagctc ctggagctgc aagaagttga ctccctcctg cggggccgcc aggtccgccg

3421 tttccacgtc cagctcagca accctaagtt tggggcccac ctgggccagc cccactccac 3481 caccatcatc atcagggacc cagatgaact ggaccggagc ttcacgagtc agatgttgtc

3541 atcacagcca ccccctcacg gcgacctggg cgccccgcag aaccccaatg ctaaggccgc

3601 tgggtccagg aagatccatt tcaactggct gcccccttct ggcaagccaa tggggtacag

3661 ggtaaagtac tggattcagg gtgactccga atccgaagcc cacctgctcg acagcaaggt

3721 gccctcagtg gagctcacca acctgtaccc gtattgcgac tatgagatga aggtgtgcgc 3781 ctacggggct cagggcgagg gaccctacag ctccctggtg tcctgccgca cccaccagga

3841 agtgcccagc gagccagggc gtctggcctt caatgtcgtc tcctccacgg tgacccagct

3901 gagctgggct gagccggctg agaccaacgg tgagatcaca gcctacgagg tctgctatgg

3961 cctggtcaac gatgacaacc gacctattgg gcccatgaag aaagtgctgg ttgacaaccc

4021 taagaaccgg atgctgctta ttgagaacct tcgggagtcc cagccctacc gctacacggt 4081 gaaggcgcgc aacggggccg gctgggggcc tgagcgggag gccatcatca acctggccac

4141 ccagcccaag aggcccatgt ccatccccat catccctgac atccctatcg tggacgccca

4201 gagcggggag gactacgaca gcttccttat gtacagcgat gacgttctac gctctccatc

4261 gggcagccag aggcccagcg tctccgatga cactggctgc ggctggaagt tcgagcccct

4321 gctgggggag gagctggacc tgcggcgcgt cacgtggcgg ctgcccccgg agctcatccc 4381 gcgcctgtcg gccagcagcg ggcgctcctc cgacgccgag gcgccccacg ggcccccgga

4441 cgacggcggc gcgggcggga agggcggcag cctgccccgc agtgcgacac ccgggccccc

4501 cggagagcac ctggtgaatg gccggatgga ctttgccttc ccgggcagca ccaactccct

4561 gcacaggatg accacgacca gtgctgctgc ctatggcacc cacctgagcc cacacgtgcc

4621 ccaccgcgtg ctaagcacat cctccaccct cacacgggac tacaactcac tgacccgctc

4681 agaacactca cactcgacca cactgcccag ggactactcc accctcacct ccgtctcctc

4741 ccacgactct cgcctgactg ctggtgtgcc cgacacgccc acccgcctgg tgttctctgc 4801 cctggggccc acatctctca gagtgagctg gcaggagccg cggtgcgagc ggccgctgca

4861 gggctacagt gtggagtacc agctgctgaa cggcggtgag ctgcatcggc tcaacatccc

4921 caaccctgcc cagacctcgg tggtggtgga agacctcctg cccaaccact cctacgtgtt

4981 ccgcgtgcgg gcccagagcc aggaaggctg gggccgagag cgtgagggtg tcatcaccat

5041 tgaatcccag gtgcacccgc agagcccact gtgtcccctg ccaggctccg ccttcacttt 5101 gagcactccc agtgccccag gcccgctggt gttcactgcc ctgagcccag actcgctgca

5161 gctgagctgg gagcggccac ggaggcccaa tggggatatc gtcggctacc tggtgacctg

5221 tgagatggcc caaggaggag ggccagccac cgcattccgg gtggatggag acagccccga

5281 gagccggctg accgtgccgg gcctcagcga gaacgtgccc tacaagttca aggtgcaggc

5341 caggaccact gagggcttcg ggccagagcg cgagggcatc atcaccatag agtcccagga 5401 tggaggaccc ttcccgcagc tgggcagccg tgccgggctc ttccagcacc cgctgcaaag

5461 cgagtacagc agcatcacca ccacccacac cagcgccacc gagcccttcc tagtggatgg

5521 gctgaccctg ggggcccagc acctggaggc aggcggctcc ctcacccggc atgtgaccca

5581 ggagtttgtg agccggacac tgaccaccag cggaaccctt agcacccaca tggaccaaca

5641 gttcttccaa acttgaccgc accctgcccc acccccgcca cgtcccacta ggcgtcctcc 5701 cgactcctct cccggagcct cctcagctac tccatccttg cacccctggg ggcccagccc

5761 acccgcatgc acagagcagg ggctaggtgt ctcctgggag gcatgaaggg ggcaaggtcc

5821 gtcctctgtg ggcccaaacc tatttgtaac caaagagctg ggagcagcac aaggacccag

5881 cctttgttct gcacttaata aatggttttg ctactgctaa

1 gggtggggaa gcttagagac cggtgaggga gcagagctgg ggcgcctgtg tacagggata 61 gagcccggcg gcagcagggc gcggcttccc tttcccgggg cctggggccg caatcaggtg

121 gagtcgagag gccggaggag gggcaggagg aaggggtgcg gtcgcgatcc ggacccggag

181 ccagcgcgga gcacctgcgc ccgcggctga caccttcgct cgcagtttgt tcgcagttta

241 ctcgcacacc agtttccccc accgcgcttt ggattagtgt gatctcagct caaggcaaag

301 gtgggatatc atggcatcta tctgggttgg acaccgagga acagtaagag attatccaga 361 ctttagccca tcagtggatg ctgaagctat tcagaaagca atcagaggaa ttggaactga

421 tgagaaaatg ctcatcagca ttctgactga gaggtcaaat gcacagcggc agctgattgt

481 taaggaatat caagcagcat atggaaagga gctgaaagat gacttgaagg gtgatctctc

541 tggccacttt gagcatctca tggtggccct agtgactcca ccagcagtct ttgatgcaaa

601 gcagctaaag aaatccatga agggcgcggg aacaaacgaa gatgccttga ttgaaatctt 661 aactaccagg acaagcaggc aaatgaagga tatctctcaa gcctattata cagtatacaa

721 gaagagtctt ggagatgaca ttagttccga aacatctggt gacttccgga aagctctgtt

781 gactttggca gatggcagaa gagatgaaag tctgaaagtg gatgagcatc tggccaaaca

841 agatgcccag attctctata aagctggtga gaacagatgg ggcacggatg aagacaaatt

901 cactgagatc ctgtgtttaa ggagctttcc tcaattaaaa ctaacatttg atgaatacag 961 aaatatcagc caaaaggaca ttgtggacag cataaaagga gaattatctg ggcattttga

1021 agacttactg ttggccatag ttaattgtgt gaggaacacg ccggcctttt tagccgaaag

1081 actgcatcga gccttgaagg gtattggaac tgatgagttt actctgaacc gaataatggt

1141 gtccagatca gaaattgacc ttttggacat tcgaacagag ttcaagaagc attatggcta

1201 ttccctatat tcagcaatta aatcggatac ttctggagac tatgaaatca cactcttaaa 1261 aatctgtggt ggagatgact gaaccaagaa gataatctcc aaaggtccac gatgggcttt

1321 cccaacagct ccaccttact tcttctcata ctatttaaga gaacaagcaa atataaacag

1381 caacttgtgt tcctaacagg aattttcatt gttctataac aacaacaaca aaagcgatta

1441 ttattttaga gcatctcatt tataatgtag cagctcataa atgaaattga aaatggtatt

1501 aaagatctgc aactactatc caacttatat ttctgctttc aaagttaaga atctttatag 1561 ttctactcca ttaaatataa agcaagataa taaaaattgt tgcttttgtt aaaagtaaaa

1 tgcagactga tatggattca ccactgctaa cacctcctgg ttggaactac aggaatagaa

61 ctggaaaggg aaaaaaggca gcattcacca catcccaatc ctgaatccaa gagtctaaga 121 tagtccccca ctcctatctc aggcttagag gattagatta atctcctgga gggaagactc 181 ttccttgaaa catttttttt tatctgcctg tagctattgg gataattcgg gaaatccaca 241 gggacagttc aagtcatctt tgtcctctac tttctgttgc actctcagcc ttgttctctt 301 tttagaaact gcatggtaac tattatatag ctaaagaaga gcattctgac ctctgccctg 361 ggacttcctg gatcctcctc ttcttataaa tacaagggca gagctggtat cccggggagc 421 caggaagcag tgagcccagg agtcctcggc cagccctgcc tgcccaccag gaggatgaag 481 gtctccgtgg ctgccctctc ctgcctcatg cttgttgctg tccttggatc ccaggcccag 541 ttcataaatg atgcagagac agagttaatg atgtcaaagc ttccactgga aaatccagta 601 gttctgaaca gctttcactt tgctgctgac tgctgcacct cctacatctc acaaagcatc 661 ccgtgttcac tcatgaaaag ttattttgaa acgagcagcg agtgctccaa gccaggtgtc 721 atattcctca ccaagaaggg gcggcaagtc tgtgccaaac ccagtggtcc gggagttcag 781 gattgcatga aaaagctgaa gccctactca atataataat aaagagacaa aagaggccag 841 ccacccacct ccaacacctc ctgtgagttt cttggtctga aatacttaaa aaatatatat 901 attgttgtgt ctggtaatga aagtaatgca tctaataaag agtattcaat ttttt

1 cgggggggta ctgtgcgagc cctcaaggag gtggctgttc tgtagctgga gagctccgtg 61 ggtggcagga ctgaacttga acaccagaaa caacccccaa gccttgtgac ctgggaggca

121 ggaggcgggt ctgtctccct gggacttggg tggctgagcc gaggtactcg ggaccctgtc

181 ccgcgcatgg cagagtggct cctcacagcc tgaagctcat ccttctgcac gggccagcca

241 ggccagcaca gaggcaccag ggcagcagtg cacacaggtc cccggggacc ccaccatgtg

301 gagcggatgg tggctgtggc cccttgtggc cgtctgcact gcagacttct ttcgggacga 361 ggcagagagg atcatgaggg actcccctgt cattgatggg cacaatgacc tcccctggca

421 gctgctggat atgttcaaca accggctgca ggacgagagg gccaacctga ccaccttggc

481 cggcacacac accaacatcc ccaagctgag ggccggcttt gtgggaggcc agttctggtc

541 cgtgtacacg ccctgcgaca cccagaacaa agacgccgtg cggaggacgc tggagcagat

601 ggacgtggtc caccgcatgt gccggatgta cccggagacc ttcctgtatg tcaccagcag 661 tgcaggcatt cggcaggcct tccgggaagg gaaggtggcc agcctgatcg gcgtggaggg

721 cggccactcc attgacagca gtttgggcgt cctgcgggca ctctatcagc tgggcatgcg

781 gtacctgacc ctcacccaca gctgcaacac gccctgggct gacaactggc tggtggacac

841 gggagacagc gagccccaga gccaaggctt gtcacccttt gggcagcgtg tggtgaagga

901 gctgaaccgt ctgggggtcc tcatcgactt ggctcacgtg tctgtggcca ccatgaaggc 961 caccctgcag ctgtccagag ccccggtcat cttcagccac tcctcggcct acagcgtgtg

1021 cgcaagccgg cgcaacgtgc ctgacgacgt cctgaggctg gtgaaacaga cagacagcct

1081 ggtgatggtg aacttctaca acaattacat ttcctgcacc aacaaggcca acctgtccca

1141 agtggccgac catctggatc acatcaagga ggtggcagga gccagagccg tgggttttgg

1201 tggggacttt gatggtgttc caagggtccc tgaggggctg gaggacgtct ccaagtatcc 1261 agacctgatc gctgagctgc tcaggaggaa ctggacggag gcggaggtca agggcgcact

1321 ggctgacaac ctgctgaggg tcttcgaggc tgtggaacag gccagcaacc tcacacaggc

1381 tcccgaggag gagcccatcc cgctggacca gctgggtggc tcctgcagga cccattacgg

1441 ctactcctct ggggcttcca gcctccatcg ccactggggg ctcctgctgg cctccctcgc

1501 tcccctggtc ctctgtctgt ctctcctgtg aaacctggga gaccagagtc ccctttaggg

1561 ttcccggagc tccgggaaga cccgcccatc ccaggactcc agatgccagg agccctgctg

1621 cccacatgca aggaccagca tctcctgaga ggacgcctgg gcttacctgg ggggcaggat

1681 gcctggggac agttcaggac acacacacag taggcccgca ataaaagcaa cacccctt

1 agccatggca ggcccccgat acccagtttc agtgcaaggg gcagccctgg tgcagatcaa 61 gaggctccaa acgtttgcct tctctgtgcg ctggtcagac ggcagcgaca ccttcgtgcg

121 caggagttgg gacgaattca ggcagctcaa gaagaccctc aaggagacct tcccggtgga

181 ggcgggcctg ctgcggagat ctgaccgcgt tctcccaaag cttctcgatg caccactgtt

241 gggacgcgtg gggcgcacga gccgcggcct ggcgcgcctg cagctgttgg aaacctattc

301 tcggaggctg ctggcgactg cagagcgcgt ggcacggagc ccgacgatca ctggcttctt 361 cgcaccgcaa cccctggacc tggagcccgc gctgccaccc ggcagccggg tgatcctgcc

421 caccccagag gagcagcctc tttctcgcgc tgcgggccgc ctctccatcc acagtctgga

481 ggctcagagc ctgcgctgcc tgcagccctt ctgtacccag gacacgcggg ataggccttt

541 tcaggcgcag gcccaggaga gcctggacgt gctgctgcgg cacccctcag gctggtggct

601 ggtggagaac gaagaccggc agaccgcctg gtttccagcg ccctacctgg aggaggcggc 661 cccgggccaa ggccgggagg gaggcccgtc cctagggagc agcggtcccc agttctgtgc

721 ttcccgcgcc tacgagagca gccgcgcaga tgagctgtcc gtgcccgcgg gggcgcgcgt

781 gcgcgtgttg gaaacgtcag accgcggctg gtggctatgc aggtacggcg accgggcggg

841 cctactcccc gcggtgctgc tgcggccgga agggctgggc gctctcctga gcgggacggg

901 gttccgtgga ggagacgacc cggcgggtga ggcccggggc ttccctgaac cctcccaggc 961 caccgcccct ccccccaccg tgcccacccg accttcgccg ggcgccatcc agagccgctg

1021 ctgcaccgtc acacgcaggg ccctggagcg gcgcccacgg cgccagggcc gccctcgagg

1081 gtgcgtggac tctgtgccgc accccacgac ggagcagtga gcgcgaggat cc

1 gggaacacat ccaagcttaa gacggtgagg tcagcttcac attctcagga actctccttc

61 tttgggtctg gctgaagttg aggatctctt actctctagg ccacggaatt aacccgagca 121 ggcatggagg cctctgctct cacctcatca gcagtgacca gtgtggccaa agtggtcagg 181 gtggcctctg gctctgccgt agttttgccc ctggccagga ttgctacagt tgtgattgga 241 ggagttgtgg ctgtgcccat ggtgctcagt gccatgggct tcactgcggc gggaatcgcc 301 tcgtcctcca tagcagccaa gatgatgtcc gcggcggcca ttgccaatgg gggtggagtt 361 gcctcgggca gccttgtggc tactctgcag tcactgggag caactggact ctccggattg 421 accaagttca tcctgggctc cattgggtct gccattgcgg ctgtcattgc gaggttctac 481 tagctccctg cccctcgccc tgcagagaag agaaccatgc caggggagaa ggcacccagc 541 catcctgacc cagcgaggag ccaactatcc caaatatacc tggggtgaaa tataccaaat 601 tctgcatctc cagaggaaaa taagaaataa agatgaattg ttgcaactct tcaaaa

1 acctctgggc agagaaacaa agctctatat gcacagccca gcaaagagca gcacacagct

61 gaaagaaaaa ctcagaagac agagctgaaa aagaaaactg gtgatggatc tcattccaaa 121 ctttgccatg gaaacatggg ttcttgtggc taccagcctg gtactcctct atatttatgg 181 gacccattca cataaacttt ttaagaagct gggaattcct gggccaaccc ctctgccttt 241 tctgggaact attttgttct accttagggg tctttggaat tttgacagag aatgtaatga 301 aaaatacgga gaaatgtggg ggctgtatga ggggcaacag cccatgctgg tcatcatgga 361 tcccgacatg atcaaaacag tgttagtgaa agaatgttac tctgtcttca caaaccagat

421 gcctttaggt ccaatgggat ttctgaaaag tgccttaagt tttgctgaag atgaagaatg

481 gaagagaata cgaacattgc tatctccagc tttcaccagt gtaaaattca aggaaatggt 541 ccccatcatt tcccaatgtg gagatatgtt ggtgagaagc ctgaggcagg aagcagagaa

601 cagcaagtcc atcaacttga aagatttctt tggggcctac accatggatg taatcactgg

661 cacattattt ggagtgaact tggattctct caacaatcca caagatccct ttctgaaaaa

721 tatgaagaag cttttaaaat tggatttttt ggatcccttt ttactcttaa tatcactctt

781 tccatttctt accccagttt ttgaagccct aaatatcggt ttgtttccaa aagatgttac 841 ccatttttta aaaaattcca ttgaaaggat gaaagaaagt cgcctcaaag ataaacaaaa

901 gcatcgagta gatttctttc aacagatgat cgactcccag aattccaaag aaacaaagtc

961 ccataaagct ctgtctgatc tggagcttgt ggcccagtca attatcatca tttttgctgc

1021 ctatgacaca actagcacca ctctcccctt cattatgtat gaactggcca ctcaccctga

1081 tgtccagcag aaactgcagg aggagattga cgcagtttta cccaataagg cacctgtcac 1141 ctacgatgcc ctggtacaga tggagtacct tgacatggtg gtgaatgaaa cgctcagatt

1201 attcccagtt gttagtagag ttacgagagt ctgcaagaaa gatattgaaa tcaatggagt

1261 gttcattccc aaagggttag cagtgatggt tccaatctat gctcttcacc atgacccaaa

1321 gtactggaca gagcctgaga agttctgccc tgaaaggttc agtaagaaga acaaggacag

1381 catagatctt tacagataca taccttttgg agctggaccc cgaaactgca ttggcatgag 1441 gtttgctctc acaaacataa aacttgctgt cattagagca ctgcagaact tctccttcaa

1501 accttgtaaa gagactcaga tcccactgaa attagacaat ctaccaattc ttcaaccaga

1561 aaaacctatt gttctaaaag tgcacttaag agatgggatt acaagtggac cctgactttc

1621 cctaaggact tccactttgt tcaagaaagc tgtatcccag aacactagac acttcaaatt

1681 gttttgtgaa taaaactcag aaatgaagat gagcttaatt aacctagtat actgggtgaa 1741 taattagaaa ttctctacat tcattgagct ctcattgtct gggtagagta ttacacgttg

1801 catactacaa agcaggtgac aaatcaatgc caaataagta cagtcatctt ctctagttct

1861 cataagacta tctccccgcc acctatagtt agtaccctca agtcctcctg agctgtgatc

1921 agagaataaa catttctcaa caattttacc aacaattttt aatgaaaagg aaaattatac

1981 ttgtgattct cgtagtgaca tttatattac atgttccatt tgtgatattc tataataagt

2041 attatattga gaaagtcaac aagcacctct ttacaaaact gttatctgat gtcttcctgc

2101 atattaagga tgaatctaca gaattagatc aataaggatc aacaaataaa tatttttggt

2161 catt

1 gtggcggctt cgcccgcgag tccagaggca ggcgagcagc tcggtcgccc ccaccggccc 61 catggcagcc cccggcgccc cagctgagta cggctacatc cggaccgtcc tgggccagca

121 gatcctggga caactggaca gctccagcct ggcgctgccc tccgaggcca agctgaagct

181 ggcggggagc agcggccgcg gcggccagac agtcaagagc ctgcggatcc aggagcaggt 241 gcagcagacc ctcgcccgga agggccgcag ctccgtgggc aacggaaatc ttcaccgaac

301 cagcagtgtt cctgagtatg tctacaacct acacttggtt gaaaatgatt ttgttggagg

361 ccgttcccct gttcctaaaa cctatgacat gctaaaggct ggcacaactg ccacttatga

421 aggtcgctgg ggaagaggaa cagcacagta cagctcccag aagtccgtgg aagaaaggtc

481 cttgaggcat cctctgagga gactggagat ttctcctgac agcagcccgg agagggctca 541 ctacacgcac agcgattacc agtacagcca gagaagccag gctgggcaca ccctgcacca

601 ccaagaaagc aggcgggccg ccctcctagt gccaccgaga tatgctcgtt ccgagatcgt

661 gggggtcagc cgtgctggca ccacaagcag gcagcgccac tttgacacat accacagaca

721 gtaccagcat ggctctgtta gcgacaccgt ttttgacagc atccctgcca acccggccct

781 gctcacgtac cccaggccag ggaccagccg cagcatgggc aacctcttgg agaaggagaa 841 ctacctgacg gcagggctca ctgtcgggca ggtcaggccg ctggtgcccc tgcagcccgt

901 cactcagaac agggcttcca ggtcctcctg gcatcagagc tccttccaca gcacccgcac

961 gctgagggaa gctgggccca gtgtcgccgt ggattccagc gggaggagag cgcacttgac

1021 tgtcggccag gcggccgcag ggggaagtgg gaatctgctc actgagagaa gcactttcac

1081 tgactcccag ctggggaatg cagacatgga gatgactctg gagcgagcag tgagtatgct 1141 cgaggcagac cacatgccgc catccaggat ttctgctgca gctactttca tacagcacga

1201 gtgcttccag aaatctgaag ctcggaagag ggttaaccag cttcgtggca tcctcaagct

1261 tctgcagctc ctaaaagttc agaatgaaga cgttcagcga gctgtgtgtg gggccttgag

1321 aaacttagta tttgaagaca atgacaacaa attggaggtg gctgaactaa atggggtacc

1381 tcggctgctc caggtgctga agcaaaccag agacttggag actaaaaaac aaataacaga 1441 ccatacagtc aatttaagaa gtaggaatgg ctggccgggc gcggtggctc acgcctgtaa

1501 tcccagcact ttgggaggcc aaggcgggcg gatcacgagg tcaggagttc gagaccagcc

1561 tgaccaacat ggtttgctgt ggaatttgtc atctaatgac aaactcaaga atctcatgat

1621 aacagaagca ttgcttacgc tgacggagaa tatcatcatc cccttttctg ggtggcctga

1681 aggagactac ccaaaagcaa atggtttgct cgattttgac atattctaca acgtcactgg 1741 atgcctaaga aacatgagtt ctgctggcgc tgatgggaga aaagcgatga gaagatgtga

1801 cggactcatt gactcactgg tccattatgt cagaggaacc attgcagatt accagccaga

1861 tgacaaggcc acggagaatt gtgtgtgcat tcttcataac ctctcctacc agctggaggc

1921 agagctccca gagaaatatt cccagaatat ctatattcaa aaccggaata tccagactga

1981 caacaacaaa agtattggat gttttggcag tcgaagcagg aaagtaaaag agcaatacca 2041 ggacgtgccg atgccggagg aaaagagcaa ccccaagggc gtggagtggc tgtggcattc

2101 cattgttata aggatgtatc tgtccttgat cgccaaaagt gtccgcaact acacacaaga

2161 agcatcctta ggagctctgc agaacctcac ggccggaagt ggaccaatgc cgacatcagt

2221 ggctcagaca gttgtccaga aggaaagtgg cctgcagcac acccgaaaga tgctgcatgt

2281 tggtgaccca agtgtgaaaa agacagccat ctcgctgctg aggaatctgt cccggaatct 2341 ttctctgcag aatgaaattg ccaaagaaac tctccctgat ttggtttcca tcattcctga

2401 cacagtcccg agtactgacc ttctcattga aactacagcc tctgcctgtt acacattgaa

2461 caacataatc caaaacagtt accagaatgc acgcgacctt ctaaacaccg ggggcatcca

2521 gaaaattatg gccattagtg caggcgatgc ctatgcctcc aacaaagcaa gtaaagctgc

2581 ttccgtcctt ctgtattctc tgtgggcaca cacggaactg catcatgcct acaagaaggc 2641 tcagtttaag aagacagatt ttgtcaacag ccggactgcc aaagcctacc actcccttaa

2701 agactgagga aaatgacaaa gtattctcgg ctgcaaaaat ccccaaagga aaacacctat

2761 ttttctacta cccagcccaa gaaacctcaa aagcatgcct tgtttctatc cttctctatt

2821 tccgtggtcc cctgaatcca gaaaacaaat agaacataat tttatgagtc ttccagaaga

2881 cctttgcaag tttgccacca gtagataccg gccacaggct cgacaaatag tggtctttgt

2941 tattagggct tatggtacat ggcttcctgg aatcaaaatg tgaattcatg tggaagggac

3001 attaatccaa taaataagga aagaagctgt tgcattactg ggattttaaa agtttgattt 3061 acatttatat tccttttctg gttcccatgt tttgtcactc atgtgcacat tgcttcgcca

3121 ttgggcctcc agtgtattgt tctgcagtgt tgaaacagaa tggaaatgac aagaaatatc

3181 tgcagttatc caggagaaag tataatggca aaattattgg tttctttctt tactttgtgc

3241 ttgtttttat ccccttgggt tgtttttctc tgatttttaa ataaacttaa gaaatttaga

3301 ttacagagta tgcatgactg taagaaaaag aaattgagag gaagtgatca tagcaaatta 3361 aagaagtctt ttcctcccag aacttaaagt aaaataaaaa ataaataaat aaataaaatc

3421 ttttccacag agaaaggcaa ctgtgatgat aaaatttaac gttcccccaa acactgagtc

3481 aatgagattt ttctcaggag atactttacc tataacaacg ccgttaaatc caaatctctt

3541 ctaaacgatg gcattctatg taatgccttt cctggacttt tttggccact gccctggact

3601 agtgaaagaa tggactctat ctttatctgc aagaggaact aaggccttct atcagactgc 3661 ctggccagcc tggggcactg aaaatacggc tcatgttaat gagttacatt atcagccagc

3721 ccagccttgc ccaccattta agaaatatca cagagccact agatctcata tgatcttctt

3781 caagccatta ttttaactca agaaaactct agagaagaaa agtgaagaag tcatgttgaa

3841 gaagatgtaa gaatgtgtca agaccatcca gaaatgatat gagaaatact gatattttaa

3901 atggttgaca tcatccagcg aaatgaatct acattaaatg ttgttttaac tgcgctatga 3961 ttaaaaccat tcatatagag ttagtcttta caactactat tctgttattt ttttttttaa

4021 tctgacaaca tttgtcctaa gtaagataag caaaaaaatt cttcaactcc ttttggcaag

4081 aaaactgtaa cagaaaataa attttgaatg tgtacttaag tctttattat atttgaagca

4141 attttttttc aattttaaaa gctgaatgaa gacaacttag gttgctaacc tagttcaaaa

4201 tgaaattatt tagataccaa tttttaaaat actggagaga atttatatgt ctttttccag 4261 agttctgatg ataagcattt ggagtgcatt tattcctcca gataataaat gtgtgttcag

4321 aactttttgt gttttttaag gcattaataa agccttcgat aatattaaat acaaaatgaa